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Abstract 
Background  
Idiopathic pulmonary fibrosis is a progressive condition with limited treatment options and 
median survival of 3-5 years. Gastro-oesophageal reflux (GOR) has been described in up to 
90% of patients. Pulmonary aspiration has been suggested to contribute to IPF, with calls for 
aggressive antireflux therapy. Whilst medical therapy can usually control acid reflux, surgery 
may be required to control non-acid refluxate, which may also be harmful if aspirated into 
the lung. The risks of surgery in the IPF population are significant. There is no validated 
technique with which to measure aspiration in this group and furthermore, patient attitudes 
towards the treatment of reflux and aspiration in IPF are unknown. As a result, the 
population that might benefit from antireflux therapy has yet to be defined. The current 
study comprised two main aims. The first was to characterise reflux and aspiration in an IPF 
cohort. The second was to evaluate patient attitudes towards the burden of IPF disease as 
compared to the burden of antireflux therapy. 
Methods 
Symptoms of reflux and lung health were assessed using a panel of structured 
questionnaires. Oesophageal function and gastro-oesophageal reflux were objectively 
assessed using manometry and pH-impedance monitoring. A standardised bronchoscopy 
and bronchoalveolar lavage, with biochemical and cytological analysis, was used to assess 
pulmonary aspiration. 
A separate group of individuals with IPF participated in an interview study. Respondents’ 
own health was evaluated using a visual analogue scale, the EuroQOL-5D -3L survey and a 
standard gamble utility analysis. Vignettes were constructed to describe mild- and 
moderate-severity IPF health states and adverse outcomes from medical and surgical 
antireflux therapy. Patient attitudes towards these four health states were assessed with a 
ranking exercise and a series of standard gambles. 
 Results 
pH-impedance monitoring demonstrated supranormal levels of gastro-oesophageal reflux in 
22 of 36 study subjects (61%). Eleven subjects had pre-existing evidence of gastro-
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oesophageal reflux and questionnaire assessment suggested GORD in 29% of subjects. 
Oesophageal manometry identified abnormal oesophageal function in 56%. 
Supranormal levels of pepsin were detected in bronchoalveolar lavage fluid in 16 subjects. 
The combination of pepsin quantification and oesophageal monitoring identified a subgroup 
of subjects with evidence of reflux and aspiration, but there was no correlation between 
levels of reflux and pepsin concentrations. Cytological staining results correlated poorly with 
gastro-oesophageal reflux. After formal multidisciplinary review, two patients who 
participated in the current study have undergone fundoplication. Both have enjoyed a stable 
disease course since surgery. 
In the interview study, respondents recorded mean utilities of 0.611 to 0.798 for their own 
health. Amongst 59 respondents, 38 regarded both IPF health states as preferable to the 
outcomes of either antireflux therapy outcome; the remainder disagreed. An adverse 
outcome from antireflux surgery was generally regarded as the worst of the health states. 
Discussion 
Oesophageal physiology and BAL fluid analysis may be combined to investigate reflux and 
aspiration in IPF. The current data suggest that reflux is common and frequently 
asymptomatic. Aspiration may only be significant in the minority of patients. Oesophageal 
dysmotility, a relative contra-indication to fundoplication, was evident in the majority of 
subjects. 
This is the first report of health state utilities for IPF and demonstrates a disease burden 
comparable to advanced lung cancer. Opinion was divided as to the relative burden 
associated with IPF disease and the potential outcomes of antireflux therapy.  
In conclusion, it remains difficult to identify the IPF patients for whom antireflux surgery 
might be most beneficial. For a proportion, the risks of such treatment will be prohibitive. 
The complexity of surgical decisions in this group suggests a requirement for a standard of 
care that includes a multidisciplinary team, informed by objective aerodigestive physiology 
and imaging. 
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Chapter 1. Introduction  
1.1 Idiopathic pulmonary fibrosis 
1.1.1 Introduction 
Idiopathic pulmonary fibrosis (IPF) is a progressive, scarring lung condition of unknown 
aetiology. It is the commonest of the interstitial lung diseases and, in contrast to several 
others, has well-defined clinical, radiological and histopathological features. The aetiology 
and pathogenesis of the condition are not well understood and treatment options are 
limited. Transplantation offers the only definitive treatment but few patients are eligible. 
1.1.1 Epidemiology 
The epidemiology of IPF has proved challenging for two main reasons. Clinically, the early 
features of IPF are often non-specific, which can lead to diagnostic uncertainty (Fell et al., 
2010). From a research perspective, the nomenclature and disease classification of 
interstitial lung disease has evolved over the last 30 years, with significant inconsistencies 
between studies (Bradley et al., 2008). 
Table 1-1 summarises the major studies of IPF incidence and prevalence from Europe and 
North America. The best estimates come from disease-specific registries and national 
datasets. Other studies have relied on clinic surveys which generate lower estimates and are 
more likely to underestimate disease occurrence (Karakatsani et al., 2009; Musellim et al., 
2014).  
Two consistent findings from these studies are that IPF is more common amongst men and 
that the incidence of the disease appears to be increasing. In the UK, Navaratnam et al 
analysed the Office of National Statistics mortality data in combination with a large primary 
care database over the period 1968-2008 (Navaratnam et al., 2011). Annual death certificate 
reporting rose six-fold (0.92-5.1 per 100 000) over the period and the incidence of IPF 
reported by General Practitioners rose from 5.8 to 8.0 per 100 000 between 2000 and 2008. 
The authors could find no firm evidence of improving survival rates, which makes 
ascertainment bias less likely. If milder cases were increasingly recognised over the study 
period then the survival rate be expected to increase over time. 
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Table 1-1. Epidemiological studies of IPF from Europe and North America. 
First author Country 
and study 
period 
Methodology Incidence 
/100,000 
person 
years 
Prevalence 
/100,000 
Europe 
Thomeer (Thomeer 
et al., 2001) 
 
Belgium 
1992-1996 
Population-based ILD registry 1.25 0.22 
Hodgson (Hodgson 
et al., 2002) 
 
Finland 
1997-98 
Nationwide survey of respiratory clinics 
and hospital databases (accuracy of 
coding validated within a sample and 
extrapolated to the study group) 
- 16-18 
Von Plessen (von 
Plessen et al., 2003) 
Norway 
1984-98 
Hospital registry 4.3 23.4 
Gribbin (Gribbin et 
al., 2006) 
 
UK 
1991-2003 
Primary care database and ONS mortality 
records 
4.6 - 
Navaratnam 
(Navaratnam et al., 
2011) 
 
UK 
2000-09 
Primary care database and ONS mortality 
records 
7.44 - 
North America 
Coultas (Coultas et 
al., 1994) 
 
US 
1988-90 
Medical records, pathology reports, 
death certificates and autopsy reports 
7.4 (F) 
10.7 (M) 
13.2 (F) 
20.2 (M) 
Raghu (Raghu et al., 
2006b) 
 
US 
1996-2000 
Insurance claims database 6.8-16.3 14-42.7 
Fernandez-Perez 
(Fernandez Perez et 
al., 2010) 
 
US 
1997-2005 
County-wide medical record linkage 
system 
17.4 47 
 
1.1.2 Clinical course 
Patients generally present with worsening breathlessness between 50 and 70 years of age 
(Navaratnam et al., 2011). Symptoms have often been present for many months or years by 
the time of specialist evaluation and diagnosis (du Bois, 2012).  In time, the cardinal features 
of exertional dyspnoea and a non-productive cough develop. Eventually, patients will 
experience dyspnoea at rest as respiratory function declines. In the UK, the median survival 
from diagnosis is three to five years (NICE, 2013a). 
The trajectory of disease progression in IPF remains a matter of debate. In a proportion of 
patients at least, periods of stability are punctuated by unpredictable exacerbations, with a 
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resultant loss of pulmonary function, Figure 1-1 (Collard et al., 2007). Acute exacerbations in 
IPF are defined as idiopathic, but risk factors have been identified. Functional and 
radiological markers of severity put patients at higher risk (Ryerson et al., 2015). Several 
triggers have also been suggested: exacerbations appear more common in the winter 
months, during periods of immunosuppression, and following infection (Wootton et al., 
2011; Raghu et al., 2012; Collard et al., 2013b). Both thoracic and non-thoracic surgical 
procedures have also been cited (Yuksel et al., 2006; Ghatol et al., 2012).  
Although the progression seen in IPF is often rapid, the chronic and variable nature of the 
disease course complicates research into pathogenesis. As a result, the significance of 
suspected aetiological factors and the potential benefits of therapeutic intervention are 
difficult to prove. 
Figure 1-1. The disease trajectory that has been postulated in IPF comprises a series of unpredictable 
exacerbations, separated by periods of stability 
 
1.1.3 Assessment and diagnosis 
Plain chest radiograph most commonly reveals diffuse, reticular opacities over the lower 
lung zones. High resolution computed tomography (HRCT) scanning is increasingly used to 
evaluate parenchymal lung disease.  HRCT can detect early changes in the context of a 
normal plain film and is better able to determine disease severity and differentiate between 
different lung pathology (Grenier et al., 1991).  On HRCT, the changes of IPF appear as 
patchy, subpleural densities with a basal preponderance. Contiguous areas of reticulation 
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and normal lung give rise to a “geographical” pattern. In more advanced disease the typical 
pattern of honeycombing is seen as cystic air spaces develop between thickened interlobular 
septa. The accuracy of HRCT for diagnosing IPF is operator dependent but appears to be 
around 90% (Grenier et al., 1991).  
In cases where the clinico-radiological diagnosis remains uncertain and confirmation will 
affect management, tissue may be sampled by means of a transbronchial or surgical lung 
biopsy. Histologically, IPF presents as usual interstitial pneumonia with a “patchwork 
pattern”, honeycombing and characteristic lesions known as fibroblastic foci (Katzenstein et 
al., 2008). As with HRCT, the patchy appearance arises from the temporal heterogeneity of 
fibrotic changes in adjacent sections of lung. Katzenstein and Myers coined the term 
“fibroblastic foci” to describe the hyperplastic reparative epithelium overlying aggregates of 
myofibroblasts (Katzenstein and Myers, 1998). Myofibroblasts are differentiated 
mesenchymal cells which contribute to the deposition of extracellular matrix and scar 
formation in both physiological and pathological states (Hinz et al., 2007). These are the cells 
mainly responsible for the excessive deposition of extracellular matrix seen in the IPF lung. 
1.1.4 Treatment options in IPF 
Until relatively recently, lung transplantation was considered to be the only effective 
treatment for IPF. Recent guidelines incorporate some new options, but the range of 
treatment options available remains extremely limited (NICE, 2013a). 
Non-pharmacological options 
Lung transplantation 
Whilst the evidence base is weak, lung transplantation does appear to improve survival in 
IPF (Thabut et al., 2003). Long-term survival after transplantation for IPF is favourable 
compared to survival after transplantation for other indications (Keating et al., 2009). IPF is a 
disease of the elderly and age is a relative contraindication in lung transplantation. The 
proportion of patients who are eligible for transplantation and for whom a window of 
opportunity arises is small. The data from the latest survey of the International Society of 
Heart and Lung Transplantation suggest that 14.5% of adult sequential bilateral lung 
transplants are performed for IPF (Christie et al., 2009). 
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Oxygen therapy 
Indirect evidence from studies of unselected patients with hypoxaemia suggests that long-
term oxygen therapy improves exercise capacity. In obstructive lung disease, a survival 
benefit has been demonstrated (Nocturnal Oxygen Therapy Trial Group, 1980). There is no 
direct evidence of benefit in IPF but the use of long-term oxygen therapy has been 
recommended nonetheless (Raghu et al., 2011). 
Pulmonary rehabilitation 
Pulmonary rehabilitation combines physical conditioning, education and psychosocial 
support. In a controlled trial which randomised 57 ILD patients  (34 IPF) to receive either 
supervised exercise training or weekly telephone support, those in the exercise group had a 
short term benefit in terms of function and symptomatology (Holland et al., 2008). The 
benefit was not sustained at six months. 
Pharmacological options 
Corticosteroids 
Prednisolone has immunosuppressive and anti-inflammatory effects. There is some evidence 
to support short-term use in a minority of IPF patients (Neuner et al., 2001; Richeldi et al., 
2003).  Overall, the response to corticosteroid therapy in IPF is almost universally poor. In 
clinical practice short-term trials are often used, but the side effect profile and limited 
evidence base led international guidelines to recommend against their use as monotherapy 
(Raghu et al., 2011). 
Combination therapy 
Azathioprine is an immunosuppressant that inhibits synthesis of the purine framework of the 
DNA bases adenine and guanine. N-acetyl cysteine (NAC), a precursor of the antioxidant 
glutathione, has also been used in the treatment of IPF. The combination was studied in a 
randomised controlled trial published in 2005 (Demedts et al.). The Idiopathic Pulmonary 
Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study 
randomised 182 patients to receive either high-dose NAC or placebo in addition to “standard 
therapy” with prednisolone and azathioprine. Those in the NAC group had a slower 
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deterioration of vital capacity (VC) and carbon monoxide diffusing capacity (DLCO). 
Limitations of the study include the lack of a placebo arm and a 30% dropout rate. 
The same combination (NAC, azathioprine and prednisolone) was compared to placebo and 
NAC monotherapy in PANTHER-IPF (Prednisone, Azathioprine, and N-Acetylcysteine: A Study 
That Evaluates Response in Idiopathic Pulmonary Fibrosis) (The Idiopathic Pulmonary 
Fibrosis Clinical Research Network, 2012). This trial was terminated after interim analysis 
revealed an excess of hospitalisation and mortality in those receiving triple therapy. The 
placebo and NAC arms were continued but there was no difference in the primary endpoint 
of change in FVC over a 60-week period. 
Pirfenidone 
Pirfenidone is a small, orally available molecule that demonstrates anti-inflammatory and 
antifibrotic effects in vitro and in vivo (Schaefer et al., 2011). Early mechanistic studies in 
hamsters demonstrated reduced expression of several profibrotic factors in lung tissue and 
or bronchoalveolar lavage (BAL) fluid. Pirfenidone has been shown to prevent the 
accumulation of hydroxyproline, procollagen I and III, inflammatory cells and transforming 
growth factor-beta (TGF-b) (Iyer et al., 1995; Iyer et al., 2000). Many of these findings have 
since been reproduced in different species and in human lung fibroblast cells in vitro 
(Kakugawa et al., 2004; Nakayama et al., 2008; Oku et al., 2008; Conte et al., 2014). 
In a series of Japanese studies looking at the role of pirfenidone in IPF, patients in the 
treatment group exhibited better disease stability than those in the placebo arm (Taniguchi 
et al., 2010). Two multinational RCTs were subsequently reported in concert (Noble et al., 
2011). Both CAPACITY (Clinical Studies Assessing Pirfenidone in idiopathic pulmonary 
fibrosis: Research of Efficacy and Safety Outcomes) trials used the same primary end-point 
of change in percentage predicted forced vital capacity (FVC). Initial analysis suggested that 
patients in the pirfenidone group had a significantly lower decline in FVC in only one of the 
two studies (CAPACITY 004). In the second study, patients in the placebo group had a lower 
than expected rate of decline, which may account for the negative findings (CAPACITY 006). 
A recent Cochrane meta-analysis evaluated the progression-free survival data reported as 
secondary endpoints in all three trials. In this analysis, pirfenidone reduced the risk of 
disease progression by 30% (Spagnolo et al., 2010). 
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The US Food and Drug Administration ruled against pirfenidone approval in 2010. The 
ASCEND trial was then initiated (Assessment of Pirfenidone to Confirm Efficacy and Safety in 
Idiopathic Pulmonary Fibrosis) and randomised 555 IPF patients to receive either pirfenidone 
or placebo (King et al., 2014). In this study, the pirfenidone group had a better outcome with 
respect to the primary endpoint of change in FVC or death at week 52. This work adds to the 
body of evidence in favour of pirfenidone in selected cases of IPF, but the endpoints are of 
questionable clinical significance. The best study parameters have been described as those 
which measure how well patients feel, function or survive (Richeldi, 2013). To date, 
progression-free survival has not been properly validated as a marker of survival in IPF. 
The National Institute for Health and Care Excellence approved the use of pirfenidone in a 
specified subset of IPF patients and the FDA followed suit in 2014 (NICE, 2013b; U.S. Food 
and Drug Administration, 2014). 
Nintedanib 
Several other novel agents are currently under investigation for the treatment of IPF 
(Woodcock and Maher, 2014). Amongst these, the drug most likely to feature in clinical 
practice in the near future is nintedanib, a tyrosine kinase inhibitor. Nintedanib has 
inhibitory effects on platelet-derived growth factor receptors, fibroblast proliferation and 
fibroblast-myofibroblast transformation (Wollin et al., 2014). 
In the phase 2, double-blinded TOMORROW (To imprOve pulMOnaRy fibROsis With BIBF 
1120) study, nintedanib was compared with placebo in a total of 432 patients with IPF 
(Richeldi et al., 2011). The patients in the treatment arm received one of four escalating 
doses. Compared with placebo, the difference in the primary endpoint of change in FVC 
failed to reach statistical significance for any of the treatment arms; p=0.06 for the highest 
dose (150mg twice daily) group. Treatment with nintedanib was associated with improved 
quality-of-life scores and fewer acute exacerbations. 
Two replicate phase 3 trials of nintedanib have also been reported (Richeldi et al., 2014). The 
INPULSIS-I and -2 (Efficacy And Safety Of Nintedanib In Patients With Idiopathic Pulmonary 
Fibrosis) studies randomised a total of 1066 patients to nintedanib or placebo and recorded 
annual rate of decline in FVC as the primary endpoint. The patients in the treatment arms 
both had a significantly lower decline in FVC. In INPULSIS-2 alone, the patients in the 
treatment group had a longer time to first exacerbation and a lower decline in health-related 
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quality of life. There was no significant difference in survival but the treatment groups 
tended to better outcomes. The proportion of patients who died from any cause was 5.5% in 
the nintedanib group and 7.8% in the placebo group. Following publication of these data, 
nintedanib has been widely approved for clinical use in IPF (Raghu et al., 2015b). 
Since its recognition as a distinct disease entity, drug development in IPF has been slow. 
These recent publications represent modest progress in the field, but meaningful advances 
remain elusive. Significant improvements in treatment for IPF rely on an improved 
understanding of the factors driving the fibrotic process. 
1.1.5 Aetiopathogenesis 
IPF results in a morphology of lung disease known as usual interstitial pneumonia (UIP) 
which is characteristic and well described. In contrast the causative agents resulting in IPF 
are unknown and the cellular pathogenesis is not well understood. 
IPF was originally thought to be a disease of inflammation (Keogh and Crystal, 1982). 
Alveolitis was reported as a consistent feature of IPF lungs and was considered to provide a 
unifying pathogenic explanation for IPF and a range of other interstitial lung diseases 
(Carrington and Gaensler, 1978; Keogh and Crystal, 1982). After fibrotic foci became 
recognised in IPF, the evidence for alveolitis as the primary disorder came into question: 
inflammation is not a prominent finding in UIP and anti-inflammatory and 
immunosuppressive therapy fails to improve disease outcome (Selman et al., 2001). 
Genetic studies 
In 2001, Nogee et al reported the association of a mutation in SFPC, the gene encoding 
surfactant protein C, with interstitial lung disease in a mother and her child (Nogee et al., 
2001). Other groups have since identified mutations in SFPA2 (encoding surfactant protein 
A2) and further mutations in SFPC. These surfactant proteins are expressed solely by type 2 
alveolar epithelial cells (AECIIs).  
In 2007, two independent groups studying familial pulmonary fibrosis identified mutations in 
TERT (encoding telomerase reverse transcriptase) and TERC (encoding the RNA component 
of the telomerase complex). Telomerase repairs damage that occurs as telomeres are 
shortened with each round of mitosis. Interestingly, short telomeres have been 
demonstrated in AECIIs in a high proportion of individuals with sporadic IPF, suggesting a 
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role for telomerase dysfunction in non-familial forms of the disease. The link between IPF 
and telomerase dysfunction may help to explain why the disease is predominantly a disease 
of older people (Tsakiri et al., 2007). 
More recently, a whole genome linkage study of IPF identified a common polymorphism in 
the promoter of the mucin gene MUC5B (Seibold et al., 2011). This mutation was found in 
34% of cases of familial pulmonary fibrosis, 38% of cases of sporadic IPF and 9% of healthy 
controls.   
Alveolar epithelial cells in the pathogenesis of IPF 
A common theme amongst all the mutations identified to date is that they affect genes that 
are expressed in type 2 epithelial cells (e.g. SFPC, SFPA, MUC5B) or lead to identifiable 
changes within them (TERT, TERC)(Wolters et al., 2014). AECIIs make up 60% of all alveolar 
epithelial cells (Crapo et al., 1982). In addition to their role in surfactant production, they 
contribute to immune defences and fluid balance in the lung (Pison et al., 1994; Fehrenbach, 
2001). AECIIs have become a focus of research into IPF pathogenesis. 
Within all cells, the endoplasmic reticulum (ER) is the site of newly synthesised secretory and 
membrane proteins. After translation, proteins must be appropriately folded and modified 
before they can be transported. These processes rely on chaperone proteins and a 
conducive environment within the endoplasmic reticulum. If the functional capacity of the 
ER is overwhelmed, an unfolded protein response (UPR) is initiated in an attempt to restore 
homeostasis (Zhang and Kaufman, 2004). Markers of the UPR include over-expression of BiP 
(binding immunoglobulin protein, an ER-associated chaperone protein) and the transcription 
factor X-box-protein 1 (XBP-1). A persistent state of stress will result in apoptotic cell death, 
which is mediated by the signalling proteins CHOP and ATF-6 (Zhang and Kaufman, 2004).  
The SP-C mutation originally described by Nogee results in a failure of normal truncation of 
surfactant, prior to its release from the ER (Beers et al., 1998). In a human lung epithelial cell 
line, SFPC mutations led to increased expression of BiP and XBP-1. Cells expressing mutant 
SFPC also had increased activation of caspase-4, an ER-specific caspase that triggers 
apoptosis in the setting of overwhelming ER stress (Mulugeta et al., 2005). Expression of 
these markers of ER stress has subsequently been demonstrated in AECIIs in both familial 
and sporadic IPF (Lawson et al., 2008). Furthermore, in stained sections of IPF lungs, 70-80% 
of AECIIs demonstrated ongoing signs of apoptosis (Korfei et al., 2008). 
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TGF-β activation 
Transforming growth factor β (TGF-β) is a highly conserved, pro-fibrotic cytokine. It is 
released in an inactive form, bound to the latency-associated peptide (LAP) and latent TGF-
β-binding proteins. Levels of active TGF-β are increased in IPF (Krein and Winston, 2002). 
As lung fibrosis develops, AECs express increased levels of the integrin αvβ6, which can bind 
to LAP and activate TGF-β (Munger et al., 1999; Jenkins et al., 2006; Horan et al., 2008). 
Active TGF-β does not appear to be released in a soluble form, so the resultant signalling is 
localised within the lung. Given the spatial heterogeneity of usual interstitial pneumonia, this 
property makes for an attractive pathogenic candidate in IPF. Possible pro-fibrotic processes 
associated with TGF-β activation include differentiation of fibroblasts to myofibroblasts and 
activation of programming that promotes mesenchymal transition of epithelial cells (Kim et 
al., 2006; Scotton and Chambers, 2007). 
Epithelial to mesenchymal transition 
Epithelial cells are derived from the embryological endoderm. They are anchored on a 
basement membrane and have a polarity, with basal and apical surfaces contributing to 
function. Mesenchymal cells originate in the embryological mesoderm. Mesenchymal tissue 
is characterised by loosely associated cells surrounded by an extracellular matrix. They lack 
polarity and can migrate easily (Kalluri and Neilson, 2003; Lee et al., 2006). 
Epithelial-mesenchymal transition (EMT) is a process by which epithelial cells 
transdifferentiate into mesenchymal stem cells. EMT is not required for normal tissue 
haemostasis but it does play a role in normal development and wound healing. In disease, 
EMT can result in fibrosis and malignancy. 
In IPF lungs, immunohistochemical and RNA quantitation techniques have been used to 
demonstrate co-localisation of proteins associated with epithelial and mesenchymal cells. 
Thyroid transcription factor 1 and pro-surfactant protein B (AECII markers) were seen in 
association with α-smooth muscle actin (a mesenchymal protein) in the majority of AECs in 
IPF lungs; there was no co-localisation in normal lungs (Willis et al., 2005; Marmai et al., 
2011). 
Despite these reports, the role of EMT in IPF remains unproven. It is not clear whether 
epithelial cells acquire sufficient mesenchymal characteristics that they can be classified as 
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fibroblasts (Kage and Borok, 2012). It is also possible that cells undergo mesenchymal-to-
epithelial transition. This alternative process of transformation may also give rise to similar 
patterns of co-localisation (Li et al., 2010). 
From epithelial cell injury to fibrosis 
The existence of fibroblastic foci in the IPF lung indicates a potential, much needed and 
logical pathophysiological mechanism in the aetiology of IPF. It also emphasises the 
significance of the lung epithelium. The links between genetic predisposition, epithelial cell 
injury, ER stress and fibrosis remain unclear. In mice, lung fibrosis can be induced using 
bleomycin, an antibiotic and chemotherapeutic produced by Streptomyces verticillus. This 
model has been used extensively in IPF research but does not correlate perfectly with 
human pathogenesis. Pulmonary fibrosis develops in the bleomycin mouse model over 
weeks and months rather than years, as is the case in humans (Wolters et al., 2014). In 
addition, the pattern of disease that is induced is airway-centric, in contrast to the sub-
pleural predominance seen in the IPF lung (Baron et al., 2012). 
Mutated forms of surfactant proteins A and C have been associated with up-regulation of 
the unfolded protein response and EMT in murine models (Bridges et al., 2006; Lawson et 
al., 2011; Tanjore et al., 2011). Increased levels of active TGFβ have also been demonstrated 
(Maitra et al., 2012). Furthermore, there is some evidence that ER stress can result in EMT 
(Zhong et al., 2011). 
Whilst these links between genetic predisposition and EMT are intriguing, the end result of 
fibrosis has yet to be demonstrated in the mouse model. This may relate to the short murine 
life span but alternatively, it may indicate a role for external factors in the pathogenesis of 
IPF (Wolters et al., 2014). Indeed, the fibrotic response to bleomycin was accentuated in 
mice in which ER stress had been induced (Lawson et al., 2011). Similarly, the effect of 
herpes virus infection was more pronounced in aged mice, in which ER stress would be 
induced more easily (Sueblinvong et al., 2012). 
Additional mechanisms have been proposed to explain how the initiation and propagation of 
fibrosis in IPF relate to the interaction between the epithelial cells and the mesenchyme. 
TGFβ, released by epithelial cells, can signal to fibroblasts and convert them to αSMA-
producing myofibroblasts (Xu et al., 2003). AECs also produce higher than normal levels of 
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the cytokine platelet-derived growth factor (PDGF) in IPF (Bergeron et al., 2003). PDGF has 
been shown to promote fibroblast proliferation (Hetzel et al., 2005).   
The dysregulated IPF epithelium may also play a role in cellular recruitment from the 
circulation. Fibrocytes are a unique population of blood-borne cells that display a specific 
cell-surface phenotype. They are thought to migrate to tissues to support wound healing and 
fibrotic tissue repair (Quan et al., 2006). Alveolar epithelial cells express ligands with 
corresponding receptors on fibrocytes, the levels of which are increased in IPF lungs 
(Mehrad et al., 2007; Andersson-Sjoland et al., 2008; Strieter et al., 2009). 
Wnt proteins are also over-expressed in IPF lungs. These soluble glycoproteins are produced 
by epithelial cells and deposited locally in an insoluble form after release (Nusse, 2003). A 
series of studies led to the identification of Wnt3a as a stimulator of type I collagen 
production (Wolters et al., 2014). The related downstream signalling molecule has been 
localised in nuclei of fibroblastic foci (Chilosi et al., 2003; Kim et al., 2009). 
Several other lines of investigation are currently underway. The matrix in IPF is grossly 
modified and it has been shown that the increased stiffness may contribute to increased 
levels of pro-fibrotic cytokines, with the potential for a feed-forward auto-amplified loop 
mediated by αSMA and COX2 expression (Liu et al., 2010; Booth et al., 2012; Marinkovic et 
al., 2012). There are also numerous parallels between the pathogenicity of IPF and cancer, 
with CD44 and hyaluronan synthase proposed as mediators of the invasive activated 
myofibroblast phenotype seen in IPF (Li et al., 2011). Lastly, a number of recent epigenetic 
studies may help to explain the durable phenotypic changes seen in IPF lungs (Pandit et al., 
2010; Rabinovich et al., 2012).  
In summary, some important observations regarding the pathogenesis of IPF have been 
made. The role of the alveolar epithelial cells and the complex interactions between AECIIs 
and the mesenchymal cells are better understood but the relative importance of the various 
molecular mechanisms remains unclear. The current paradigm holds that in a susceptible 
individual, a series of subclinical insults damages the alveoli over time. An aberrant repair 
response, with excess matrix deposition and architectural remodelling, gives rise to the 
typical clinical, radiological and pathological features (Selman et al., 2001; Murray and 
Nadel, 2005). 
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Much of the current research in IPF is aimed at modifying this aberrant response within the 
lungs. Relatively little work has been done to identify the factors responsible for the initial 
damage. 
Aetiological factors 
The role of several environmental agents has been explored. Cigarette smoking is associated 
with the development of IPF. In one study the odds ratio for ever smoking was 1.6 (95% CI: 
1.1 to 2.4) but no clear exposure-response pattern has been demonstrated (Baumgartner et 
al., 1997). Epidemiological data also suggests an increased odds ratios for developing IPF 
after exposure to birds, livestock and several dusts (Kottmann et al., 2009). Viruses have also 
been implicated in the pathogenesis of IPF, including Epstein-Barr virus, human herpes 
viruses 7 and 8 and cytomegalovirus (Yonemaru et al., 1997; Tang et al., 2003). To date, no 
causative role has been demonstrated for any of these agents. 
Over the last forty years a body of evidence has emerged in support of an association 
between IPF and gastro-oesophageal reflux disease (GORD). Whilst the data to support a 
contributory role for GORD remains at an early stage, evidence for the link between the two 
conditions is increasingly persuasive (section 1.3). GORD is common and amenable to 
treatment and as a result, it has been identified as a research priority in IPF (NICE, 2013a). 
The following sections cover the assessment and treatment of gastro-oesophageal reflux and 
aspiration, and explore the link that has been suggested between these conditions and IPF. 
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1.2 Gastro-oesophageal reflux and aspiration 
Aspiration occurs when oesophageal or oropharyngeal contents penetrate the larynx and 
then cross the glottis into the trachea, Figure 1-2. Aspiration from the oesophagus is the 
result of gastro-oesophageal reflux of material originating from the stomach and/or 
duodenum. The possibility that reflux might contribute to the pathogenesis of interstitial 
lung disease has been considered for over forty years (Pearson and Wilson, 1971). 
Figure 1-2. Schematic anatomy of the mouth, pharynx and upper aerodigestive tracts. Adapted from Cranial 
Nerves, 3rd edition. (Reproduced from (Pauwells et al., 1998)). 
 
1.2.1 Gastro-oesophageal reflux disease 
Gastro-oesophageal reflux disease (GORD) is defined as reflux that causes troublesome 
symptoms, mucosal injury in the oesophagus, or both (Vakil et al., 2006). It is one of the 
commonest triggers for medical consultation in the developed world and its treatment 
accounts for the biggest single drug expenditure in the NHS.  Prevalence estimates vary 
widely due to differing disease definitions, but the best estimates lie between 10 and 20% in 
the developed world (Dent et al., 2005; El-Serag et al., 2009). 
The cardinal symptoms of GORD are heartburn and regurgitation. Heartburn is generally 
described as a burning retrosternal pain. It is the result of distal oesophageal acid exposure 
(Bredenoord et al., 2013). Regurgitation is defined as the backflow of gastric contents into 
the mouth, often with an acidic or bitter taste. Volume regurgitation, vomiting and 
dysphagia may also be experienced. Symptoms of extra-oesophageal reflux can arise from 
laryngopharyngeal reflux (LPR) or microaspiration. Voice change, pharyngitis, dental decay 
and chronic cough can all occur. In a large cohort study of reflux oesophagitis, elderly 
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patients had less typical and more-nonspecific symptoms than younger groups (Pilotto et al., 
2006). 
Accurate diagnosis can be challenging, as a significant proportion of symptomatic cases are 
associated with a normal endoscopy, a condition described as non-erosive reflux disease. 
Conversely, up to 20% of patients with endoscopic oesophagitis and/or Barrett’s oesophagus 
never experience heartburn (Sloan et al., 1992).  Over the years, the concept of the disease 
has evolved in light of emerging diagnostic tools, each with their own strengths and 
limitations (Table 1-2). 
Table 1-2. Evolving techniques with which GORD has been investigated 
Era Modality of investigation Abnormality identified Limitation 
1940s- Plain radiography Hiatus hernia GORD can occur without 
hiatus hernia; hiatus hernia 
can exist without GORD 
1960s- Upper gastro-intestinal 
endoscopy 
Mucosal inflammation and 
disruption 
Non-erosive reflux disease 
not detected 
1970s- Ambulatory pH monitoring Supranormal distal 
oesophageal acid exposure 
Non-acid and weakly acid 
refluxate not detected 
 
The antireflux barrier 
Retrograde flow of gastric contents into the oesophagus is a physiological event that helps to 
vent the stomach. The symptoms and signs of GORD can occur when the frequency or 
volume of reflux is excessive, or the oesophageal mucosa is hypersensitive or frankly injured. 
The balance of factors that predispose to or protect against reflux are essentially 
mechanical. On the one hand the oesophagus is largely exposed to the negative pressure of 
the chest, whilst the stomach is normally exposed to the positive pressure of the abdomen. 
This is the only site within the gastrointestinal tract where a segment of the gut is in 
continuity with a distal region at higher pressure. Continuous gastro-oesophageal reflux is 
prevented by the structure and function of the gastro-oesophageal junction and the 
diaphragm. In addition, peristalsis is a barrier as it returns refluxate to the stomach. 
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Extra-oesophageal factors 
The diaphragmatic crura are tendinous structures that attach inferiorly to the anterior 
aspect of the vertebral column. The right crus forms a sling that surrounds the distal 
oesophagus, creating a teardrop-shaped canal known as the oesophageal hiatus. This 
structure serves as an extrinsic sphincter. 
In normal anatomy, the terminal oesophagus and the proximal stomach are orientated at an 
acute angle (Figure 1-3). This configuration is jointly maintained by the orientation of certain 
fibres within the wall of the stomach and also by the phreno-oesophageal ligament, running 
between the under-surface of the diaphragm and the oesophagus (Atkinson and Sumerling, 
1959; Bombeck et al., 1966). 
As a result, the terminal portion of the oesophagus is intra-abdominal. Pressure spikes are 
therefore transmitted to the oesophageal lumen, preventing a net gastro-oesophageal 
pressure gradient and protecting against reflux. In addition, the angle between the 
oesophagus and stomach creates a flap-valve mechanism that also prevents reflux (Figure 
1-3). 
Figure 1-3. The gastro-oesophageal junction. Left: 3D reconstruction, illustrating the intra-abdominal portion 
of the terminal oesophagus and its acute angle of entry into the stomach. An endoscope is seen in the 
retroflexed position. Right: Endoscopic view in retroflexion. Taken from Hill et al. (1996). 
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Lower-oesophageal sphincter 
In addition to the external elements, there is a length of tonically contracted circular muscle 
within the terminal oesophagus that acts as an intrinsic barrier to reflux. Although the lower 
oesophageal sphincter cannot be defined anatomically, manometry reveals a high-pressure 
zone of around 1-4cm that behaves as a physiological sphincter (Fox and Bredenoord, 2008). 
Relaxation is observed with swallowing and a hypertonic response is seen due to abdominal 
compression (bending, straining, coughing) or a drop in intrathoracic pressure (deep 
inspiration, sniffing)(Bredenoord et al., 2013).  With the development of oesophageal 
manometry, the concept of a Transient Lower Oesophageal Sphincter Relaxation (TLOSRs) 
was introduced (Mittal et al., 1995).  The resting tone of the crural diaphragm is inhibited 
due to a vagally mediated reflex triggered by gastric distension (Mittal and Fisher, 1990). 
TLOSRs serve to vent gas from the stomach.  
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Pathophysiology of GORD 
The pathogenesis of GORD relates to the thoraco-abdominal pressure gradient and the 
constituents of the antireflux barrier. 
With respect to the lower oesophageal sphincter, TLOSRs represent the most important 
cause of reflux. In healthy individuals, physiological reflux occurs almost exclusively as the 
result of TLOSRs, rather than from defective basal LOS pressure (Dent et al., 1980). In 
subjects with GORD, spontaneous reflux across a hypotonic LOS accounts for a greater 
proportion of reflux events, but TLOSRs remain the dominant mechanism (Dent et al., 1988).  
Historically, the presence of a hiatus hernia was regarded as crucial to the pathogenesis of 
GORD. It is now understood that the majority of patients with a hiatus hernia are 
asymptomatic(Kahrilas et al., 1999). This may be explained by the action of a strong layer of 
endo-abdominal fascia known as the phreno-oesophageal ligament (Cohen and Harris, 
1971). Whilst a portion of the stomach can be seen above the diaphragm on an x-ray, its 
encasement within this layer maintains the pressure gradient across the gastro-oesophageal 
junction. 
The presence of a hiatus hernia is, nonetheless, a significant risk factor for GORD. As more of 
the stomach moves up into the chest, the flap-valve mechanism is lost. The length of the 
sphincter exposed to intra-abdominal pressure is also significant: DeMeester demonstrated 
that a low basal LOS pressure and/or a short intra-abdominal sphincter length resulted in a 
90% incidence of abnormal GOR (Joelsson et al., 1982). 
Post-prandially, an unbuffered “acid pocket” may be demonstrated within the proximal 
stomach, sitting above the meal (Beaumont et al., 2010). This results from the absence of 
peristaltic contractions in the proximal stomach. In the presence of a hiatus hernia, this 
acidic reservoir sits above the diaphragmatic crura, ready to reflux back into the oesophagus. 
Above the gastro-oesophageal junction, dysfunction of the oesophageal body may also 
predispose to GORD. Prolonged acid clearance correlates with both the severity of 
oesophagitis and the presence of Barrett’s metaplasia (Gillen et al., 1987; Singh et al., 1992). 
Failed peristalsis and hypotensive contractions can both result in incomplete oesophageal 
emptying and prolonged mucosal exposure to refluxate (Kahrilas et al., 1988). Any condition 
that chronically increases intra-abdominal pressure will also amplify GOR. Pregnancy is a 
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physiological example. The association of obesity has also been proven (Derakhshan et al., 
2012). 
Diagnosis of GORD 
Given that gastro-oesophageal reflux (GOR) is a physiological occurrence, it is not surprising 
that many people regard the milder symptoms of GORD as normal. Self–medication with 
over-the-counter treatments is common. For those patients who present to primary care 
with symptoms that respond to acid-suppressive medications, no further tests are required. 
Patients who present with “alarm” symptoms such as dysphagia, weight loss and 
haematemesis require investigation with flexible upper gastro-intestinal video-endoscopy. 
The test serves to rule out alternative pathology such as infection, eosinophilic oesophagitis 
and malignancy and also to identify oesophagitis and metaplastic change. 
Ambulatory monitoring 
GORD is routinely diagnosed using 24-hour oesophageal pH monitoring. Stationary 
oesophageal manometry is used to accurately locate the lower oesophageal sphincter and 
the pH probe is then inserted. The number and duration of pH drops are recorded using an 
electronic recording box and compared with values recorded from studies of healthy 
volunteers (Zerbib et al., 2005). The patient is asked to record symptom episodes by button-
press so that symptom-event correlation may be calculated. 
The major limitation of stand-alone pH monitoring is that weakly acid and non-acid reflux 
are missed. The solution to this problem came in the form of combined pH-impedance 
monitoring. The addition of 8 metal rings to the catheter allows measurement of the 
electrical resistance across 6 oesophageal segments. The resting impedance is that of the 
oesophageal mucosa and the passage of liquid and gas can be detected based on their 
impedance properties, Figure 1-4. In this way, the timing and proximal extent of any 
refluxate may be recorded be it acid, weakly acid or non-acid. 
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Figure 1-4. The configuration of impedance and pH catheters within an intraluminal probe. The impedance 
drop illustrated is first detected distally before ascending to the most proximal channel. The pH trace, 
measured 5cm proximal to the LOS, remains above 4. This recording therefore demonstrates proximal, 
weakly acid reflux. [Oesophageal schematic taken from software licensed to MMS International (Enschede, 
The Netherlands)].  
 
 
1.2.2 Treatment of GORD 
The treatment of GORD may be thought of as a ladder, ranging from lifestyle modifications 
through to surgery. 
Lifestyle  
Due to the mechanical nature of GORD, simple measures to address thoraco-abdominal 
pressure imbalance are often effective. Weight loss and the avoidance of tight clothing are 
advised as appropriate. Late meals should be avoided as oesophagogastric peristalsis is 
diminished overnight and the antireflux effect of gravity is also lost. For patients affected by 
nocturnal symptoms, elevating the head of the bed may help. Smoking and excessive alcohol 
consumption are associated with an increased risk of GORD but there is no evidence that 
cessation is helpful in controlling symptoms (Nilsson et al., 2004; Kaltenbach et al., 2006). 
Antireflux diets have been marketed but there is no strong evidence to support their use. 
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Pharmacological 
Non-prescription treatments for GORD include simple antacids (e.g. Rennies) and alginate 
raft therapies (e.g. Gaviscon). Simple antacids work to buffer gastric acid, whilst raft 
therapies are designed to form a layer on top of gastric contents and provide a mechanical 
barrier to reflux. They may also protect the mucus and cells in the oesophagus (Mandel et 
al., 2000) . 
Acid-suppression therapies provide effective relief from GORD in the majority of patients. 
The introduction of histamine type 2 receptor blockers (H2RBs) in the 1970s revolutionised 
the treatment of duodenal ulcer disease, but are less effective for GORD. Proton-pump 
inhibitors (e.g. Omeprazole) were introduced into clinical practice in the late 1980s and are 
far more effective for both symptom control and for the healing of oesophagitis. A 
proportion of patients have symptoms refractory to maximum dose PPI, commonly those 
with worse oesophagitis (Hetzel et al., 1988). Despite initial treatment success, some 
patients will go on to develop breakthrough symptoms, often requiring higher doses to 
maintain symptom control. Inadequate acid suppression or the injurious effects of non-acid 
components may be responsible (Kauer et al., 1995). 
Prokinetics are often used in the treatment of GORD, albeit in the absence of robust clinical 
evidence. Cisapride, which accelerates oesophagogastric emptying through increased 
acetylcholine release, was proven to be effective as a treatment for GORD (McCallum et al., 
1988). Concerns regarding its cardiac safety profile have since led to its withdrawal in the UK 
and elsewhere (Committee on Safety of Medicines, 2000). Domperidone is an 
antidopaminergic prokinetic that is also used in GORD, but there is limited evidence to 
support its use (Halter et al., 1997; Veldhuyzen van Zanten et al., 2001). 
Surgery 
Patients with volume reflux and symptoms refractory to maximal medical therapy may be 
considered for antireflux surgery. Those reluctant to use PPI therapy lifelong will also be 
considered by some surgeons. The majority of procedures are now undertaken 
laparoscopically as faster recovery times and lower rates of incisional hernia have been 
demonstrated (Peters et al., 2009). 
The original antireflux procedure was described in 1956 by Rudolf Nissen and the principles 
he set out are still respected today (Nissen, 1956). The gastric fundus is mobilised and 
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wrapped around the gastro-oesophageal junction so as to tighten it and anchor it within the 
abdomen. In a randomised controlled trial in which 372 patients were followed up for five 
years, the remission rates for laparoscopic antireflux surgery and esomeprazole PPI 
treatment were equivalent. By the end of the study period, acid regurgitation was more 
common in the PPI cohort and dysphagia, bloating and flatulence were more common in the 
fundoplication group (Galmiche et al., 2011). 
The operation that Nissen originally described is a 360o posterior fundoplication but tailored 
wraps have also been used in an attempt to reduce the risk of dysphagia and gas-related 
symptoms. Over the last five years, several meta-analyses have compared the outcomes of 
anterior partial, posterior partial and total fundoplication. The results are conflicting. Partial 
fundoplication may carry a lesser risk of side-effects but the relative treatment efficacy 
remains unclear (Ramos et al., 2011; Ma et al., 2012; Broeders et al., 2013). 
Novel techniques 
A range of innovative techniques has been developed for the treatment of GORD. 
Endoscopic options include suturing devices, transmural staplers, and radiofrequency 
ablation. Surgical developments include the placement of a flexible band of magnetic beads 
and implantation of an electrical stimulator. Initial studies of the surgical techniques have 
demonstrated encouraging results but high quality trials with extended follow-up will be 
required before uptake is more widespread (Bonavina et al., 2010; Rodriguez et al., 2012).  
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1.3 The association of reflux and IPF 
Reflux and aspiration have been recognised as precipitants of acute lung injury since early in 
the 20th century but the relevance to chronic lung disease has only been recognised more 
recently (Mendelson, 1946). In 1971, Pearson reported six cases of chronic pulmonary 
fibrosis within a series of 143 patients with hiatus hernia (Pearson and Wilson, 1971).  Mays 
later reported that 26 of 48 patients with idiopathic fibrosis had fluoroscopic evidence of 
pathological gastro-oesophageal reflux, in comparison with 23 of 270 age-matched controls 
(Mays et al., 1976).  
El-Serag referred to endoscopic records to provide more robust evidence of the association: 
in an analysis of population data, the odds ratio for pulmonary fibrosis in 100,000 patients 
with erosive oesophagitis was 1.36 (95% C.I. 1.25-1.48 )(El-Serag and Sonnenberg, 1997). 
In a retrospective study, the spatial and temporal patterns of fibrosis were analysed in a 
group of patients with IPF. A group of 32 patients was found to have asymmetrical disease 
across the right and left lungs. When compared to a control group with more symmetrical 
disease, these individuals had high levels of GOR and numerous acute exacerbations. The 
authors concluded that asymmetrical IPF may be related to locoregional factors including 
reflux (Tcherakian et al., 2011). 
Tobin made the first use of ambulatory pH monitoring to compare the rate of GOR in IPF and 
other interstitial lung diseases (Tobin et al., 1998). This important study reported that 16 of 
17 patients with IPF had abnormal distal and/or proximal acid exposure compared with four 
of eight controls. Significantly, only four of the IPF patients with GORD had typical reflux 
symptoms such as reflux and heartburn. This finding has been reproduced consistently in 
subsequent studies (Raghu et al., 2006a). In addition, Tobin’s report demonstrated proximal 
supine reflux to be commonplace. This may have clinical relevance as the resting upper 
oesophageal sphincter pressure is lower at night, so transit of refluxate into the oropharynx 
would occur more easily (Kahrilas et al., 1987). The significance of the findings was limited 
by the sample size and the technique used to site the pH probe; the lower oesophageal 
sphincter was identified according to the increase in pH from the stomach to the 
oesophagus. In cases of hiatus hernia, this technique can be unreliable (Mattox et al., 1992). 
More recent ambulatory pH studies have made use of oesophageal manometry, improving 
localisation of the lower oesophageal sphincter and providing data on oesophageal motility 
(Savarino et al., 2013).  
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Only two of these studies included comparison groups. Raghu et al studied 133 asthmatics 
with symptoms of reflux and Soares included 28 connective tissue disease-related ILD 
patients (Raghu et al., 2006a; Soares et al., 2011).  There was objective evidence of GORD in 
68% and 82% of these groups, respectively. 
More recently, the concentration of gastroduodenal biomarkers have been analysed in BAL 
samples in an attempt to quantify microaspiration. The stomach contains a mixture of 
substances including food, acid and bile salts. The physiological origin of these potential 
aspirates is illustrated in Figure 1-5. 
Figure 1-5. Schematic diagram to illustrate the anatomy of duodeno-gastric and gastro-oesophageal reflux 
(Modified from (UPMC, 2015)) 
 
 
In one study, 40 IPF patients had more gastro-oesophageal reflux and higher levels of BAL 
pepsin and bile salts than non-IPF ILD patients and healthy volunteers. Specific 
methodological issues limit the significance of these findings. Bile salts were measured using 
a commercially available spectrophotometric assay, for which the quoted lower detection 
limit was significantly higher than the bile salt concentrations reported in the paper 
(Savarino et al., 2013). 
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In another recent publication, BAL pepsin concentrations were measured with a 
commercially available ELISA and correlated with clinical follow-up data in 54 IPF patients. 
The measured pepsin levels in the patients who suffered acute exacerbations during the 
study period were significantly higher than the levels seen in the stable group (Lee et al., 
2012).  
Cause and effect in reflux and fibrosis 
The studies discussed above provide preliminary evidence of an association between GOR 
and IPF, but the nature of the relationship remains unclear. GOR may contribute to IPF, but 
the possibility that fibrosis causes GORD in people with IPF must also be considered. There 
are several mechanisms that could account for this latter relationship: More negative intra-
thoracic pressures are required for inspiration in fibrotic lungs and this amplifies the normal 
gastro-oesophageal pressure gradient. Significant intra-thoracic fibrosis may contribute to 
the oesophageal dysmotility seen in IPF.  This would result in slower oesophageal bolus 
clearance and prolonged oesophageal volume exposure, in turn worsening reflux symptoms 
and ambulatory pH results. Finally, lung fibrosis may disrupt the relationship of the crural 
diaphragm and the lower oesophageal sphincter, weakening the antireflux barrier. 
Given the mechanical nature of these effects it may be assumed that more advanced fibrosis 
would be associated with more severe reflux. Such a link has never been demonstrated. 
Noth studied the link between hiatus hernia and IPF using multidetector CT scanning (Noth 
et al.). The study population included 100 patients with IPF, in whom hiatus hernia was 
identified more commonly than in control patients. There was no correlation between hiatus 
hernia and disease severity, as assessed by lung function tests. 
In an important study describing the link between anti-reflux therapy and IPF survival 
outcomes, Lee et al also considered radiological disease severity and physiological measures 
of thoracic restriction (Lee et al., 2011). GOR medication use was associated with less 
radiologic fibrosis and there was no correlation between GOR medication use and thoracic 
restriction. 
Lastly, studies of ambulatory pH monitoring have failed to correlate IPF disease severity with 
objective evidence of reflux (Tobin et al., 1998; Patti et al., 2005; Raghu et al., 2006a). 
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The results of these studies are contrary to the hypothesis that pulmonary fibrosis and 
mediastinal distortion significantly exacerbate gastro-oesophageal reflux but the evidence is 
scarce and indirect. Further study is required to clarify this issue. 
Experimental models of microaspiration 
The link between gastro-oesophageal reflux, aspiration and lung disease has also been 
explored through animal models and in vitro. Early work originated in anaesthetics with the 
observation that single large-volume aspiration events were associated with significant 
mortality (Mendelson, 1946). Early studies outlined the acute phase pathophysiology 
observed in aspiration pneumonitis: in small and medium-size animal models, intra-tracheal 
instillation of large volumes of acidic gastric juice resulted in endothelial cell damage, 
increased capillary permeability, and scattered intra-alveolar haemorrhage (Teabeaut, 1952; 
Greenfield et al., 1969). Several hours later, an acute inflammatory response follows, 
comprised primarily of alveolar neutrophils and macrophages. These observations provide a 
useful blueprint as to the effects of gastric aspiration into the lungs, but the volumes instilled 
limit their relevance to chronic microaspiration. 
In a pig model, Popper et al described the longer term effects of aspiration in addition to the 
administration of putative treatments (Popper et al., 1986). Twelve pigs had gastric juice 
instilled into the right main bronchus and a further nine were given either hydrochloric acid, 
pepsin (either dissolved or neutralised) or bicarbonate-buffered gastric juice. In the 
“experimental” arm of the study, a further 25 animals were treated with acid suppression 
therapy, antacids or kallikrein inhibitor before or after gastric juice aspiration. 
The initial insult involved necrosis of pneumocytes and bronchial epithelial cells. 
Inflammation was propagated via the complement cascade and arachidonic acid 
metabolites. Macrophages predominated in the early cell response and later, fibroblasts and 
myofibroblasts were seen. The neutralisation of gastric juice did not prevent the 
development of lung fibrosis and aspiration of both hydrochloric acid and pepsin also 
resulted in lung fibrosis. Consistent with the findings of a previous experiment in dogs 
(Schwartz et al., 1980), the work by Popper was one of the earliest reports to suggest that 
acidity may not be critical to the lung damage observed in aspiration syndromes. The same 
conclusion has been reached in studies employing models of chronic aspiration and 
alloimmunity (Hartwig et al., 2006; Downing et al., 2008). 
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The link with aspiration has been supported by the findings of more recent studies. Amigoni 
et al developed a low mortality mouse model in which repeated small volume aspirates 
resulted in scar formation that was histologically evident at 2 weeks post injury (Amigoni et 
al., 2008).  More recently, Samareh Fekri et al used another mouse model to demonstrate 
that repetitive acid aspiration resulted in an increase in TGF-β1 in the bronchoalveolar 
lavage fluid, with associated increases in fibronectin and type III and IV collagen (Samareh 
Fekri et al., 2014). 
The mechanisms driving this fibrosis were partially elucidated by Appel et al (2007). 48 rats 
underwent weekly instillation of either gastric juice or normal saline for up to 16 weeks. In 
this study, gastric juice resulted in giant cells, fibrosis and lymphocytic bronchiolitis. There 
were higher macrophage and T cell concentrations, an increased CD4:CD8 T cell ratio and 
higher concentrations of IL-1α, IL-1β, IL-2, TNFα and TGFβ, suggesting a TH1 cytokine-
dominated profile. The authors propose that the resultant lymphocyte trafficking and 
activation could make for an inflammatory milieu, with the individual’s response influencing 
the phenotypic response in the lung. Most patients would respond with a normal reparative 
response whereas others may be more prone to persistent fibrosis. 
Interestingly, the inflammatory responses reported in these animal models appear to be 
largely localised to the affected lungs. Downing et al subjected rats to weekly aspiration of 
isolated components of gastric juice or normal saline (Downing et al., 2008). In addition to 
histological evaluation, serum cytokine analysis was reported, which suggested that the 
effects of aspiration in the model were localised. 
A number of studies have been designed to clarify the effect of specific components of 
gastric juice. Particulate food matter has consistently been shown to be harmful and is 
generally associated with an intense granulomatous response. The earliest animal studies 
concluded that the acidity of gastric juice is a significant factor but more recent studies 
provide compelling evidence that the effects of gastric juice aspiration are acid-independent. 
Pepsin, even in isolation, appears harmful; a recent report of a rat model of chronic 
aspiration suggested that pepsin aspiration resulted in more marked inflammation and 
fibrosis than comparable quantities of gastric juice or hydrochloric acid but these findings 
have not been widely replicated. The available data on the role of bile acids from rodent 
models of aspiration is also conflicting. Some investigators have reported a toxicity profile 
that exceeds comparable quantities of gastric juice and provided early descriptions of the 
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cytokine pathways that may be responsible (Porembka et al., 1993; Su et al., 2013), whilst 
others report a pulmonary response equivalent to the aspiration of normal saline (Downing 
et al., 2008). 
In a canine model, use of a balloon-catheter to induce upper airways obstruction 
demonstrated a significant positive correlation between negative intrathoracic pressures 
and acid reflux (Boesch et al., 2005). This small study (n=4) may provide evidence as to how 
long-term pressure changes affect gastric aspiration. 
Perhaps the most likely explanation to account for these various strands of evidence is that 
reflux and fibrosis may both contribute to each other (Brownlee et al., 2010). Ultimately, 
clinical trials of the effectiveness of antireflux therapy in IPF are required. 
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1.3.1 Pharmacological treatment of GORD in IPF 
Published data on the treatment of GORD in IPF come from retrospective studies reporting 
on heterogeneous patient groups. To date, two have focused on the medical management of 
reflux disease. 
In 2006, Raghu reported a series of four patients with IPF who declined conventional medical 
therapy with steroids or immunomodulation (Raghu et al., 2006c). Beyond home oxygen, the 
only treatment was directed at acid suppression: all patients were treated with proton pump 
inhibitors and one with fundoplication in addition. In contrast to the intractable decline in 
lung function normally seen in the disease, these patients demonstrated either stabilisation 
or improvement of their pulmonary function tests. The patients were followed up for a 
mean of 55 months, during which time no acute exacerbations were suffered and no specific 
treatment for respiratory problems was required. The significance of these results is clearly 
limited by the sample size. In addition, oxygen therapy is now recognised as an effective 
treatment adjunct in IPF (Morrison and Stovall, 1992; Raghu et al., 2011). 
Lee et al reported a retrospective review of 204 IPF patients that sought to assess the impact 
of antireflux therapy (Lee et al., 2011). Use of antireflux medication was independently 
associated with lower radiological fibrosis scores and longer survival. The retrospective, 
uncontrolled design of the study precludes any formal comparison between the two groups. 
In addition, the use of acid-suppressive medication does not exclude gastro-oesophageal 
reflux; a significant proportion of patients with IPF have abnormal GOR despite taking PPI 
(Raghu et al., 2006a). 
Recently, the effect of high dose acid-suppression therapy on cough was studied in a small 
group of IPF patients (n=14) (Kilduff et al., 2014). After eight weeks, there was a significant 
decrease in the number of acid reflux events but no change in cough frequency, as measured 
with a 24-hour cough monitor. Interestingly, non-acid reflux events increased (p=0.01). 
One of the most challenging aspects of this area of clinical management is that PPIs and H2 
receptor blockers (H2RBs) can only increase the pH of refluxate (Vela et al., 2001; Hemmink 
et al., 2008). The frequency of reflux events is unaffected and it is unclear whether the 
volume of refluxate is reduced. It is possible that reducing the volume of gastro-oesophageal 
refluxate may serve to concentrate non-acid components, resulting in a more injurious 
microaspiration. 
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1.3.2 The role of antireflux surgery in IPF 
Effective gastro-oesophageal reflux therapy requires a mechanical barrier and the only 
proven technique to date is antireflux surgery. Such intervention requires general 
anaesthesia and mechanical ventilation for the duration of the procedure. People with IPF 
have impaired respiratory function and, often, significant comorbidity. Relatively few are 
good surgical candidates. In a disease as rare as IPF, these factors make the design of 
research studies challenging. 
Nadrous et al reported the first study of fundoplication in interstitial lung disease in abstract 
form in 2003. Of the 15 patients included, 13 had IPF and their outcomes were mixed. Five 
patients had follow-up data available. Pulmonary function tests suggested that two 
stabilised and three deteriorated. 
Linden et al reported on 14 IPF patients awaiting lung transplantation, in whom 
fundoplication resulted in a significant stabilisation in oxygen requirement when compared 
with 31 non-fundoplicated IPF controls (Linden et al., 2006). No significant differences in 
pulmonary function or 6-minute-walk tests were observed. 
More recently, Hoppo reported an experience of 43 end-stage lung disease patients 
(including 14 with IPF) undergoing antireflux surgery before or after lung transplantation 
(Hoppo et al., 2011). FEV1 improved in both the pre- and post-transplant groups at one year 
post antireflux surgery (p<0.01). Episodes of pneumonia and acute rejection were 
significantly reduced in post-transplant patients (p=0.03) or stabilised in pre-transplant 
patients (p=0.09). The results are not stratified by lung disease and the proportion of 
patients transplanted for IPF (3 of 24) reflects the rarity with which this treatment option is 
deployed in IPF. In addition, the vagotomy often associated with lung transplantation 
generally results in a pattern of dysphagia not otherwise seen. The applicability of these data 
to the IPF cohort as a whole is therefore limited. 
These preliminary reports suggest that there may be a role for antireflux surgery in a well-
selected subset of IPF patients. The limited nature of the evidence base reflects the 
difficulties encountered in this area of research: IPF is rare and patients often have 
significant comorbidity. Furthermore, the natural history of the disease means that the 
benefits of surgery can be difficult to show (section 1.1.1). 
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Two key points emerge from this preliminary literature. In controlled studies of IPF, 
antireflux surgery has been associated with an improvement in measurable physiology, but 
not functional status or survival. Secondly, the benefits that have been shown across the 
groups who have undergone antireflux surgery as a whole have been modest. It is possible 
that more effective patient selection, for example using biomolecular markers of 
microaspiration, might yield more favourable results. 
A multicentre randomised controlled trial to investigate antireflux surgery in IPF is ongoing in 
the United States (Collard et al., 2013a). WRAP-IPF (Weighing Risks and Benefits of 
Laparoscopic Anti-Reflux Surgery in Patients With Idiopathic Pulmonary Fibrosis) randomises 
patients to receive either antireflux surgery or standard antireflux therapy, as per clinician 
discretion. The recruitment target is 58 and to be eligible, subjects must be willing to 
undergo antireflux surgery and fit enough to do so. The primary endpoint is decline in FVC 
between enrolment and 48 weeks.   
This is an important study but it is unlikely that the findings will directly inform clinical 
practice. The paucity of pilot data indicates that the recruitment target is a pragmatic one. 
The likelihood of a positive result is therefore unclear. The relevance of antireflux surgery to 
the IPF patient group as a whole will be difficult to assess.  In addition, no quality of life 
analysis is planned. 
Even as better evidence becomes available, decisions will remain challenging for clinicians 
and patients alike. Section 1.5 below considers some of the techniques that may be used to 
explore patient attitudes and facilitate shared decision-making in this challenging area of 
clinical practice. 
1.4 Detection of proximal reflux and pulmonary aspiration 
1.4.1 Oropharyngeal pH measurement 
The detection of gastro-oesophageal reflux is established in clinical practice and helps to 
identify a group of patients who may be at increased risk of pulmonary aspiration. For 
aspiration to occur, the material must ascend the length of the oesophagus and pass 
through the pharynx. In theory therefore, more proximal detection of gastro-oesophageal 
refluxate is an appealing technique in the IPF population. 
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Laryngopharyngeal reflux (LPR) is the condition in which the detection of proximal reflux has 
been most extensively appraised. Sufferers are thought to experience their symptoms of 
hoarseness, cough and sore throat because of exposure of the sensitive laryngopharyngeal 
mucosa to gastric contents.  
At flexible laryngoscopy, characteristic visual changes have been described in association 
with LPR. These include erythema, oedema, hypertrophy, mucus and granulation within the 
hypopharynx, Figure 1-6. The Reflux Finding Score was designed to record the severity of 
these changes and is well validated (Belafsky et al., 2002). The significance of these findings 
is not universally accepted as they have also been shown to occur in 64-86% of healthy 
controls (Reulbach et al., 2001; Hicks et al., 2002; Joniau et al., 2007). 
Figure 1-6. Appearance of the hypopharynx at flexible endoscopy: 1) Normal  2) Diffuse erythema at the 
vocal folds and arytenoid walls  3) Severe oedema in the posterior larynx  4) Vocal fold granuloma. Images 
reproduced from (Park, 2013; Vivero, 2015) 
 
The biochemical detection of supra-oesophageal reflux is also challenging: oropharyngeal 
refluxate has been shown to exist predominantly as an aerosol and conventional pH probes 
have poor sensitivity for the droplets of refluxate (Kawamura et al., 2004; Kawamura et al., 
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2007). Supra-oesophageal pH probes are also susceptible to drying effects which results in 
widespread artefact (Harrell et al., 2007). Pharyngeal reflux events have been demonstrated 
in 30-35% of normal controls (Merati et al., 2005; Ulualp et al., 2005). 
The Dx-pH probe is a novel “ion-flow sensor” that has been developed to measure 
oropharyngeal (OP) pH (Restech, San Diego, CA). It is an ambulatory transnasal device which, 
according to its manufacturers, can detect the pH change resulting from aerosolised 
refluxate within the pharyngeal environment. Normative OP pH ranges have been defined 
although the studies are relatively small and the exact thresholds remain controversial (Ayazi 
et al., 2009; Chheda et al., 2009; Sun et al., 2009). 
The results of early studies were promising. An in vitro model of supra-oesophageal reflux 
was used to demonstrate the Dx-pH probe provided faster, more accurate detection of pH 
than conventional pH probes (Yuksel et al., 2013). In another small clinical study of 15 
patients, all pharyngeal “reflux” events were preceded by distal oesophageal pH drops 
(Wiener et al., 2009). 
Larger analyses have since correlated the findings of the Dx-pH probe with the results of 
multilumen oesophageal pH-impedance monitoring and the findings are less convincing. In 
these studies, the proportion of pharyngeal refluxes that correlated with conventionally 
defined oesophageal reflux events was reported as 0-17%, 10-15%, 18% and 37-55%, 
respectively (Becker et al., 2012; Ummarino et al., 2013; Hayat et al., 2014b; Mazzoleni et 
al., 2014). Proponents of the technology would argue that this supports a higher sensitivity 
for the oropharyngeal probe. Concerningly, 5-35% of the refluxes defined by the Dx-pH 
probe were found to correlate with swallows, as demonstrated by impedance analysis 
(Ummarino et al., 2013; Mazzoleni et al., 2014). 
The significance of a measurable drop in OP pH therefore remains unclear. The pH variation 
of exhaled breath and acid produced by OP bacteria may both interfere with results 
(Mazzoleni et al., 2014). To date, the ENT community have yet to recognise the clinical utility 
of dual-probe pH monitoring or the Dx-pH probe. 
1.4.2 Scintigraphy 
In both adults and children, radionuclide imaging has been assessed as a technique for the 
detection and quantification of gastro-oesophageal reflux. Typically, a volume of dilute 
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Technetium-99 is ingested and subsequently a gamma camera is used to assess the 
distribution of the radiolabel within the body. In some centres, gastro-oesophageal reflux 
scintigraphy is used routinely in paediatric practice but it has not gained widespread 
acceptance in adults (Thomas et al., 2003). The use of radionuclide imaging to assess 
pulmonary aspiration secondary to gastro-oesophageal reflux remains experimental. 
Gastro-oesophageal reflux and pulmonary aspiration were assessed in a group of 51 patients 
with refractory respiratory symptoms, using a combination of ambulatory pH monitoring and 
Tc-99 scintingraphy (Ravelli et al., 2006). Thirteen of 51 had evidence of gastro-oesophageal 
reflux on pH monitoring. 25 of 51 had evidence of pulmonary aspiration based on 
scintigraphy. Interestingly, only 6 of the 25 patients with aspiration had abnormal pH results. 
The authors suggest non-acid reflux as an explanation for these findings (Zerbib et al., 2005). 
The ability of scintigraphy to detect pulmonary aspiration was also assessed in two smaller 
studies of patients (combined n=23) with confirmed GORD and co-existent pulmonary 
symptoms (Ghaed and Stein, 1979; Fawcett et al., 1988).  Neither supported the sensitivity 
or specificity of the technique in this role. 
1.4.3 Pepsin measurement in sputum and saliva 
The invasive nature of ambulatory probe testing has prompted the development of non-
invasive methods. Peptest is a commercially-available, near-patient test which has been 
designed to provide a diagnosis of GORD (Strugala et al., 2007)(RD Biomed, Hull, UK). It is a 
lateral flow device which makes use of two unique human monoclonal antibodies to pepsin 
3. The premise of the technique is that the presence of pepsin in a sample of sputum/saliva 
represents evidence of retrograde flow of gastric contents. Minimal laboratory equipment is 
required and the result is returned in around 15 minutes and read with the naked eye or a 
meter, in a manner similar to a urinary pregnancy test (Figure 1-7). 
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Figure 1-7. Pepsin lateral flow device showing the result of a gastric juice sample positive for pepsin. 
C=control band. T=test sample band. Reproduced from (Saritas Yuksel et al., 2012). 
 
 
To date, the technology has not been extensively validated. Saritas Yuksel et al used a 
modified version of the Peptest which incorporated semi-quantitative colorimetry to 
differentiate between sterile water and gastric juice using a receiver operating 
characteristics (ROC) curve analysis (Saritas Yuksel et al., 2012). The sensitivity and specificity 
were reported as 87%. 
Three clinical validation studies have analysed the performance of the test in comparison 
with the combination of ambulatory probe testing and endoscopy as a gold standard. In the 
second phase of the study mentioned above, the sensitivity and specificity of the lateral flow 
device to identify those patients with objective evidence of GORD, defined as supranormal 
pH and or endoscopic oesophagitis, was reported as 50% and 87%, respectively (Saritas 
Yuksel et al., 2012). Against a population prevalence of 47%, the positive predictive value 
was 85%. 
Peptest has also been evaluated as a means to differentiate between patients with 
symptoms due to reflux and patients with symptoms related to reflux (Hayat et al., 2014a). 
The significance of this distinction is that the first group, comprising individuals with 
supranormal levels of reflux or a hypersensitive response to normal reflux, should be treated 
with medical or surgical antireflux therapy. In contrast, individuals in whom there is no 
correlation between symptoms and reflux events can be described as having functional 
heartburn (FH). Aggressive treatment is not indicated in this group. 
De Bortoli et al compared the results of the lateral flow device with MII-pH studies in a small 
group of subjects with non-erosive reflux disease (NERD, n=16), hypersensitive oesophagus 
(HO, n=12) or without evidence of reflux disease (n=7)(de Bortoli et al., 2012). Peptest was 
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positive in 93.7% of NERD, in 58.3% of HO, and negative in 100% of normal subjects. Whilst 
the sensitivity and PPV were both reported as 100%, the specificity and negative predictive 
value were significantly lower at 79% and 54%, respectively. 
Hayat et al published a larger validation study, again comparing the lateral flow device with 
MII-pH monitoring (Hayat et al., 2014a). Three saliva samples were taken from each of 87 
healthy volunteers and 111 subjects with typical symptoms of GORD. Based on ambulatory 
monitoring, the symptomatic group were subdivided into individuals with GORD, HO or FH. If 
at least one sample was positive, the test showed a sensitivity of 77.6% and specificity of 
63.2%, with a negative predictive value of 80.4%. Using a modified version of the lateral flow 
device, the positive results were quantified and the highest readings (>210ng/ml) offered a 
specificity and positive predictive value in excess of 95% (D. Sifrim, personal 
communication). 
Proponents of the lateral flow device suggest a potential for it to guide the use of invasive 
testing for GORD. With further development, such a role may be possible in the future. 
1.4.4 Bronchoalveolar lavage 
The most compelling evidence for recurrent pulmonary aspiration would come from direct 
bronchoalveolar detection and quantification of substances which originate exclusively in 
the stomach.  At bronchoalveolar lavage, a narrow bore flexible endoscopy is used to inject 
and then aspirate a standardised volume of isotonic solution into the bronchoalveolar space. 
Analysis of the aspirate permits direct measurement of the environment within the distal 
airways.  Cytological and biochemical measurement techniques have been used. 
Cytological markers 
In early paediatric studies, microscopy and lipophilic staining of bronchoalveolar lavage fluid 
was regarded as the gold standard for the detection of pulmonary aspiration. Oil Red O and 
Sudan Red G are the most commonly used stains (Corwin and Irwin, 1985; Colombo and 
Hallberg, 1987; Nussbaum et al., 1987).  
Several studies demonstrated that the absolute presence or absence of lipid-laden alveolar 
macrophages (LLAMs) was not a good predictor of aspiration. As a result quantification 
systems have been described based on the number of LLAMs and the density of intracellular 
staining (Colombo and Hallberg, 1987; Kitz et al., 2012). 
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In many of the validation studies, the results of single or dual-probe pH monitoring has been 
compared with a specified index of LLAMs. The majority of studies report on children and 
demonstrate statistically significant associations between the results of pH monitoring and 
LLAM counts (Colombo and Hallberg, 1987; Nussbaum et al., 1987; Ahrens et al., 1999; Bibi 
et al., 2001; Sacco et al., 2006; Borrelli et al., 2010; Hopkins et al., 2010). 
Negative studies have also been reported (Sacco et al., 2000; De Baets et al., 2010; Kitz et al., 
2012). In the largest of these, Kitz et al compared a LLAM index with dual probe pH in 446 
children with bronchitis, bronchial hyper-reactivity or recurrent pneumonia. In their 
experience, there were no correlations between LLAM count and any reflux parameters, 
even when the analysis was restricted to those with reflux (Kitz et al., 2012). 
To date, a single study has compared MII-pH monitoring with LLAM quantification (Borrelli et 
al., 2010).  In a group of 21 children with suspected pulmonary aspiration, LLAM counts were 
positively correlated with the total number of reflux episodes, the number of non-acid reflux 
episodes and the number of proximal non-acid reflux episodes (coefficients r=0.73, 0.61 and 
0.64, respectively. 
Pepsin 
Pepsin is an acid protease released in the stomach. Detection in the oesophagus provides 
evidence of gastro-oesophageal reflux and, with bronchoalveolar lavage, pepsin can be used 
as a biomarker for pulmonary aspiration. 
Pepsin was the first human enzyme described and its nomenclature over the years has been 
somewhat confused (Florkin, 1957). High performance chromatography has led to the 
identification of six pepsin subtypes in humans (Roberts, 2006). Subtypes 1-4 are now 
collectively known as pepsin A and subtypes 5 and 6 are known as pepsin C (Roberts, 2006). 
Pepsin is released from chief cells in the stomach as the precursor pepsinogen and then 
activated to pepsin by hydrochloric acid, released from gastric parietal cells. Pepsin exhibits 
maximal proteolytic activity from pH 2-4 (Johnston et al., 2003; Bulmer et al., 2010). It 
remains active up to pH 6, above which it becomes inactive. This change is still reversible up 
to pH 7.5 (Pearson et al., 2011). The stability and residual activity of pepsin at higher pH is 
clinically relevant as weakly acid reflux is common in IPF. Additionally, re-exposure to acid in 
the oesophagus, pharynx or lungs could lead to reactivation. This could occur with a second 
wave of reflux or an acidic drink. 
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Several groups have established pepsin quantification assays, which fall into two categories. 
Activity assays measure the rate of liberation of small soluble peptide fragments, which are 
easily detected by absorbance (Roberts, 2006). Activity can also be quantified by 
determination of liberated amino groups from cleavage of peptide bonds, the N-terminal 
assay (Hutton et al., 1990). Alternatively, pepsin concentration can be measured by 
immunoassay. Several techniques have been developed and commercial kits are also 
available (Metheny et al., 2002; Farrell et al., 2006; He et al., 2007; Stovold et al., 2007). In 
the experience of our research group, the lower limit of detection is as low as 1ng/ml 
(Stovold et al., 2007). The concentration of pepsin within gastric fluid has been measured at 
100-600 µg/ml (Wallace, 1989; Gotley et al., 1991). Given that bronchoalveolar lavage 
results in a 100-200 fold dilution, concentrations of pepsin may be as low as 0.5-6 µg/ml. In 
studies of pepsin as a biomarker for aspiration, reported lower limits of detection range 
from 1 ng/ml to 1 µg/ml (Metheny et al., 2002; Stovold et al., 2007). 
To date, pepsin has been utilised as a biomarker of aspiration in the study of lung 
transplantation, laryngopharyngeal reflux and a range of non-transplant lung conditions. 
Quantification in bronchoalveolar lavage fluid is nonetheless associated with a number of 
limitations. 
Standardisation of any biochemical quantification in BAL is challenging. The pulmonary 
airways are a complex anatomical space and the volume and distribution of fluid within 
them is variable. In addition, the methodology of bronchoalveolar lavage has not been 
standardised so the results of different experiments are difficult to compare (Wells, 2010). 
Secondly, the decay of pepsin within the pharynx and lungs is not well understood. The 
temporal significance of pepsin detection is therefore unclear (Bohman et al., 2013). 
Production of pepsin within the lung has been reported. In vitro, pepsinogen C has been 
identified as a product of type 2 alveolar epithelial cells, thought to play a role in the 
processing of surfactant protein B (Gerson et al., 2008). Pepsin C has also been detected in 
the bronchoalveolar fluid of subjects with no clinical suggestion of reflux: Elabiad et al 
performed post-mortem immunohistochemical staining on neonatal pulmonary and gastric 
tissues (Elabiad and Zhang, 2011). Pepsinogen A was detected in 12 of the 13 stomach 
sections, mainly in the chief cells, but not in any lung sections. Pepsinogen C was detected in 
all stomach sections in chief and mucus cells and in 9 of the 16 lung sections, mainly in type 
II pneumocytes. In an adult study, 51 adult patients undergoing elective orthopaedic surgery 
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had pepsin A and pepsin C concentrations derived from a small volume bronchoalveolar 
lavage (Bohman et al., 2013). Eleven individuals (22%) had measurable pepsin 
concentrations, all of which had pepsin C but not pepsin A. Whilst endotracheal intubation 
introduces the possibility of iatrogenic aspiration, this is unlikely to be a major confounder in 
patients who underwent uncomplicated intubation for elective surgery (Bohman et al., 
2013). 
Bile acids 
Bile acids are steroid acids synthesised in the liver and released into the duodenum. They act 
as detergents, converting dietary fats into particles (micelles) which can be absorbed in the 
intestine. Duodenogastric reflux is a physiological event within the normal population, so 
bile acids can also be used as a marker of gastro-oesophageal reflux and pulmonary 
aspiration (Klokkenburg et al., 2009). 
Cholic acid and chenodeoxycholic acid are the two primary bile acids produced from 
cholesterol in the liver. They are dehydroxylated into the secondary bile acids deoxycholic 
acid and lithocholic acid by bacteria in the colon. Bile acids are then conjugated with the 
amino acids taurine and glycine in the liver to form bile salts. In humans taurocholic acid and 
glycocholic acid (from cholic acid) and taurochenodeoxycholic acid and 
glycochenodeoxycholic acid (from chenodeoxycholic acid) are the major bile salts in bile 
(Hofmann, 1999). The concentration of these four components is roughly equal. 
As a biomarker for aspiration, bile acids have been studied extensively within the lung 
transplant literature. Most studies have used one of two commercially available 
spectrophotometric detection methods for quantification. These rely on the action of a 
steroid dehydrogenase generating reduced nicotinamide adenine dinucleotide (NADH). Both 
methods were developed for serological assessment of liver disease and their use in the 
measurement of bronchoalveolar lavage fluid samples is contentious. In serum, the normal 
range of total bile acids is quoted as ≤6 to ≤10 µmol/l (Korman et al., 1974; Wong et al., 
2008). The kit manufacturers claim lower limits of detection of 1 µmol/l. Despite this, major 
reports in the transplant literature include measured levels as low as 0.2 µmol/l using these 
techniques (D'Ovidio et al., 2005; Blondeau et al., 2008). 
The most accurate method with which to detect bile acids is tandem mass spectrometry 
(TMS), which is widely used in the setting of neonatal screening in high volume reference 
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laboratories. Parikh et al compared the results of TMS and commercially available 
spectrophotometric techniques in the quantification of bile acids in gastric juice and 
bronchoalveolar lavage fluid (Parikh et al., 2013). In the latter study, the lower limits of 
detection for TMS and spectrophotometric analysis were 0.1 and 5 µmol/l, respectively. This 
latter figure is consistent with the findings of Klokkenburg et al (2009). 
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1.5 Evaluating patient attitudes towards antireflux therapy in IPF 
As discussed above, the investigation and management of gastro-oesophageal reflux in 
idiopathic pulmonary fibrosis is a challenging area of practice. There are no validated 
techniques with which to quantify chronic aspiration. Definitive therapy, in the form of 
antireflux surgery, is associated with greater risk in an elderly population with significant 
comorbidities. It is therefore essential that patients are properly informed about the 
limitations of the current evidence base before they agree to invasive tests and, potentially, 
to surgical treatment. 
For clinicians, the role of reflux and aspiration in lung disease is emerging. The ability to 
effectively communicate the risks and benefits is hampered by a weak evidence base and 
limited clinical experience. Within the constraints of a time-limited medical consultation, it 
would be difficult to fully convey the uncertainties of therapy in such a way that patients 
could make an informed choice about their care. Similarly, it is crucial that patient attitudes 
inform the direction of future research. 
The logical response to this challenge is to investigate patients’ attitudes towards the 
potential risks and benefits associated with possible therapies, by exploring how IPF patients 
value their own quality of life and to assess the level of risk they would accept for a chance 
to stabilise their future health. 
There are two sides to this question. The first relates to the burden of IPF as a disease state 
and the second to the risks and benefits that may be attributed to antireflux therapy. For 
patients with IPF and minimal reflux symptoms, the benefit of antireflux therapy may be 
closely linked to their pulmonary symptoms or the prognosis attached to their lung disease. 
At present, the natural history of IPF remains unclear, and the respiratory benefits of 
antireflux surgery are even less well understood. For these reasons, a balanced assessment 
of patient attitudes towards antireflux therapy in IPF is not feasible. Nonetheless, if clinicians 
could be afforded a better appreciation of how their patients perceive the respiratory 
burden of their disease as compared with the burden of antireflux surgery, a more informed 
consultation might result. The following section explores the measurement of health and 
healthcare and describes how such an analysis might be constructed. 
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1.5.1 Measuring health 
With ageing populations, diminishing resources and increasingly complex therapies, 
healthcare budgets are under ever greater pressure. Quantifying the perceived value of a 
given health state, or the benefit derived from an intervention, is increasingly important. 
Governments rely on such analyses in order to maximise efficiency in healthcare spending. 
These pressures have contributed to significant developments in health economics in recent 
years. Before resources can be deployed, health must first be measured. 
Certain indicators are unambiguous; infant mortality rate would be an example. As 
expectations of healthcare have risen over the years, perceptions of health have shifted 
away from mortality, through functional ability and on to quality of life. The measurement of 
these concepts is increasingly complex, and modern day health economics draws influences 
from psychometrics, consumer theory and decision analysis. 
When two different treatments for the same disease are to be compared, a cost-
effectiveness analysis may be undertaken. Two different antihypertensives may be 
compared in terms of pounds per mmHg blood pressure reduction. In contrast, evaluating 
the effectiveness of joint replacement as a treatment for arthritis would require a different 
unit of measurement. Deciding how much of a limited healthcare budget to spend on 
competing interventions requires a method of comparing the generic value they provide. For 
the purposes of the current study, the concept of generic valuation is crucial. The morbidity 
associated with IPF is very different from that associated with reflux disease and its 
treatment. 
How to measure that generic value has been the subject of extensive debate.  One available 
method is contingent valuation, a survey-based approach in which people are questioned on 
their willingness to pay for a specific resource (Diamond and Hausman, 1994). Valuation is 
contingent upon a specified hypothetical scenario. Contingent valuation has not been widely 
used to evaluate healthcare provision because, in general, healthcare is not directly paid for 
at the point of access. Secondly, willingness-to-pay reflects an individual’s wealth, which can 
skew results (Gold et al., 1996). 
The more common approach is the quality-adjusted life year (Weinstein et al., 1996; 
National Institute for Health and Care Excellence, 2012). QALYs measure the quantity and 
quality of life that results from a healthcare intervention. A lung transplant might be deemed 
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to increase quality of life by 25% for ten years would be said to offer 2.5 QALYs (Torrance 
and Feeny, 1989). Further, by calculating the total cost of a lung transplant, the cost per 
QALY could be defined. QALYs have now become de facto currency with which to measure 
health effects in the NHS (National Institute for Health and Care Excellence, 2013). 
The use of QALYs requires the assignment of weights to represent the quality of the health 
state in question. Such valuations should reflect the experience of those individuals affected 
by the condition in question, as well as the preferences of the population who provide the 
relevant funding. 
1.5.2 Scaling, value and utility 
The simplest way to quantify estimates of healthiness is to ask directly for a numerical 
answer. Subjects might be asked how bad their pain is on a scale of 0 to 100. The answers 
from such tasks will be highly subjective and do not provide easily comparable data. 
Measurement thus requires the assignment of numerical scores to some form of description. 
There are a wide variety of scaling techniques, with different forms generating data that 
might be nominal, ordinal or interval in nature. 
Scaling procedures generally fall into two main categories, which can be considered 
psychometric and econometric (McDowell, 2011). Psychometric scaling procedures generally 
rate feelings, opinions or attitudes and concern the present. These techniques make use of 
values, which refers specifically to preferences expressed under conditions of certainty. 
Econometric scaling, by contrast, derives from studies in economics and decision analysis of 
consumer choices between products, often under conditions of risk or uncertainty. For 
health economists, the concept of uncertainty is inherent to the judgments and preferences 
that relate to the future as well as the present. Practically, utilities are simply numbers 
ranging on a scale from 0 (the worst) to 1 (the best). 
In healthcare evaluation, utility is generally defined in accordance with von Neumann and 
Morganstern’s Theory of Games and Economic Behavior (von Neumann and Morgenstern, 
1944). Often denoted as vNM utility, the model explains how a rational individual “ought” to 
make decisions when faced with uncertain outcomes so as to achieve the best outcome 
(Torrance and Feeny, 1989; Dolan et al., 1996b). 
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When QALYs are used to measure a health benefit, time provides the measure of quantity 
and utilities provide the measure of quality. 
1.5.3 Measurement of utilities  
Amongst the various methods used to measure health state utility, three predominate: the 
rating scale, the time trade-off and the standard gamble. The following sections outline the 
processes involved and the theoretical basis for these tools. The empirical evidence 
supporting them is discussed in section 1.5.4 below. 
Rating scale 
The rating scale is the most straightforward technique and consists simply of a line, with 
anchoring points defined at the two ends. This is sometimes represented as a thermometer. 
The two extremes might be identified as zero or death at one end and 100 or perfect health 
at the other.  Respondents have a health state described to them and they simply draw a 
mark on the line to express their perception of the health-related quality of life between the 
two anchoring states provided. The physical location of the mark on the line is taken to 
represent the respondent’s utility for the specified health state. 
The theoretical validity of this method has been challenged as there is no explicit choice or 
sacrifice involved (Brazier, 2008). The rater does not have to justify their response in terms 
of time, money or any other unit of value, so the response may be highly arbitrary. Utilities 
determined using a rating scale fail to satisfy the criteria of an interval scale: the difference 
between utilities of, for example, 0.2 and 0.3 cannot be taken as equivalent to the difference 
between utilities of 0.8 and 0.9 (Richardson, 1994). In addition, there is no transparent 
relationship between the units on the scale, on the one hand, and the measure of welfare or 
preference that is believed to be appropriate to resource allocation (Green et al., 2000). 
Time trade-off 
In a time trade-off (TTO) experiment, respondents are asked whether they would prefer to 
spend a given length of time in a defined health state of less-than-perfect health or an 
alternative duration in perfect health, after which the outcome is death. At the start of the 
experiment, the respondent is asked to choose between ten years in perfect health and ten 
years in a health state representing less-than-perfect health, and would be expected to opt 
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for the former. The duration of time available in perfect health is then incrementally 
decreased until the respondent is indifferent between the two options. The point of 
indifference indicates the utility score: if a patient was indifferent between 10 years in a 
defined health state and six years of perfect health, the utility for that health state would be 
recorded as 0.6. 
TTO incorporates a choice based on sacrifice, as respondents must consider the opportunity 
cost of extra years of life. Respondents are asked directly about the specific number of years 
in full health which they value as equal to a (longer) period in the health state being 
measured. Thus it collapses the relationship between the duration and the value of a health 
state into a single measure. Critics of the technique argue that TTO relies on the unproven 
assumption that longevity is proportional to utility (Green et al., 2000).  
A further criticism of TTO relates to the assumption that individuals are consistently 
prepared to trade a proportion of their remaining years of life in order to improve their 
health status. Empirical data suggest this may not be true (Dolan et al., 1996b). 
Standard gamble 
In the standard gamble respondents are asked to choose between two alternatives, where 
one is the certainty of a defined health state (i) and the other is a gamble with two possible 
outcomes (Torrance, 1986). The two outcomes in the gamble are defined such that one is 
more favourable and one is less favourable than the health state in question. Conventionally, 
the two outcomes are a return to full health (with probability p), and immediate death 
(probability 1-p).  
At the outset the probability of the favourable outcome is set at 100%. At this stage, 
respondents would be expected to opt for the gamble. As the interview proceeds, the 
relative probabilities of the two gamble outcomes is altered. The conclusion is the point at 
which the respondent is indifferent between the certain outcome (the defined health state) 
and the gamble. At this point, the probability (p) of the favourable gamble outcome is 
recorded as the utility value for the health state in question. 
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Figure 1-8. Decision tree for a standard gamble evaluating a chronic health state considered better than 
death. Reproduced from (Torrance, 1986) 
 
 
The inclusion of a gamble, with two possible outcomes, means that respondents make their 
decisions under uncertainty. As a result, the standard gamble is generally considered as most 
appropriate to the measurement of vNM utility and thus commonly regarded as the gold 
standard for cost-utility analysis (Mehrez and Gafni, 1989; Torrance and Feeny, 1989). 
This special status is not universally accepted. The strongest challenge relates to the “specific 
utility associated with risk, which varies between respondents” (Richardson, 1994). 
Richardson argues that many individuals would associate the process of gambling with 
anticipation and excitement and for others, it would confer feelings of anxiety and fear. The 
range of attitudes to risk can be said to introduce an additional factor, unrelated to the 
respondent’s utility for a given health state. Others argue that varying attitudes to risk are 
no different from varying attitudes towards time (Green et al., 2000).  
One practical criticism is that respondents may struggle to understand risk as represented by 
probabilities. Standard gamble boards have therefore been developed to help visualise the 
effect of changing probabilities within the gamble outcomes. With the use of a board, good 
completion rates have been reported (Morss et al., 1993). 
1.5.4 Empirical support for measurement tools 
The choice-based methods are the focus of the remainder of this section, which considers 
the practical evidence to support the use of the standard gamble (SG) and the time trade-off 
(TTO). 
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Validity 
Health state utility can be regarded as a theoretical construct, as preferences are never truly 
revealed. The absence of a gold-standard makes it difficult to validate the techniques with 
which utilities are derived. The fact that healthcare expenditure can be determined by the 
results these techniques generate makes this a significant challenge. The standard gamble, 
for example, tends to generate higher utility values than other methods (Torrance et al., 
1996). 
Studies designed to validate the different utility measurement techniques have largely relied 
on comparison with a predetermined rank ordering. Such a ranking might originate from an 
individual’s stated preferences, or from a logical comparison within a set of health state 
definitions. Another approach involves concurrent validation, which describes how well two 
methods agree with each other.  If two techniques generate comparable results, they are 
likely to value similar aspects of health-related quality of life (Torrance, 1976; Read et al., 
1984). 
In a study of 350 respondents, Dolan et al made use of the EQ5D-3L multi-attribute scale to 
compare the standard gamble and the time trade-off (Dolan et al., 1996b). EQ5D-3L is a 
written health-related quality of life survey in which respondents select one of three 
statements for each of five domains best representing their health at the time of response. 
The domains relate to generic factors such as pain and mobility. Any combination of five 
responses can be taken to represent a hypothetical health state.  The nature of the 
statements within EQ5D-3L is such that certain health states are inherently more attractive 
than others: respondents would be expected to prefer to have “no problems in walking 
about” than “some problems in walking about”. The extent to which the SG and the TTO 
evaluated the EQ5D-3L health states in accordance with their rational ordering was 
assessed. Whilst there was no significant difference in the results, TTO performed slightly 
better: reported logical consistency was 91.7% vs 83.8% for SG. The statistical significance of 
this result is not reported. 
In a more recent study of 96 respondents with irritable bowel syndrome, the construct 
validity of the SG and TTO were compared through correlation of the derived utilities with 
the results of disease-specific and generic questionnaires (Puhan et al., 2007). In this 
analysis, the results of the SG were significantly better correlated with the results of the 
other tools than were the utilities generated by the TTO. 
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The convergent validity of the SG and TTO were compared with the results of the Short 
Form-36 HRQOL scale in another study of 878 subjects, made up of patients under treatment 
for heart disease and healthy volunteers (Lalonde et al., 1999). Overall, the correlation of the 
TTO was slightly higher than that of the SG with reference to SF-36 General Health 
Perception score (0.36 vs 0.30). 
In a similar study of 25 patients with the condition systemic lupus erythematosus, Moore et 
al demonstrated that TTO had better correlation with SF36 subscales than SG (Moore et al., 
1999). 
When these results are assimilated, there is no clear signal from the published literature that 
either of the choice-based methods has superior validity.  
Reliability 
In cost-utility analysis, reliability measures the stability of a tool between two 
administrations assuming a constant health state. This can be assessed over time or 
between raters. The majority of studies have focused on test-retest reliability, as 
summarised in Table 1-3. 
Table 1-3. Test-retest reliability of the standard gamble and time trade-off in studies reporting direct 
comparisons. Test statistic specified as intraclass correlation in studies indicated (*) and unspecified in the 
remainder. 
Test-retest time period Standard gamble Time trade-off 
≥1-week 0.80 (O'Connor et al., 1987) 0.87 (O'Connor et al., 1987) 
6- to 16-week 0.63* (Dolan et al., 1996a) 0.83* (Dolan et al., 1996a) 
1-year 0.53 (Torrance, 1976) 0.62 (Torrance, 1976) 
Other (time-specified) 
 
0.82 (Reed et al., 1993) 
0.8* (Gage et al., 1996) 
0.84* (Kim et al., 2012) 
0.74 (Reed et al., 1993) 
0.67-0.92* (Gage et al., 1996) 
0.83* (Kim et al., 2012) 
 
When the test-retest reliability was reported on the group level, as opposed to the individual 
level as in the studies summarised above, the results are significantly improved (Green et al., 
2000).   
Overall, comparative studies report slightly higher reliability for the time trade-off than the 
standard gamble, but it is not possible to choose one method over another based on this 
criterion. 
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To date, the majority of studies have employed the TTO but this may relate to the fact that it 
is quicker and therefore cheaper to administer. In the UK, the National Institute for Clinical 
Effectiveness published a statement that was mirrored by that of Panel on Cost-
effectiveness in Health and Medicine in the U.S (Weinstein et al., 1996; National Institute for 
Health and Care Excellence, 2008). Both recommend the use of choice-based methods in the 
measurement of health state utilities, but neither specifies a single technique. 
1.5.5 Choice of respondents in health state valuation 
Health state utilities have been measured amongst patients, amongst clinicians and amongst 
sample populations drawn from the general public. Each method is associated with 
advantages and disadvantages. 
Patients who have personal experience of a given condition will have the best understanding 
of what it means to live with that condition, and the effect that it has on their lifestyle and 
quality of life. This is reflected in a statement from NICE, suggesting that patients should 
ideally be used in the generation of utilities (National Institute for Health and Care 
Excellence, 2008). 
One concern with patients as respondents is the so-called disability paradox: many people 
with serious and persistent disabilities report that they experience a good or excellent 
quality of life, when to most external observers their quality of life seems poor (Albrecht and 
Devlieger, 1999). Empirically, the health state utilities reported by patients with first-hand 
experience of a condition tend to be higher than the values assigned by members of the 
general public given detailed descriptions of that condition (Sackett and Torrance, 1978; 
Froberg and Kane, 1989). 
Clinicians have been used in cost-utility analysis studies. After direct contact with patients 
affected by a given condition, clinicians provide a perspective on the range of health states 
that might be associated with a given disease. In addition, clinicians may be able to frame 
that perspective within the context of other health problems. Clinicians have been reported 
to overestimate the gravity of a condition, which may represent efforts to increase its status 
or resource allocation (Torrance and Feeny, 1989). 
Non-patients have also been used to measure utility. In a publicly funded healthcare system, 
it is the general public whose resources are available for allocation, so their views should be 
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accounted for (Dolan and Olsen, 2002).  As a study population, members of the public will 
provide aggregated utilities, unconstrained by vested interests (Gold et al., 1996). 
In summary, the choice of study subjects boils down to the aims and objectives in hand. For 
resource allocation, the use of society’s preferences have been advocated (Gold et al., 1996). 
In guideline development and in individual decision-making, the use of utilities obtained 
from actual patients is generally preferred.  
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1.6 Unanswered questions about reflux, aspiration and IPF 
In recent years, much has been written on the subject of reflux as a potential contributing 
factor in IPF. Earlier this year the National Institute for Health and Clinical Excellence 
identified the treatment of reflux as a research priority in IPF.  
Most would agree that the quality and quantity of evidence available remains limited. To 
date, there has been no convincing demonstration of causality and no prospective data exist 
on the treatment of reflux in IPF. High quality, prospective studies of the prevalence of reflux 
in IPF are lacking and microaspiration remains difficult to quantify. When compared to 
conditions with a similar prognosis, the therapeutic advances in IPF have been modest. In 
this context, it is doubly important that a potentially treatable aetiology is properly 
appraised. 
How the investigation and management of reflux in IPF might be translated to clinical 
practice is another topic that has received little attention to date. The widespread use of 
standard tests and surgery for reflux may be very different amongst the IPF population than 
it is in an adult surgical clinic. Patient-reported outcome measures may or may not play a 
role. Furthermore patient attitudes have yet to be explored. It is difficult to predict how 
patients with varying degrees of respiratory compromise will approach the risks and benefits 
of aggressive antireflux treatment.
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Chapter 2. Hypothesis, Aims and Objectives 
2.1 Hypothesis 
Hypothesis 1: IPF patients are willing and able to undergo investigation and, in appropriate 
cases, surgical treatment of gastro-oesophageal reflux and microaspiration. 
Hypothesis 2: Gastro-oesophageal reflux and microaspiration are commonly found when 
state-of-the-art investigative techniques are used. 
Hypothesis 3: The investigation and management of reflux in idiopathic pulmonary fibrosis 
may be effectively delivered by a multidisciplinary team. 
2.2 Aims 
2.2.1 Primary aim 
1. To characterise the frequency and nature of gastro-oesophageal reflux and aspiration 
in IPF 
2.2.2 Secondary aims 
1. To evaluate aerodigestive symptomatology and health-related quality of life in IPF 
2. To evaluate the feasibility of selected clinical and experimental techniques for use in 
clinical investigation in this patient population 
3. To explore attitudes towards antireflux surgery within the IPF population 
4. To assess the feasibility of a novel multi-disciplinary team to investigate and manage 
reflux in IPF and related conditions 
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2.3 Objectives 
A. Selection and use of a panel of validated questionnaires with which to assess 
symptoms and health-related quality of life in IPF 
B. To perform high-resolution manometry and ambulatory impedance/pH monitoring in 
a consecutive series of IPF patients 
C. Assessment of markers of aspiration and lung inflammation using per bronchoscopic 
bronchoalveolar lavage providing: 
a. total cell count 
b. differential cell count  
c. presence of lipid-laden macrophages 
d. presence of haemosiderin-laden macrophages 
e. in-house quantitative ELISA measurement of pepsin 
f. quantitation of bile acids by spectrophotometry 
D. To use a standard gamble to measure health state utilities associated with the 
burden of IPF and the potential burden of antireflux surgery 
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Chapter 3. Methods 
3.1 Characterisation of reflux and aspiration in IPF 
3.1.1 Ethical approval 
Ethical permission for the study was granted on 22nd February 2010 by the  County Durham 
& Tees Valley 2 Research Ethics Committee, (reference number 10/H0908/9). The NHS 
sponsor for the study was the Newcastle-upon-Tyne NHS Hospitals Foundation Trust. Study 
approval was granted by the Trust Research and Development department on 18th May 2010 
(ref 5183). 
All participating individuals gave written informed consent after an opportunity to review 
approved study information sheets. 
3.1.2 Recruitment 
In an earlier phase of study conducted by a doctoral student within our research group, 20 
subjects with idiopathic pulmonary fibrosis underwent oesophageal physiology assessment, 
bronchoscopy and bronchoalveolar lavage fluid (BALF) analysis. Study methodology was 
consistent with the current work. These data were analysed in conjunction with the results 
from the current group of study participants. 
The previous group of 20 subjects also completed the Reflux Symptoms Index questionnaire, 
the results of which were pooled across the two phases of study. 
The recruitment target for the current phase of the study was 15-20 patients. This was a 
pragmatic target based on the number of patients attending the clinic and the participation 
rate recorded from the previous phase of research. 
IPF patient identification 
Consecutive adult patients with a secure diagnosis of idiopathic pulmonary fibrosis were 
identified and recruited from the regional Interstitial Lung Disease (ILD) clinic with the 
support of clinicians with a specialist interest. Diagnosis was verified through discussion at 
55 
the regional ILD multi-disciplinary team, with input from respiratory physicians, thoracic 
radiologists and histopathologists with an interest in lung disease. The diagnostic criteria 
proposed jointly by the European Respiratory Society and American Thoracic Society were 
used, Box 1. 
Box 1. Consensus guidelines for the diagnosis of idiopathic pulmonary fibrosis. Reproduced from (Raghu et 
al., 2011). 
1. Exclusion of other known causes of interstitial lung disease (e.g. environmental exposures, 
connective tissue disease and drug toxicity). 
2. The presence of a usual interstitial pneumonia pattern on high-resolution computed tomography 
(HRCT) in patients not subjected to surgical lung biopsy. 
3. Specific combinations of HRCT and surgical lung biopsy pattern in patients subjected to surgical 
lung biopsy. 
 
Exclusion criteria 
Lack of capacity to consent to the study protocol 
Use of long-term oxygen therapy 
Conditions precluding cessation of proton pump inhibitor medications, including 
Zollinger-Ellison syndrome and complicated Barrett’s oesophagus 
Co-existing respiratory disorder  
Overt congestive cardiac failure 
Patients regarded unfit for any other reason by their respiratory physician 
Control population 
A small population of healthy volunteers was recruited from the university staff in order to 
derive reference data for the bronchoalveolar lavage fluid analysis (one female; median age 
39 years, range 32-46 years). All were non-smokers and none had any significant respiratory 
symptoms or existing respiratory diagnoses.  
3.1.3 Study overview 
Participants were asked to complete a panel of symptom questionnaires. Those taking 
proton-pump inhibitors discontinued therapy prior to study and then repeated the 
questionnaires after two weeks off treatment. On- and off-treatment responses were 
therefore recorded. 
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On the first study day written consent was recorded and a stationary oesophageal 
manometry assessment was performed in a designated oesophageal physiology lab. An 
oesophageal pH-impedance catheter was then inserted and ambulatory monitoring 
commenced.  
The subject returned the following morning and the pH-impedance catheter was removed. 
Bronchoscopy and a standardised bronchoalveolar lavage were performed. Lavage samples 
were transferred to Newcastle University for processing, analysis and storage. 
3.1.4 Selection of patient-reported outcome measures 
The Ovid-Medline database was searched over the period January 1980 to May 2013 to 
identify questionnaires suitable for the symptomatic evaluation of gastro-oesophageal reflux 
disease and extra-oesophageal reflux disease in adults. Questionnaires were evaluated 
based on their development, psychometric evaluation and ease of completion. 
During the study, questionnaires were either handed to patients in clinic or posted out. 
Questionnaires that were designed to be administered by an interviewer were therefore 
excluded. Given the two-week cessation period for proton-pump inhibitors, questionnaires 
that could only be used for longer recall periods were avoided. 
Symptoms of gastro-oesophageal reflux disease 
The following search string was used within Medline: [gastro-esophageal reflux OR GERD OR 
gastro-oesophageal reflux OR GORD] AND [questionnaire OR scale OR patient reported 
outcome OR instrument OR measure OR index] AND [symptoms OR diagnosis OR evaluation] 
AND [validity OR reliability or responsiveness OR psychometric properties]. The references of 
relevant review articles were also screened (Stanghellini et al., 2004; Mouli and Ahuja, 2011; 
Vakil et al., 2013). Instruments designed to assess health-related quality of life and 
instruments relating to reflux surgery were excluded. 
A total of 20 tools were identified and evaluated using a priori selection criteria described in 
section 3.1.4. As a result, 17 were rejected (Table 3-1). The development and validation of 
the three remaining questionnaires were then reviewed in further detail (Table 3-2).
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Table 3-1. Questionnaires rejected for assessment of symptoms of gastro-oesophageal reflux 
Name Source Basis for rejection 
Infant gastroesophageal 
reflux questionnaire 
(Orenstein et al., 1993) Specifically designed for use in infants 
GERD symptom score (DeMeester et al., 1980) No validation available 
GERD specific questionnaire (Carlsson et al., 1998) Validation incomlete: author-reported 
specificity of 19% at the chosen diagnostic 
cut-off 
GERD score (Allen et al., 2000) Administered 
Gastroesophageal Activity 
Index (GRACI)  
(Williford et al., 1994) Part-interview 
Leeds Dyspepsia 
Questionnaire 
(Moayyedi et al., 1998) Administered 
Dyspepsia symptom score (Buckley et al., 1997) Unvalidated; administered 
Gastrointestinal Symptom 
Rating Scale 
(Talley et al., 2001) Designed to assess IBS and peptic ulcer 
disease. The reflux syndrome scale contains 
only two items and has not been evaluated 
in isolation. 
Digestive Health Status 
Instrument 
(Shaw et al., 2001) Based on criteria for IBS and dyspepsia 
Dyspepsia Symptom 
Severity Index 
(Leidy et al., 2000) Designed to assess dyspepsia 
HK index of dyspepsia (Hu et al., 2002) Designed to assess dyspepsia 
GERD specific esophageal 
symptom questionnaire 
(Greatorex and Thorpe, 
1983) 
Reliability and responsiveness not assessed 
GERQ (Locke et al., 1994) Lengthy: 60 items 
GERD questionnaire (Johnsson et al., 1993) Heartburn not assessed 
GERD screener (Ofman et al., 2002) Administered 
GSFQ (Pare et al., 2003) Regurgitation not assessed 
Hearburn diary card (Junghard and Wiklund, 
2008) 
4 week recall period 
GERD Inventory (Zimmerman, 2004) 4 week recall period 
PASS (Armstrong et al., 2005) Exclusively assesses treatment-resistant 
symptoms 
ReQuest (Bardhan et al., 2004) Lengthy – over 60 items 
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Table 3-2. Questionnaires considered for the symptomatic assessment of gastro-oesophageal reflux 
Name Source Strengths Weaknesses Comments 
GERD Symptom 
Assessment Scale 
(GSAS)  
(Rothman 
et al., 
2001) 
1 week recall 
Responsiveness tested 
with a 2 week window 
Designed to be evaluative 
Validity 
demonstrated 
against HRQL tools 
No nocturnal 
symptoms 
15 items 
Reflux Disease 
Questionnaire 
(RDQ)  
(Shaw et 
al., 2001) 
Validity tested against 
physician diagnosis 
Previously used in a 
randomised controlled 
trial 
Originally validated 
with a 4 week recall 
Dyspepsia 
symptoms included 
12 items  
Gastro-
esophageal reflux 
disease 
questionnaire 
(GerdQ)  
(Jones et 
al., 2009) 
Brief: 6 items 
Includes nocturnal 
symptoms and treatment 
response 
Validity demonstrated 
against a multimodal 
diagnostic workup 
Reliability not 
assessed 
Assesses 
symptom 
frequency 
alone 
 
Once the search had been narrowed to these three remaining tools, the strengths and 
limitations of each were reviewed in further detail: 
GERD Symptom Assessment Scale (GSAS)  
25 core symptoms of reflux disease were established through literature review, focus groups 
and expert consultation. A questionnaire was designed to assess the frequency, severity and 
distress of each of these symptoms. 185 patients with GORD were identified from a 
nationwide population based survey and, after an initial telephone assessment, were asked 
complete the questionnaire at baseline and two weeks. They were also asked to complete 
four HRQL scales in addition. 
Assessment of the psychometric properties of the GSAS was undertaken. Reliability and 
responsiveness were acceptable but validity was not assessed against any external standard: 
 “Validity was demonstrated by testing the hypotheses that first, symptom distress 
would be associated with lower general perceptions of health, and, second, symptom 
distress would be more strongly associated with patient perception of functioning and 
well-being than symptom frequency. Both were supported.” (Rothman et al., 2001) 
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Based on the results of the pilot survey, symptoms endorsed by less than 25% of the subjects 
were dropped from further analysis, yielding a 15-item symptom scale. 
Reflux Disease Questionnaire (RDQ) 
The RDQ aims to provide a validated patient-reported tool for the purposes of GORD. The 
domains assessed are regurgitation, heartburn and dyspepsia.  The time recall in the original 
survey was four weeks but in a later validation study, for which the tool was translated into 
Swedish and Norwegian, a recall of one week was used. 
Content validity was informed by literature review, expert opinion and cognitive interviews.  
Predictive validity analyses of all scales and items used gastroenterologist diagnosis as a gold 
standard.  Good inter-rater agreement between physicians was demonstrated with the use 
of actors primed with scripts based on confirmed cases of GORD, irritable bowel syndrome 
and combinations of the two. 
Responsiveness was assessed by “observed treatment effect” between two clinic 
attendances and by analysing those reporting at least moderate change.  Stability was 
assessed by constructing intra-class correlation coefficients in patients with stable 
symptoms. 
Gastro-Esophageal Reflux Disease- Questionnaire (GERD-Q) 
The GERD-Q was designed as a tool with which to support accurate, symptoms-based 
diagnosis of GORD by general practitioners and also to monitor the effect of therapy over 
time.  The development was based on data from the Dutch study on Initial Management Of 
Newly diagnosed Dyspepsia (DIAMOND), in which GORD was diagnosed on the basis of any 
one of the following criteria (Dent et al., 2010):  
 (i) Oesophageal pH<4 for >5.5% of a 24-h period on ambulatory pH monitoring; 
(ii) Los Angeles grade A-D oesophagitis at endoscopy (Lundell et al., 1999); 
(iii) Indeterminate 24-h oesophageal pH in combination with a positive response to 14 
days’ esomeprazole (proton pump inhibitor) treatment; 
(iv) Positive (>95%) Symptom Association Probability. 
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Based on Receiver Operating Characteristic (ROC) curve analysis, logistic regression and data 
from previous studies and qualitative interviews, six items from the different questionnaires 
were chosen for inclusion in the questionnaire.  These included four positive and two 
negative predictive factors.  Further ROC curve analysis indicated that a questionnaire score 
of 8 points or more provided the highest sensitivity and specificity for diagnosing GORD. 
Focus group feedback suggested that patients preferred to score symptoms by frequency 
rather than severity, as it was easier to recall. In addition, ROC curve analysis suggested that 
symptom frequency scoring provided equivalent sensitivity and specificity for diagnosis 
when compared to the use of symptom frequency and severity in combination. As a result, 
all six items within GerdQ assess symptom frequency. 
In order to assess the responsiveness of the GerdQ, the effect size and the standardized 
response mean of the pre- and post-treatment questionnaire results distributions were 
compared. Using these techniques, the GerdQ was found to be as responsive as the RDQ, a 
comparable but lengthier tool. 
The evaluation methodology, brevity and reported performance of the GerdQ make it 
particularly attractive. 
Symptoms of extra-oesophageal reflux 
A further Medline literature review was undertaken, incorporating the terms “extra-
oesophageal reflux” and “laryngo-pharyngeal reflux” into the string detailed above.  Six tools 
were identified with which to evaluate the symptoms of extra-oesophageal reflux. Four were 
deemed unsuitable (Table 3-3). 
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Table 3-3. Questionnaires rejected for assessment of extra-oesophageal reflux symptoms 
Name Source Basis for rejection 
Laryngopharyngeal reflux 
health-related quality of life 
questionnaire 
(Carrau et al., 2005) 4 week recall period 
Extra-oesophageal 
symptoms questionnaire 
(Gisbert et al., 2009) Not validated 
Supraesophageal Reflux 
Questionnaire 
(Dauer et al., 2006) Lengthy – reported median completion 
time 10 minutes 
Hull Airway Reflux 
Questionnaire 
(Morice et al., 2011) Majority of items (8/14) relate to cough 
 
The Reflux Symptom Index (RSI) is a brief questionnaire designed to assess laryngeal 
symptoms secondary to laryngopharyngeal reflux.  It is well validated and the normal range 
of scores has been published (0-13) (Belafsky et al., 2002).  The RSI has been used in our 
research group previously. 
Assessing quality of life related to reflux and lung disease 
The putative relationship between reflux and lung disease makes it more appropriate to 
assess health-related quality of life from a respiratory perspective. The St. George’s 
Respiratory Questionnaire is the best validated tool with which to assess respiratory-specific 
health-related quality of life (Jones et al., 1991).  It was originally designed and validated for 
use in chronic obstructive airways disease.  It has now been validated for use in idiopathic 
pulmonary fibrosis, bronchiectasis, asthma, and cystic fibrosis and used in numerous clinical 
trials (Wilson et al., 1997; Sanjuas et al., 2002; Schunemann et al., 2003; Jones, 2005; Padilla 
et al., 2007; Swigris et al., 2010; Swigris et al., 2014).  
A total score is calculated which summarises the impact of the disease on overall health 
status. Scores are expressed as a percentage of overall impairment where 100 represents 
worst possible health status and 0 indicates best possible health status. Normal ranges are 
described. 
62 
 
Summary and selection of questionnaires 
For the current study, the Gastro-Esophageal Reflux Disease Questionnaire was used to 
assess typical symptoms of reflux, the Reflux Symptoms Index to assess extra-oesophageal 
reflux symptoms and the St George’s Respiratory Questionnaire to assess respiratory health-
related quality of life. 
This panel of questionnaires was combined and tested in a sample of five staff from the 
university. The median time for completion of all four questionnaires was five minutes and 
free-text feedback suggested that they were acceptable as a group. Questionnaires are 
reproduced in the appendices. 
3.1.5 Clinical data collection 
The results of key pulmonary function tests were extracted from clinical correspondence: 
 Forced expiratory volume (1 second) = volume exhaled at the end of the first second 
of forced expiration 
 Forced vital capacity = the determination of vital capacity from a maximally forced 
expiratory effort 
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3.1.6 Preparation for oesophageal physiology testing 
I arranged for the current study subjects to attend the oesophageal physiology lab within the 
endoscopy department at the Royal Victoria Infirmary. I performed all tests and data 
analysis. 
In preparation for these studies, I completed a programme of training. I began by shadowing 
the nurse practitioner who ran the physiology lab at the time of the study (Joy Candler). I 
observed her performing and analysing the tests, and studied the theory and practice of 
oesophageal manometry and ambulatory oesophageal monitoring. I familiarised myself with 
practice guidelines published by the British Society of Gastroenterology, the Association of 
Gastro-Intestinal Physiologists and the International High Resolution Manometry Working 
Group (Bodger and Trudgill, 2006; Bredenoord et al., 2012; Association of Gastrointestinal 
Physiologists, 2013). 
Over the following six weeks I attended regular lists and performed tests and analysis with 
progressively greater independence. At the end of this process, I performed four combined 
manometry/pH-impedance tests independently and received feedback on my reports. 
I subsequently travelled to Enschede in The Netherlands for a three-day residential training 
course on manometry and ambulatory monitoring. Teaching was delivered by Arjan 
Bredenoord, principal author of the Chicago Classification system of High Resolution 
Manometry (Bredenoord et al., 2012). 
Before recruiting the first patient to this study, I was independently performing and 
interpreting clinical tests at the Royal Victoria Infirmary in Newcastle upon Tyne. 
Once recruited to the study, subjects received instructions as to how to prepare for the 
tests. This was included within a standard letter (Appendix A). 
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In summary, participants were asked to: 
 discontinue medications that affect the investigations in advance (2 weeks for proton 
pump inhibitors; 48 hours for H2-receptor blockers and antacid medication) 
 fast for a minimum of 4 hours before the study appointments 
  arrange to be accompanied home after the visit, in the event that sedation was used 
for bronchoscopy 
3.1.7 Oesophageal manometry 
A water-perfused system was used for all manometry recordings (Medical Measurement 
Systems, Enschede). For the first 11 subjects in the previous phase of study, manometry was 
assessed using a “conventional” 8-channel manometry system. Following an equipment 
upgrade in the physiology laboratory, the remaining tests were performed using a high-
resolution 20-channel system. Investigations were undertaken in line with manufacturers’ 
instructions and in accordance with guidelines published by the Association of Gastro-
Intestinal Physiologists (Association of Gastrointestinal Physiologists, 2013). 
A single-use catheter was connected to the manometry system, comprising a low 
compliance pneumo-hydraulic perfusion pump and a manometer corresponding to each 
channel. Transducers relay the pressure signals to the analysis software (MMS, Enschede, 
The Netherlands). 
The catheter was perfused with sterile water for ten minutes and air bubbles excluded from 
the system. The system was checked by elevating the catheter above the manometers and 
confirming a uniform pressure increase across all channels. The catheter tip was introduced 
through the nose after lubrication. The use of local anaesthetic was avoided, so as not to 
interfere with pharyngeal sensation. After insertion, the pressure readings are calibrated 
against the level of the midpoint of the subject’s oesophagus. 
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8-channel manometry - technique 
In the 8-channel probe, the four channels closest to the tip are arranged radially at the same 
level, and the remaining four channels are arranged at intervals of 5cm. The measurement 
span of the probe is therefore 20cm in total (Figure 3-1). 
Figure 3-1. The orientation of side-holes in an 8-channel manometry cather 
 
The catheter tip is inserted to a depth of 70cm. After insertion, the subject was asked to lie 
in a semi recumbent position, which has been used to derive the normative data for the 
procedure. Gastric placement is confirmed by observing a pressure rise with inhalation. The 
assessment is then conducted in two stages. The lower oesophageal sphincter (LOS) is 
assessed first and the oesophageal body subsequently. 
As the tip is withdrawn from the stomach into the oesophagus, the high pressure zone of the 
lower LOS is demonstrated and may be assessed. With the four radially-orientated channels 
in the LOS, the subject is asked not to swallow and the mean resting pressure is recorded 
over a period of 10 seconds (baseline pressure). 5ml water is injected into the subject’s 
mouth and as they swallow, the pressure drop within the LOS is recorded. The mean residual 
pressure may be expressed in real terms (mmHg) and also as a percentage pressure drop 
relative to the resting pressure. 
The catheter is then withdrawn so that the entire 20cm span is lying within the oesophageal 
body. The patient is then asked to swallow a 5ml water bolus a further ten times and the 
propagation of the peristaltic swallow wave is visualised. After ten swallows have been 
recorded the probe is removed. 
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8-channel manometry – analysis 
The following parameters are calculated for each swallow. 
Lower oesophageal sphincter 
Location: from the point of insertion in the nose (cm) 
Length: (cm) 
Tone:   Mean resting baseline pressure (mmHg) 
Relaxation:  Mean pressure on deglutitive relaxation (mmHg) 
% relaxation: (Deglutitive relaxation pressure – Mean relaxation pressure) 
Mean relaxation pressure 
 
Oesophageal body 
Mean contractile amplitude relative to baseline pressure (mmHg) 
Peak contracticle amplitude relative to baseline pressure (mmHg) 
Conduction velocity  (cm/s) 
Based on these metrics, the individual swallows are categorised according to a semi-
automated analysis: 
 Peristaltic contractions: the proximal oesophagus contracts before the distal 
oesophagus and contraction peaks are seen in all oesophageal body channels 
 Dropped contractions: the proximal oesophagus contracts normally but in there is no 
contraction in the distal oesophagus 
 Interrupted contractions: contractions occur in the proximal and distal oesophagus, 
but are absent in the channels in between 
 Non-transmitted contractions: absence of contractile activity in the oesophagus 
following a wet swallow 
Analysis of the individual swallows was then combined to provide a global classification of 
oesophageal peristalsis, Table 3-4 (Spechler and Castell, 2001). 
67 
 
Table 3-4. Classification of oesophageal peristalsis using conventional manometry assessment 
Normal Peristalsis Normal peristalsis >70% of the time 
Mild Ineffective Oesophageal Motility Abnormal peristalsis 30-70% of the time 
Severe Ineffective Oesophageal Motility Normal peristalsis <30% of the time 
Aperistalsis Abnormal peristalsis 100% of the time 
Diffuse Oesophageal Spasm >10% of swallows simultaneous with mean amplitudes over 
30mmHg 
Nutcracker Oesophagus Mean amplitude of peristalsis >180mmHg 
Hypertonic Lower Oesophageal Sphincter >45mmHg but relaxing 
Hypotonic Lower Oesophageal Sphincter <10mmHg 
Achalasia 
 
Hypertonic LOS, absent or incomplete relaxations >70-80% of the 
time. Simultaneous contractions or aperistalsis in the 
oesophageal body 
 
High resolution manometry - technique 
High-resolution manometry (HRM) was used for the latter patients in the study. 
Conventional and high-resolution manometry are compared in Table 3-5. 
Table 3-5. Comparison of conventional and high resolution oesophageal manometry assessment 
Technique Conventional High resolution 
Number of channels 8 20 
Calibre of probe 3.9mm 4.9mm 
Span of measurement 20cm 35cm 
Setup time Shorter Longer 
Study time Longer Shorter 
Assessment of LOS and oesophageal body Sequential Simultaneous 
Oeosphageal body assessment 10 x 5ml swallows 10 x 5ml swallows 
Display Line graphs Colour density plot 
 
The probe was inserted through the nose and positioned at around 55cm, such that the LOS, 
oesophageal body and upper oesophageal sphinter (UOS) could be visualised 
simultaneously. 
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The subject was asked not to swallow for a period of 10 seconds and subsequently, 
oesophageal function is assessed over the course of 10 x 5ml water swallows. The results of 
the study are expressed as a colour plot. Different colours represent different pressures. The 
components of the swallow, as visualised by HRM are illustrated in Figure 3-2. After ten 
swallows have been recorded the probe is removed. 
Figure 3-2. Oesophageal pressure topography illustrating a normal swallow. Colours corresponding to 
specified pressures are illustrated on the left of the figure. UOS = upper oesophageal sphincter; IBP rise = 
intra-bolus pressure rise; LOS = lower oesophageal sphincter. Taken from (Fox and Bredenoord, 2008). 
 
  
69 
 
High resolution manometry - interpretation 
Individual swallows are analysed according to the Chicago classification system (Bredenoord 
et al., 2012), a semi-automated analysis of the pressure pattern. In the same way that 
contours on a map link the points of a specified height, isobaric contours can be displayed as 
a spatiotemporal colour plot and used to demarcate individual components of a swallow. 
Figure 3-3 illustrates the way in which a swallow is analysed. Two key landmarks are used: 
 Proximal pressure trough (P): the physiological trough which results from the 
interdigitation of the striated muscle in the upper oesophagus and the smooth 
muscle in the lower oesophagus. 
 Contractile deceleration point (CDP): the inflection point along the 30 mmHg isobaric 
contour where propagation velocity slows. This represents the transition between 
the tubular oesophagus and the stomach. 
The following metrics are calculated as per the Chicago classification system, as illustrated in 
Figure 3-3 (Bredenoord et al., 2012). 
Lower oesophageal sphincter (LOS) 
Location and length, as measured from the point of nasal insertion of the catheter 
Tone:   Resting pressure = mean resting pressure recorded within the LOS (mmHg) 
Relaxation:  Integrated relaxation pressure = mean pressure within the oesophagogastric 
junction during the lowest pressure period of 4 seconds recorded at any time 
within the 10 seconds after swallow initiation (mmHg) 
Oesophageal body 
Peristaltic amplitude: Distal contractile index = Amplitude x duration x length of the distal 
oesophageal contraction >20 mmHg from proximal pressure trough and the contractile 
deceleration point (mmHg.s.cm) 
Duration:  Distal latency = Interval between UOS relaxation and the contractile 
deceleration point (s) 
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Propagation velocity:  Contractile front velocity = Slope of the tangent approximating the 30 
mmHg isobaric contour between P and the CDP (cm/s) 
Classification of swallow:  Timing of onset as well as velocity and amplitude of 
contraction are used to classify each swallow, as described in Table 3-6. The algorithm within 
the Chicago classification can then be used to summarise an individual’s swallow function 
based on the results of the ten recorded swallows ( 
Figure 3-4). 
Figure 3-3. Oesophageal pressure topography plot illustrating a normal water swallow as assessed by high-
resolution manometry. Pressure scale indicated by the colour bar on the left (mmHg). UES = upper 
oesophageal sphincter; LES = lower oesophageal sphincter; CFV = contractile front velocity; DCI = distal 
contractile index (dashed pink box); DL = distal latency; IRP = integrated relaxation pressure; P=proximal 
pressure trough; CDP=contractile deceleration point. Adapted from (Zerbib and Omari, 2014). 
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Table 3-6. Defining features of an individual swallow ((Bredenoord et al., 2012)) 
Integrity of Contraction  Contraction Pattern 
Intact – No peristaltic breaks 
 
Weak – Large (>5cm) or small (2-5cm) peristaltic 
breaks 
 
Absent – Minimal integrity of contour plot 
Premature (DL < 4.5s) 
 
Hypercontractile (DCI > 8000mmHg/cm/s) 
 
Rapid Contraction (CFV > 9cm/s)  
 
Normal Contraction (none of the above apply) 
 
Figure 3-4. Flow diagram to illustrate the Chicago classification system of high resolution oesophageal 
manometry (reproduced from (Bredenoord et al., 2012)) 
 
3.1.8 Ambulatory oesophageal monitoring 
After the location of the LOS was determined, gastro-oesophageal reflux was assessed using 
a multilumen endo-oeosphageal probe. It is a 1.9mm calibre single-use device consisting of 
six impedance channels and a pH probe, as illustrated in Figure 3-5 (pHersaflex catheter, 
Medical Measurement Systems, Enschede, The Netherlands). After a 10 minute pre-soak in 
deionised water, buffer solutions (pH 1 and 7) were used to calibrate the pH probe at room 
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temperature prior to nasal insertion. The probe is fixed such that the pH probe is located 
5cm proximal to the upper border of the LOS. 
Figure 3-5. The arrangement of pH and impedance sensors within the pHersaflex catheter 
 
After insertion, the probe is connected to an Ohmega ambulatory data recorder (MMS, 
Enschede, The Netherlands). The recorder has buttons for patients to record symptoms, 
meals and position (upright or supine). They were also given a standardised patient diary to 
complete. After the 24 hour period, patients returned to the lab and the catheter was 
removed. The recording box was then connected to the MMS software and the data 
uploaded. The trace was reviewed manually and the electronic diary was verified with the 
paper diary and edited appropriately. After the trace was reviewed the MMS software 
provided an automatic analysis and summary of impedance-pH events and symptoms 
scores. 
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pH assessment 
pH measurements were recorded over a period of not less than 16 hours. The following 
parameters were recorded and used to calculate the Demeester score, a composite measure 
of GOR (Johnson and Demeester, 1974). 
 Number of reflux events 
 Length of longest reflux 
 Number of reflux periods > 5minutes 
 Percentage of overall study time pH<4 
Impedance assessment 
Impedance analysis was compared to published normal ranges (Zerbib et al., 2005). The 
following parameters are recorded and analysed: 
 Reflux events 
o Acid:   pH<4 
o Weakly acid:  pH 4-7 
o Non-acid:  pH>7 
 Number of proximal events i.e. recorded at the proximal channel, 17cm from the 
catheter tip 
 % of the total reflux time during which proximal reflux was recorded 
 Oesophageal volume exposure: % time for which liquid was detected at the most 
distal channel 
 Bolus clearance time: mean delay between detection of liquid and detection of gas at 
the most distal channel 
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Symptom-event correlation analysis 
Based on the subject’s button presses, the correlation of GORD-related symptoms and reflux 
events was analysed. Association is determined by the presence of a reflux event in the two 
minutes preceding symptom onset (Bredenoord et al., 2005). Three measures are used: 
 Symptom index (SI): the proportion of symptom episodes associated with a reflux 
event (Ward et al., 1986). 
 Symptom sensitivity index (SSI): the proportion of reflux events associated with a 
symptom (Breumelhof and Smout, 1991). 
 Symptom-associated probability (SAP): a statistical analysis of the degree of 
association between the symptoms and events. SAP uses a Fisher’s exact test which 
analyses the total duration of the study as divided into in two-minute windows, 
according to a 2x2 matrix comparing symptoms (positive/negative) and reflux 
events (positive/negative)(Weusten et al., 1994). 
3.1.9 Bronchoscopy 
A standardised bronchoscopy and bronchoalveolar lavage (BAL) was performed by a single 
consultant respiratory physician within the Newcastle-upon-Tyne Hospitals NHS Foundation 
Trust (IAF). In addition to consent for study participation, consent is also recorded in line 
with routine clinical practice. 
The BAL procedure was performed in line with previous reports from our group (Stovold et 
al., 2007). Participants are offered the option of premedication with intravenous midazolam. 
4% lignocaine was applied topically to the nose, pharynx, larynx and subglottis. 
Supplemental oxygen was administered and pulse oximetry recorded. Transnasal 
bronchoscopy was then performed. One or more images of the hypopharynx and vocal cords 
were captured prior to tracheal intubation.  
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The tip of the bronchoscope was wedged into a right middle lobe subsegmental bronchus 
and a standardised 3 x 60ml lavage is performed. The quantity of fluid retrieved was 
recorded. 5ml of BAL fluid was sent to the hospital laboratory for routine culture. 
Visual assessment of laryngopharyngeal reflux 
Anonymised images were later reviewed by Mr Julian McGlashan, a Consultant Ear Nose and 
Throat surgeon with an interest in LPR. Images were scored using the Reflux Finding Score, 
Table 3-7. Scores greater than seven are said to indicate LPR (Belafsky et al., 2001). 
Table 3-7. Component scoring for the Reflux Finding Score, an instrument validated to assess the severity of 
laryngopharyngeal reflux (Belafsky et al., 2001) 
Subglottic oedema 0 = absent 
2 = present 
Ventricular 2 = partial 
4 = complete 
Erythema/hyperemia 2 = arytenoids only  
4 = diffuse 
Vocal fold edema 1 = mild 
2 = moderate 
3 = severe 
4 = polypoid 
Diffuse laryngeal edema 1 = mild 
2 = moderate 
3 = severe 
4 = obstructing 
Posterior commissure hypertrophy 1 = mild 
2 = moderate 
3 = severe 
4 = obstructing 
Granuloma/granulation tissue 0 = absent  
2 = present 
Thick endolaryngeal mucus 0 = absent 
2 = present 
 
3.1.10 Bronchoalveolar lavage fluid processing 
The BAL fluid sample was transferred on ice for processing at the Newcastle University 
research laboratories. BAL processing was performed in accordance with an established 
standard operating procedure (Appendix G). Samples were centrifuged and a total cell count 
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estimated from the reconstituted cell pellet using a haemocytometer. Cytospin preparations 
were prepared on glass slides, air-dried and stored at -20oC for later examination. A 
maximum of 6 x 1ml cell pellets were reconstituted in RNA lysis buffer (Qiagen) and 25 x 
600μl aliquots of acellular fluid were stored at -80oC. A single cytospin was stained with 
Giemsa and a differential cell count determined. 
As part of my lab training, I counted archived cytospins. Prior to recruitment, my neutrophil 
and macrophage counts were within 5% of those recorded by experienced lab personnel (GJ 
and KJ). 
3.1.11 Assessment of aspiration 
Cytology 
Cells were stained with oil red O to visualise lipid-laden macrophages, according to the 
method of (Hopkins et al., 2010). Oil red O is a Polyazo dye with higher solubility in lipid than 
in solvent. The standard operating procedure is established in our lab. Oil red O stain was 
combined with 60% isopropanol to make up a working solution. Cytospins were fixed in 
formalin in preparation before oil red O staining and counterstaining with Cilestin 
counterstain. An aqueous mountant was used. 
Using the method of Colombo and Hallberg, a lipid-laden macrophage index was calculated 
for each slide. 300 macrophages were enumerated as follows (Colombo and Hallberg, 1987): 
0 = cytoplasm not opacified 
1 = up to ¼ opacified 
2 = up to ½ opacified 
3 = up to ¾ opacified 
4 = totally opacified cytoplasm 
One in four slides was second-read by an independent observer who was blinded to 
subjects’ clinical histories and test results. 
Additional cytospins were stained to demonstrate oxidative stress through the release of 
chemically active iron. The use of Perl’s Prussian blue, which stains ferric iron from protein-
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bound tissue deposits, is also established within our group (Appendix J). Perl’s reagent was 
constituted with equal volumes of 2% hydrochloric acid and 2% potassium hexacyanoferrate. 
Cytospins were fixed in acetone before staining with Perl’s reagent and counterstaining with 
1% Neutral Red. Slides were then dehydrated in alcohol, cleared in xylene and fixed in D.P.X. 
mountant. For each slide, a haemosiderin score was calculated as described by Kahn et al. 
(1987). 200 macrophages were enumerated as follows: 
0 = no colour 
1 = faint blue in one portion of cytoplasm 
2 = deep blue in a minor portion of the cell 
3 = deep blue in most areas of the cytoplasm 
4 = deep blue throughout the cell 
The total value for all cells was calculated and divided by 2 to obtain a score for an average 
of 100 cells. The percentage of cells staining positively was also recorded. Cell counting and 
scoring was repeated by a blinded observer. 
Pepsin measurement by enzyme-linked immunosorbent assay 
Pepsin concentrations were measured by a PhD student (GZ) within the research group using 
a protocol modified from an established, locally developed enzyme-linked immunosorbent 
assay (ELISA) (Tasker et al., 2002; Stovold et al., 2007).  
At each step, wells were washed three times with 0.05% Tween 20 in PBS and incubated at 
room temperature with vigorous shaking (800rpm on a plate shaker unless specified). 100µl 
aliquots of unconcentrated sample and standard solution (0-100ng/ml porcine pepsin in PBS, 
Sigma, Dorset, UK) were incubated overnight in a 96-well plate.  
Blocking 
1% bovine serum albumin in PBS was added before incubation for 2 hours at 500rpm. 
Primary antibody binding 
Standards and samples were incubated at room temperature for 2 hours with primary 
antibody: positive wells were incubated with anti-pepsin antibody (1:100 dilution in 0.1% 
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BSA/PBS, Biodesign International, TN, USA) and negative wells with 100µl 0.1% BSA solution. 
(The primary antibody binds both pepsin and pepsinogen.) 
Secondary antibody binding 
All wells were incubated at room temperature for 2 hours with 1:1000 HRP-conjugated 
antisheep/goat in 0.01% BSA (Sigma). 
Colour development 
100µl of 2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (Sigma) was added to each 
well and allowed to develop for at least 20 minutes at room temperature with light shaking 
(100rpm). The reaction was stopped with 50µl of 1% sodium dodecyl sulphate in deionised 
water. 
Plate-reading 
The plate was measured at 405nm with the Infinite 200 Pro plate reader, using i-control 
software (Tecan, Männedorf, Switzerland). 
Bile salt measurement by spectrophotometry 
Bile acid concentration was measured using the Total Bile Acids kit (Alere, Stockport, UK). 
Three buffers are supplied in stable liquid formulation: 
R1:   Thio-NAD >0.1mM, Buffer 
R2:   3-a-HSD >2kU/L, NADH >0.1mM, Buffer 
Calibrator Conjugated cholic acids, Buffer 
270µl R1 and 4µl of sample or calibrator was incubated at 37oC for 3 minutes in triplicate. 
Blank absorbance was measured at 405nm. 
For each sample/calibrator, 90µl R2 was added to the 2 positive wells and 90µl heat-killed R2 
was added to the single negative well. The absorbance was then measured at 405nm after 1 
minute and 10 minutes. ΔA405nm was calculated as the difference between these two 
readings. 
TBA concentrations were determined using the equation: 
Sample ΔA405nm/10min – Blank ΔA405nm/10min x       Calibrator 
Standard ΔA405nm/10min – Blank ΔA405nm/10min 
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3.1.12 Formation of a novel aerodigestive multidisciplinary team 
The question of how best to investigate micro-aspiration in complex respiratory patients is 
crucial to the field of aerodigestive medicine. Greater experience of the clinical and 
experimental techniques used in the current study can help to define their role. At present, 
data generated in the course of this research must be handled sensitively so that all 
management decisions are appropriate.  
In order to discuss this challenging patient group, we established a cross-site aerodigestive 
multidisciplinary team in the Newcastle-upon-Tyne Hospitals NHS Foundation Trust. There is 
regular input from upper GI surgeons, respiratory physicians, transplant physicians and 
anaesthetists.  Team members’ attendance, the results of relevant investigations and 
decisions regarding further investigation and management were recorded prospectively. To 
our knowledge this is the first time an aerodigestive MDT has been formally convened. 
3.1.13 Statistical analysis 
Analysis was performed using Minitab 17 (State College, Pennsylvania, USA). Analysis was 
largely descriptive. Where necessary, normality of data was assessed using the Anderson-
Darling statistic and statistical significance was accepted at α<0.05.  
Proportions were compared using the Chi-squared statistic.  
For normally distributed continuous data, comparisons were made using paired T-tests and 
unpaired (Student’s) T-tests as appropriate. Correlation was assessed using Pearson’s test. 
For non-parametric data, continuous datasets were compared using the Mann-Whitney U-
test and the Kruskal-Wallis test as appropriate. Correlation was assessed using the Spearman 
Rank method. 
Physiology data were analysed with reference to published data from healthy control 
populations (Zerbib et al., 2005). Unless otherwise specified, the upper limit of normal was 
taken as the upper limit of the 95% confidence interval. 
Inter-rater agreement was assessed using appropriate correlation coefficients (Pearson r, 
Spearman and Intraclass) in addition to the Bland-Altman method (Bland and Altman, 1986). 
This latter method accounts for the mean difference between paired data points and the 
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standard deviation of the differences. Most of the differences will lie within 2 standard 
deviations of the mean difference. If the differences are Normally distributed then 95% of 
the values will lie within this range, termed the “limits of agreement”.  
Statistical methodology was reviewed with Dr Kim Pearce, Senior Statistician in the Institute 
of Cellular Medicine, Newcastle University.
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3.2 Evaluation of patient attitudes towards the treatment of reflux in IPF 
3.2.1 Ethical approval 
The study was considered by the Proportionate Review Sub-Committee of the London-
Bromley NRES Committee on 18th March 2014 (ref 14/LO/0531). The NHS sponsor for the 
study was the Newcastle-upon-Tyne NHS Hospitals Foundation Trust. Study approval was 
granted by Newcastle-upon-Tyne Hospitals R&D on 6th May 2014 (ref 6956) and by 
Gateshead Health on 23rd April 2014 (ref 928/14). 
3.2.2 Study overview 
The aim of this analysis was to evaluate the burden of antireflux therapy in the context of 
idiopathic pulmonary fibrosis. Respondents’ valuations of their own quality of life and of a 
set of written scenarios were recorded. The scenarios described i) health states relating to 
differing severities of idiopathic pulmonary fibrosis, and ii) adverse outcomes related to 
medical and surgical antireflux therapy. (As the respiratory benefit of antireflux therapy has 
yet to be quantified, good outcomes from antireflux therapy were not evaluated.) 
Study participants completed a standardised study interview which included a standard 
gamble in addition to a validated assessment of their performance status. Pulmonary 
function tests were extracted from patients’ medical records to help define disease severity. 
The strengths and weaknesses of the choice-based methods for utility measurement are 
discussed in section 1.5.3. The standard gamble was selected because it entails a choice 
between an ongoing health state and an intervention, the outcome of which is uncertain. 
This framework is consistent with the decision that a patient with IPF would have to make in 
considering the pros and cons of a specific treatment, such as antireflux therapy. 
3.2.3 Study sample and recruitment  
Prospective participants were identified from the interstitial lung disease out-patient clinics 
at the Royal Victoria Infirmary in Newcastle and the Queen Elizabeth Hospital in Gateshead. 
A letter outlining the study was posted out. At the outset, patients who did not wish to take 
part were given the opportunity to opt out by email or telephone/voicemail. 
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After a minimum of 72 hours, prospective participants were contacted by phone to discuss 
the study in more detail. Individuals keen to participate were sent a patient information 
sheet and offered an appointment for the study interview. The interview was conducted in 
the outpatient department or as a home visit. 
3.2.4 Inclusion criteria 
• Diagnosis of idiopathic pulmonary fibrosis, as defined by international consensus 
guidelines (Raghu et al., 2011) 
• Age 18 or over 
3.2.5 Exclusion criteria 
• Difficulty in understanding written or verbal information in English 
• Deterioration in lung function (as defined by change in WHO performance status in 
the preceding 4 weeks) 
• Cognitive impairment such that informed consent could not be given 
3.2.6 Sample size 
There is no previous work in this area to inform a power calculation. For analysis purposes, 
participants were divided into mild/moderate disease and moderate/severe disease. 
Stratification between these two groups was made with reference to the median adjusted 
total lung capacity for the overall study population. In accordance with published convention 
for pilot studies where no previous data is available, the recruitment target was 30 patients 
per group (Lancaster et al., 2004). The overall recruitment target was therefore 60 patients. 
3.2.7 Standard gamble method 
Standard gamble interviews were conducted with the use of a chance board (Figure 3-6). 
The chance board illustrates a choice with two alternative options: one option consists of a 
gamble between two uncertain outcomes; the other option is a single certain outcome.  The 
board is divided into two sections.  The top half of the board illustrates the uncertain Choice 
A (Alternative 1) with probability p of the most preferred health state and 1-p of the least 
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preferred health state.  Two small windows in this part of the board indicate the 
probabilities corresponding to p and 1-p.  The probabilities can be changed by turning the 
wheel on the left of the board.  On the bottom part of the board is the certain outcome 
Choice B (Alternative 2).  The chance board thus converts the probabilities into a percentage 
risk of a specified outcome.  
Figure 3-6. Chance board used as a prop to illustrate decision-making within the standard gamble. Example 
vignette featured as “Choice B”. 
 
To start, the chance board was set at a 90% chance of the preferred health state (eg 
returning to full health) and a 10% chance of the least preferred health state (eg immediate 
death).  The individual was asked to make a choice between Choice A and Choice B.  The 
probabilities were then altered using a ping-pong strategy, whereby probabilities are 
alternated back and forth between a low value and a high value until the individual is 
indifferent between Choice A and Choice B.  The percentages on the chance board convert 
to the probabilities for p and 1-p.  The probability at the point where the individual is 
indifferent between Choice A and Choice B is the utility value of the health state described in 
Choice B. 
The vignettes were presented to the subjects in random order, to avoid order-of-study bias. 
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3.2.8 Vignette design 
For the purposes of the standard gamble, it was necessary to construct a series of concise 
descriptions such that study respondents could evaluate the burden of disease associated 
with both idiopathic pulmonary fibrosis and with adverse outcomes of antireflux treatment. 
There is no accepted methodological approach to the generation of vignettes for health 
state utility analysis. In order for a health state description to provide a useful and authentic 
representation of the disease state in question, the following factors would seem important: 
 Concise description, but with sufficient detail to provide meaningful explanations 
 Symptom domains identified by patients affected by the condition 
 Symptom severity defined in line with accepted grading systems where appropriate 
 Validated by clinicians with specialist experience 
 Written in simple language, avoiding the use of jargon 
The process through which vignettes were composed and ratified is outlined in Table 3-8. 
The final version of the four vignettes is shown in Box 2. 
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Table 3-8. Iterative process through which health state scenarios were designed for the standard gamble. 
Superscript figures relate to notes detailed below the table 
Step Description Antireflux therapy Idiopathic pulmonary fibrosis 
1 Factor 
generation 
Fortnightly upper gastrointestinal surgery 
outpatient clinic interviews over  12 
months (n≈50) 1 
Following review of a qualitative research 
study undertaken on behalf of 
Boehringer-Ingelheim 2 
2 Severity 
correlation 
Summary of Product Characteristics, 
Omeprazole 3 
Dyspnoea guidelines 4 
3 Vignette 
composition 
In collaboration with health economics 
supervisors at Institute of Health and 
Society 5 
In collaboration with health economics 
supervisors at Institute of Health and 
Society 
4 Clinician 
ratification 
Interviews with  consultant oesophago-
gastric surgeons (n=4) 6 
 
Round table discussion with three senior 
registrars 7 
Interviews with consultant respiratory 
physicians with an interest in interstitial 
lung disease (n=3) 8 
 
Interview with a senior registrar training 
in respiratory medicine  9 
 
Notes 
1. Northern Oesophago-Gastric Unit (NOGU), Royal Victoria Infirmary, Newcastle-upon-
Tyne. 
2. Boehringer-Ingelhem commissioned Brains and Cheek, a qualitative research agency, 
to undertake a piece of qualitative research exploring the impact of idiopathic 
pulmonary fibrosis on quality of life in people living with the condition. The project 
consisted of in-depth interviews with a total of 18 patients and carers. The results of 
the study were presented to Boehringer-Ingelheim in a series of slides, to which I was 
allowed access. 
3. (Teva UK Limited, 2009) 
4. (Fletcher et al., 1959) 
5. Dr Laura Ternent, Senior Lecturer, Institute of Health and Society, Newcastle 
University 
Dr Peter McMeekin, Reader in Health Economics, Northumbria University 
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6. Professor Michael Griffin, Mr Nick Hayes, Mr Daya Karat, Mr Arul Immanuel; all based 
at NOGU 
7. Mr Sebastian Kwon, Mr Barry Dent, Mr Maziar Navidi; all based at NOGU 
8. Professor John Simpson, Dr Ian Forrest; Department of Respiratory Medicine, Royal 
Victoria Infirmary, Newcastle-upon-Tyne 
Dr Rob Allcock; Department of Respiratory Medicine, Queen Elizabeth Hospital, 
Gateshead 
9. Dr Jit Dutta, Department of Respiratory Medicine, Newcastle-upon-Tyne 
Box 2. Health state descriptions used in the standard gamble. Outcome W: mild IPF. Outcome X: moderate 
IPF. Outcome Y: adverse outcome from antireflux surgery. Outcome Z: adverse outcome from medical 
antireflux therapy. 
 
No definition of “Full Health” was volunteered, but if interview subjects asked specifically 
what Full Health entailed, they were told: 
“You can think of Full Health as a scenario where you are entirely free of symptoms and do 
not require any ongoing medical treatment.” 
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3.2.9 The interview process 
An interview manual and a response booklet were prepared so as to standardise instructions 
and data capture. The manual included an interview script which was read out verbatim. 
The following demographic details were recorded: 
 Gender 
 Date of birth 
 Marital status 
 Co-habitation 
 Employment status 
 Educational qualifications 
 Ethnicity 
Utility values for the four health states detailed above were calculated using standard 
gamble. The respondent’s own current health state was also measured.  
Finally, respondents were asked to complete a multidimensional health-related quality of life 
tool, EuroQOL-5D-3L (0). EuroQOL-5D-3L is brief, self-completed health-related quality of life 
survey in which respondents select one of three statements in answer to questions relating 
to five domains. The domains are pain, mobility, mood, level of function and self-care. After 
registering the study with the EuroQOL group, syntax was provided for use in the statistical 
program SPSS (IBM, New York, USA). Each respondent’s answers to the five questions were 
mapped to a predefined utility score. These figures were generated through a large time-
trade off study (Dolan, 1997). 
Euroqol-5D also includes respondents to assess their global quality of life on a visual 
analogue scale. The validated nature of this tool provides a reference point with which to 
compare respondents’ responses to the standard gamble. 
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3.2.10 Statistical analysis 
Statistical analysis was performed as described in section 3.1.13. In line with the convention 
of the health economics literature, utilities were analysed using parametric methods.
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Chapter 4. Results of Characterisation Study 
4.1 Study overview 
Thirty-seven study subjects were recruited from the regional interstitial lung disease clinic at 
the Royal Victoria Infirmary, Newcastle-upon-Tyne. The first twenty subjects were recruited 
and studied by a previous doctoral research student (Amaran Krishnan). I studied the 
remaining 16 subjects. 
Patients had already been screened to confirm their respiratory diagnosis. All had undergone 
clinical assessment, pulmonary function testing and CT scans. Clinic review was supported by 
formal multidisciplinary discussion. None of the patients underwent lung biopsy. 
After informed consent had been recorded, patients completed a panel of study 
questionnaires to assess symptoms of gastro-oesophageal reflux, laryngo-pharyngeal reflux 
and respiratory health. Those individuals who were taking proton pump inhibitors were 
asked to discontinue their medication. In this group, questionnaires were repeated after a 
two-week period of cessation. Objective study assessments were performed after this wash-
out period. 
There were two study visits, held on consecutive days at the RVI. On the first day, subjects 
underwent oesophageal manometry and naso-oesophageal intubation with an endo-
oesophageal probe, connected to an electronic data recorder. They were instructed to 
electronically record their symptoms, meal-times and supine periods over the forthcoming 
24 hours of pH-impedance monitoring. One subject was unable to tolerate naso-
oesophageal intubation and was excluded from all study analyses. The remaining 36 subjects 
completed all tests. 
On the second day the probe was removed and data were transferred to the departmental 
database for analysis. Subjects then underwent bronchoscopy and bronchoalveolar lavage. 
Study samples were transferred to the university laboratories for processing and analysis. 
A group of four control subjects were recruited from within the university staff and 
underwent the same bronchoscopy and lavage. 
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4.2 Recruitment and demographics 
The recruitment of participants in this study was managed at the regional interstitial lung 
disease clinic at the Royal Victoria Infirmary in Newcastle-upon-Tyne. This is a weekly clinic 
which was established in 2010. Suitable patients were identified from clinicians running the 
clinic, based on the inclusion and exclusion criteria detailed in section 3.1.2.  Those willing to 
discuss the work further were referred to the lead researcher and further information 
regarding the study was outlined. This was consistently undertaken in a different clinic room 
from that in which the patient was seen for their clinic appointment. As the clinic became 
increasingly busy, it was no longer practicable to discuss the research with patients face to 
face. Latterly, the study was outlined to potential participants by telephone after they had 
been identified by the clinical team. 
Seventy-nine eligible subjects were invited to participate. 36 completed the study protocol. 
Study recruitment is summarised in Figure 4-1. 
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Figure 4-1. Recruitment and completion figures for the characterisation study 
 
There were 27 males. Median age was 72.5 and the interquartile range was 64.5-77.7. Two 
subjects were active smokers at the time of recruitment. Ten patients stated they had never 
smoked. The majority were ex-smokers who had stopped more than 6 months ago; two had 
stopped within six months of recruitment.  
Ten subjects were taking corticosteroids and eight were taking N-acetylcysteine. 25 subjects 
were taking a proton-pump inhibitor (PPI) at the time of recruitment. 
Eleven patients had pre-existing evidence of GORD documented either in clinical letters or at 
recent endoscopy within the preceding two years. 
As a routine, pulmonary function testing is repeated at each visit to the regional ILD clinic. 
The spread of vital capacity recordings is illustrated in Figure 4-2. Median percentage-
predicted vital capacity was 77.6% (range 47.9-146.4). 
Invited to participate: 79  
Verbally agreed: 44 
Study visit booked: 41 
Study completed: 36 
Declined: 35   
Died prior to study: 2; relocation: 1 
Died prior to study: 2 
Oesophageal physiology not tolerated: 1 
Did not attend: 2 
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Figure 4-2. Histogram illustrating the percentage predicted vital capacity readings taken prior to participation 
in the study 
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Subjectively, patients are graded in clinic according to the MRC dyspnoea scale. Study 
subjects were categorised as detailed in Table 4-1. 
Table 4-1. Study subjects' breathlessness status at recruitment (Fletcher et al., 1959) 
Grade Degree of breathlessness related to activities Number of subjects 
1 Not troubled by breathlessness except on strenuous exercise 5 
2 
Short of breath when hurrying on the level or walking up a slight 
hill 
11 
3 
Walks slower than most people on the level, stops after a mile or  
so, or stops after 15 minutes walking at own pace 
8 
4 
Stops for breath after walking about 100 yds or after a few 
minutes on level ground 
9 
5 
Too breathless to leave the house, or breathless when 
undressing 
3 
 
Within the second phase of recruitment, subjects were asked to complete the St George’s 
Respiratory Questionnaire as a measure of respiratory health-related quality of life. Median 
SGRQ score off PPI was 44.15. 
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For the small group of subjects who completed these questionnaires both on and off-PPI, 
there was a significant difference in the scores after PPI therapy was discontinued, Table 4-2. 
In statistical terms, SGRQ scores decreased significantly after PPI was discontinued 
(p=0.005). This change is consistent with an improvement in respiratory health-related 
quality of life following cessation of PPI. 
Table 4-2. Respiratory health-related quality of life score recorded on and off PPI medication 
 
St. George’s Respiratory 
Questionnaire 
Study 
ID 
On PPI Off PPI 
22 71.07 64.60 
23 45.06 35.86 
25 50.77 42.66 
27 42.33 44.03 
28 66.69 60.68 
30 21.17 7.49 
31 73.07 60.54 
33 59.69 32.24 
34 69.75 61.94 
 
The Minimal Important Difference for SGRQ is most commonly quoted at 4, as determined 
by a range of distribution and anchor-based methods (Jones, 2002). With respect to this 
figure, there was a significant improvement in respiratory symptomatology in 89% of 
subjects. 
4.3 Assessment of gastro-oesophageal reflux 
4.3.1 Subjective assessment 
In the latter group of 16 subjects, the Gastro-esophageal reflux disease questionnaire 
(GerdQ) was used to assess classical symptoms of reflux disease (Jones et al., 2009)(Figure 
4-3). A score of 8 or more supports a diagnosis of gastro-oesophageal reflux disease. 
On PPI, two patients (22%) recorded positive GerdQ scores. This proportion increased to 
29% when subjects were off PPI. The median scores for these groups was 6 and 6.5, 
respectively. Overall, 25% of respondents recorded GerdQ scores suggestive of reflux 
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disease. All but one had pre-existing evidence of GORD based on their clinical assessment 
and/or endoscopy. 
Paired T-tests revealed there was no significant difference in the on-PPI and off-PPI scores in 
the subjects who discontinued therapy (Figure 4-3). 
Figure 4-3. GORD symptom assessed by GerdQ scores. The individual value plot is overlaid with slope-graphs 
for those patients who completed GerdQ both on and off PPI therapy. The reference line indicates the score 
which has been reported as most discriminating as a cut-off in the diagnosis of GORD (Jones et al., 2009). 
 
4.3.2 Oesophageal manometry 
Thirty-seven subjects gave informed consent and attended for oesophageal physiology. 
Thirty-six completed all components of oesophageal physiology. One was unable to tolerate 
naso-oesophageal intubation so manometric assessment was abandoned. He was excluded 
from all analyses within the study. 
All study participants underwent oesophageal manometry prior to ambulatory pH-
impedance monitoring. The first 11 subjects underwent conventional 8-channel manometry 
and the remaining 25 underwent 20-channel high-resolution manometry. There were no 
complications arising from these tests. 
The analysis of data differs for these two forms of oesophageal manometry. With reference 
to published normal ranges, it was possible to establish the proportion of normal tests for 
both (Spechler and Castell, 2001; Bredenoord et al., 2012). 
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8-channel manometry 
Lower oesophageal sphincter (LOS) pressure was within normal limits for 8 of the 11 patients 
with a mean of 21.9mmHg (range 13-32mmHg). In the remaining three patients the LOS was 
hypertonic. Only one patient had complete relaxation of the LOS with swallowing. Median 
percentage relaxation was 32% (range 0-100%). 
Seven subjects had normal peristaltic activity. One from this group had no LOS relaxation 
with swallowing, leaving six who can be described as having normal oesophageal swallows. 
The remaining four subjects had evidence of dysmotility. Three had a high proportion of 
simultaneous contractions and one had a mixture of simultaneous and dropped 
contractions, denoting non-specific oesophageal dysmotility. 
Median peristaltic amplitudes are shown in Table 4-3. Two patients had hypotonic segments 
and the remainder had proximal and distal amplitudes within the normal range. 
Table 4-3. Amplitudes of oesophageal peristalsis recorded at conventional 8-channel manometry. NA=not 
available. 
 Median 
(mmHg) 
Range 
(mmHg) 
Normal values 
(mmHg) 
Minimum Oesophageal Amplitude 23 12-51 NA 
Maximum Peristaltic Amplitude 157 104-282 NA 
Average Peristaltic Amplitude 65 40-44 30-180 
Distal Oesophageal Amplitude (5cm above LOS) 53 32-109 30-180 
Proximal Oesophageal Amplitude (15cm above LOS) 68 22-282 30-180 
 
High resolution manometry 
Twenty-five patients underwent HRM. In contrast to 8-channel manometry, HRM 
simultaneously evaluates the LOS and the peristaltic waves within the oesophageal body. 
Results for the key metrics used to assess oesophageal swallows are detailed in Table 4-4. 
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Table 4-4. Metrics used to evaluate oesophageal swallow integrity using the Chicago classification 
 Median Range Normal Values 
Distal Latency (s) 6.4 4.5 – 8.6 >4.5 
Distal Contractile Integral (mmHg.s.cm) 835 14 – 4074 <8000 
Contractile front velocity (cm/s) 5.2 <-100 - >100 ≤9 
Peristaltic Breaks (cm) 1.9 0 – 13.3 <2cm 
Integrated Relaxation Pressure (mmHg) 6.5 -3.8 – 27.6 <15 
 
These metrics are automatically combined by an algorithm within the manometry software 
to generate an overall label, as defined by the Chicago classification, Figure 4-4. 
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Ten of the 25 subjects were categorised as having a normal swallow. A further 10 subjects 
had abnormalities consistent with hypomotility. The remaining five were categorised as 
having distal spasm, rapid contractions or OGJ outflow obstruction. 
Figure 4-4. Chicago classification of HRM results 
 
 
In summary, 8-channel manometry and HRM revealed abnormal swallows in 45% and 60% of 
these respective groups.  
Distal
spasm
2
Normal
10
OGJ 
outflow 
obstruction
2Rapid 
contractions, 
normal latency
1
Weak peristalsis, 
large breaks
6
Weak peristalsis, 
small breaks
4
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4.3.3 Ambulatory monitoring 
pH monitoring 
All thirty-six study subjects underwent multichannel intraluminal pH-impedance monitoring 
using an endo-oesophageal probe positioned manometrically. The pH probe is placed 5cm 
proximal to the lower oesophageal sphincter. The median duration of monitoring was 23 h 4 
min (range: 15h 55- 24h 45). 
Twenty-five subjects were taking proton pump inhibitors at the time of recruitment to the 
study. All were asked to discontinue this medication 2 weeks prior to oesophageal 
physiology assessment. All but one subject (IPF21) discontinued therapy as requested. The 
patient who did not stated that he had forgotten to do so. (Data from this subject were 
included for analysis and are highlighted in relevant figures.) Key results are detailed in Table 
4-5. 
Table 4-5. The results of ambulatory pH monitoring. All figures are scaled so as to represent a 24 hour 
monitoring period. Long refluxes are defined as those in excess of five minutes. 
 Median Minimum Maximum Normal 
range 
Number 
supranormal 
% supranormal 
Total number of 
refluxes 
42.7 0 326.7 <50.2 17 47.2 
Number of long 
refluxes 
3.1 0 39.4 <3.2 17 47.2 
Duration of 
longest reflux 
(minutes) 
12.1 0 164.3 <9.3 21 58.3 
Total reflux time 
(%) 
6.3 0 60 <4.3 20 55.6 
DeMeester 
score 
18.5 0.2 201.6 <14.72 20 55.6 
 
The range of values recorded for the reflux index and the DeMeester score are illustrated in 
Figure 4-5. With reference to either parameter, the same 20 subjects (56%) were identified 
to have supranormal levels of reflux. 
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Figure 4-5. Individual value plots for reflux index and DeMeester score. Horizontal reference lines indicate 
the upper limit of normal for a healthy control population. 
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Impedance monitoring 
The duration of monitoring for the impedance results is identical to that for the pH studies 
as the same probe is used. As with the pH figures, results were scaled so as to be 
comparable with the 24-hour normal ranges. 
Based on impedance monitoring, the median number of refluxes over 24 hours was 31.0 
(range 9.3-119.2).  
Impedance and pH monitoring data are combined to evaluate the acidity of refluxate. The 
breakdown of total, acid (pH<4), weakly acid (pH 4-7) and non-acid (pH 7+) reflux is detailed 
in Table 4-6. Values for the individual subjects are illustrated in Figure 4-6. Seven individuals 
recorded high levels of weakly acid reflux; none recorded high levels of non-acid reflux. 
Objectively high levels of gastro-oesophageal reflux were defined as a high DeMeester score, 
a high level of total reflux on impedance monitoring, or both. According to this definition, 22 
of 36 study subjects had high levels of reflux (61.1%), Table 4-7. Two subjects with high 
levels of reflux on impedance monitoring had normal DeMeester scores of 2.0 and 4.0. Both 
had high levels of weakly acid reflux. 
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Only 29% of the subjects with objectively high levels of reflux had evidence of GORD from 
GerdQ questionnaire results. 
Table 4-6. Number of acid, weakly acid and non-acid refluxes recorded over a standardised 24 hour 
impedance monitoring period.  
 
Median number of 
refluxes (in 24h) 
Minimum 
value 
Maximum 
value 
Normal 
range 
Number 
supranormal 
Total 31.0 9.3 119.2 <75 4 
Acid 17.0 0 86.8 <50 3 
Weakly acid 10.5 0 89.8 <33 7 
Non-acid 0.0 0 3.8 <15 0 
 
Table 4-7. Number of subjects identified to have high levels of reflux by pH and impedance monitoring 
 Level of reflux as assessed by pH monitoring 
High Normal 
Level of reflux as assessed 
by impedance monitoring 
High 2 2 
Normal 18 14 
 
The exposure of the oesophagus to gastric refluxate is measured by the average bolus 
clearance time and the oesophageal volume exposure. Bolus clearance time was prolonged 
in 11 of 36 study subjects and volume exposure was prolonged in four subjects. 
The proximal channel of the oesophageal probe is 17cm up from the tip. When episodes of 
reflux are recorded at this uppermost level they are described as proximal. A median of 6.4 
proximal reflux episodes were recorded in the current study. The upper limit of the 95% 
confidence interval for a health population was reported as 30. As a proportion of the total 
number of refluxes recorded, a median of 10.6% were registered at the proximal channel 
(normal range 12-39). Only three individuals had supranormal levels of reflux over a 24-hour 
period. 
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Figure 4-6. 24-hour reflux events recorded at impedance monitoring. 95th centile reference lines indicate the 
published upper limits of normal for healthy controls (Zerbib et al., 2005). * indicates individuals with 
pathological levels of reflux on pH monitoring; †indicates individuals with pathological levels of proximal 
reflux. Subject number 21 was studied on PPI therapy. 
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4.4 pH-impedance analysis: inter-rater reliability 
To protect against reporting bias, one in three pH-impedance studies from the latter cohort 
were re-reported by a rater blinded to the results of the questionnaires and BAL analysis. 
The key results of this comparison are detailed in Table 4-8 and Figure 4-7. Pearson r and 
intraclass correlation coefficients both indicate strong inter-rater reliability.  
 
Table 4-8. Key pH-impedance results as reported by two independent raters. Rater A=Rhys Jones. Rater 
B=Amaran Krishnan, a surgical registrar and former research fellow who was blinded to the remainder of 
these individuals’ results. 
Study 
number 
24h pH 
reflux 
episodes (A) 
24h pH 
reflux 
episodes (B) 
24h 
impedance 
reflux 
episodes (A) 
24h 
impedance 
reflux 
episodes (B) 
24h 
proximal 
reflux 
episodes (A) 
24h 
proximal 
reflux 
episodes (B) 
21 36.0 36.7 43.7 50 9.8 11.1 
24 7.3 9.0 59.7 64.1 7.3 7.4 
27 53.2 53.6 16.8 19.7 0 0 
31 77.7 74.0 38.7 39 8.5 8.5 
36 59.9 59.9 27.5 31.9 12.1 12.1 
Pearson r 0.999 0.992 0.993 
Intraclass 
correlation 
0.997 0.995 0.993 
 
Figure 4-7. Scatterplots to illustrate the level of agreement between key pH-impedance reflux episode 
counts. Rater details are included in Table 4-8. 
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4.5 Assessment of laryngopharyngeal reflux and pulmonary aspiration 
4.5.1 Subjective assessment 
Symptoms of laryngopharyngeal reflux were assessed with the Reflux Symptom Index (RSI). 
Nine items are graded from 0 (no problem) to 5 (severe problem) to give a maximum score 
of 45. The normal range in a healthy population was reported as 0-13 (Belafsky et al., 2002). 
Twenty-five study subjects were taking a PPI at the time of recruitment. Twenty-three 
completed the RSI questionnaire before discontinuing their medication. Two subjects failed 
to answer at least one question and their responses were excluded. The median score for 
the on-PPI response was 14. Twelve subjects (48%) had scores greater than 13, suggesting 
evidence of laryngopharyngeal reflux. 
Off PPI, the median RSI score was 10. Thirteen patients (37%) had positive RSI scores. The 
median difference when subjects’ on-PPI and off-PPI scores were compared was -1. In 
summary, the questionnaires suggested slightly higher levels of LPR when subjects were on 
PPI therapy than when they were off PPI therapy but the difference was small. 
On and off-PPI scores are illustrated in Figure 4-8. There was no consistent pattern 
associated with PPI cessation. 
There was no good correlation between the objective measurement of proximal reflux and 
the symptoms of laryngopharyngeal reflux, as assessed by the RSI questionnaire (Pearson 
correlation coefficient 0.047),  
 
Figure 4-9. The upper limit for the 95% confidence interval for 24-hour proximal refluxes is 
30. Only three subjects had high levels of proximal reflux in the current study.  
104 
 
Figure 4-8. Extra-oesophageal symptoms as assessed by Reflux Symptom Index in patients taking PPI therapy 
at the time of study recruitment. PPI was discontinued for two weeks prior to physiology testing. 
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Figure 4-9. Scatterplot to illustrate the relationship between levels of objectively measured proximal reflux 
and symptoms of laryngopharyngeal reflux 
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Pharyngeal imaging 
Endoscopic appearances of the hypopharynx were recorded at the time of bronchoscopy 
and later evaluated for evidence of LPR by an external assessor. The Reflux Finding Score 
(RFS) has been validated for this purpose, with a normal range described as 0-7 (Belafsky et 
al., 2001).  
Representative images are illustrated in Figure 4-10. 
Scoring was possible in 35 of 36 subjects. In one, the images were of insufficient quality. RFS 
and RSI scores are detailed in Table 4-9. 
There was no clear association between RFS and RSI scores (Pearson coefficient 0.184, 
p=0.298). Similarly, there was relationship between RFS and objective measures of reflux 
(overall or proximal) or aspiration (BAL pepsin concentration). 
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Figure 4-10. Illustrative bronchoscopy images captured for an external assessor to evaluate evidence of 
laryngopharyngeal reflux using the Reflux Finding Score (Belafsky et al., 2001) 
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Table 4-9. Bronchoscopic and symptomatic assessment of laryngopharyngeal reflux. Four of the eight 
components of the reflux findings scale (RFS) are included here for illustration. RSI=Reflux symptom index. 
Images for subject IPF25 could not be scored due to insufficient image quality. 
Patient 
No  
Vocal fold 
oedema 
Diffuse 
laryngeal 
oedema 
Posterior 
Commissure 
hypertrophy 
Granuloma/ 
granulation 
tissue 
RFS Total RSI Score 
IPF1  1 0 0 0 3 10 
IPF2  2 2 2 0 9 10 
IPF3  1 1 1 0 5 12 
IPF4  2 1 1 0 9 9 
IPF5  3 2 3 0 11 34 
IPF6  2 1 1 0 4 18 
IPF7  1 1 1 0 5 7 
IPF8  2 0 0 0 4 15 
IPF9  2 2 3 0 11 39 
IPF10  3 2 2 0 11 23 
IPF11  1 1 1 0 5 5 
IPF12  0 0 0 0 0 8 
IPF13  3 2 1 0 9 7 
IPF14  2 1 0 0 6 0 
IPF15  1 2 1 0 10 4 
IPF16  0 0 1 0 1 19 
IPF17  2 1 1 0 7 25 
IPF18  0 0 1 0 1 2 
IPF19  2 1 1 0 7 10 
IPF20  1 1 1 0 6 26 
IPF21 1 1 2 0 4 NA 
IPF22 2 0 0 0 2 29 
IPF23 2 1 2 0 5 2 
IPF24 2 2 2 0 6 6 
IPF26 1 2 2 0 5 13 
IPF27 2 1 2 0 5 8 
IPF28 1 1 1 0 3 25 
IPF29 2 1 1 0 4 2 
IPF30 1 0 0 0 1 13 
IPF31 1 0 0 0 1 21 
IPF32 2 1 1 0 4 9 
IPF33 0 0 0 0 0 23 
IPF34 2 2 0 0 4 7 
IPF35 1 3 2 0 6 30 
IPF36 0 0 0 0 0 6 
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4.5.2 Bronchoscopy and bronchoalveolar lavage 
All subjects underwent a standardised bronchoscopy and bronchoalveolar lavage, using 3 x 
60ml instillations of normal saline. Thirty-four experienced no complications. One 
participant, who was taking the antiplatelet agent clopidogrel, suffered a nosebleed and the 
procedure was abandoned and repeated after clopidogrel had been suspended. Another 
participant was admitted to her local hospital the evening of the procedure with symptoms 
of lethargy and malaise. Her symptoms settled without specific treatment and she was 
discharged the following day. 
Biochemical quantification 
Pepsin 
Pepsin concentration was measured in bronchoalveolar lavage fluid using a validated in-
house ELISA. Assays were performed in two batches; standard curves are illustrated in Figure 
4-11. 
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Figure 4-11. Standard curves for the ELISA used to quantify pepsin concentrations in BAL fluid 
 
The limit of detection for both experiments was 3ng/ml. The median pepsin concentration 
for the study subjects was 0ng/ml, which was equivalent to the median value of 1.1ng/ml for 
the control subjects. The mean pepsin concentration for the IPF subjects and the controls 
was 12.0ng/ml and 1.1ng/ml, respectively. Seventeen of the thirty-six study subjects (44%) 
had pepsin concentrations above the levels recorded in the control population. The values 
for these positive readings ranged from 7-44ng/ml. Pepsin concentrations for each subject 
are listed in Table 4-10 below. 
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There was no significant correlation between pepsin concentration and summary reflux 
parameters, including DeMeester score, reflux index or total number of refluxes. Pepsin 
concentrations for the IPF patients was significantly higher than those recorded in the 
control group. 
The IPF group was then divided into those with pH-impedance evidence of GOR, and those 
without. Objective evidence of reflux was defined as a high DeMeester score, a high total 
number of refluxes at impedance monitoring, or both. The pepsin concentrations for these 
two groups, in addition to the control group, are illustrated in Figure 4-12. 
Figure 4-12. Pepsin concentrations in IPF study subjects and healthy controls. In the IPF study subjects, the 
presence of gastro-oesophageal reflux was defined at pH-impedance monitoring by a high DeMeester score, 
a high total number of refluxes, or both. 
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Table 4-10. pH-impedance monitoring results and BAL pepsin concentrations in all study subjects. Normal 
values are included in brackets (Jamieson et al., 1992; Zerbib et al., 2013). 
Study 
number 
DeMeester score 
(<14.72) 
Impedance-detected 
refluxes (<75) 
Proximal refluxes 
(1-6) 
Pepsin concentration 
(ng/ml) 
1 55.6 105.6 38.7 <3 
2 37.2 30.5 12.4 25 
3 54.5 23.3 9.5 7 
4 7.8 14.8 4.2 <3 
5 30.3 69.2 4.8 16 
6 128.9 119.2 44.5 14 
7 6.6 24.5 6.4 19 
8 6.8 62.5 14.0 0 
9 2.0 94.2 18.6 11 
10 121.3 29 6.4 <3 
11 201.6 10.8 3.2 <3 
12 45.9 31.2 19.6 35 
13 18.5 52.4 25.7 <3 
14 0.2 71.2 28.3 <3 
15 22.8 38.3 8.7 26 
16 78.2 50.2 5.2 14 
17 13.2 30.8 0.0 11 
18 2.9 17.2 2.2 19 
19 4.0 28.2 5.6 <3 
20 18.5 34.1 14.3 <3 
21 31.3 43.7 9.8 <3 
22 3.6 24.9 2.1 40 
23 1.0 9.3 0.0 <3 
24 1.7 59.7 7.3 39 
25 2.4 13.2 1.0 <3 
26 7.0 28.6 4.8 <3 
27 16.6 16.8 0 29 
28 7.6 22.7 2.8 42 
29 4.0 81.9 2 40 
30 12.8 14.5 5.8 <3 
31 25.8 38.7 8.5 <3 
32 28.0 51.5 14.7 <3 
33 29.5 58.7 35.2 <3 
34 39.4 15.8 4.2 <3 
35 25.0 33.6 5.6 44 
36 25.6 27.5 12.1 <3 
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Bile salts: spectrophotometry 
BALF bile salt concentrations are detailed in Table 4-11. Only three subjects had detectable 
levels of bile acids using the TBA assay. An additional subject had only one valid reading 
generated at spectrophotometry. Samples from these four subjects were verified with a 
further set of readings. 
One of these subjects had high levels of reflux on pH monitoring, and the other two had 
normal pH-impedance results.  
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Table 4-11. Bronchoalveolar lavage fluid bile salt concentration measured in all 35 IPF patients using a 
spectrophotometric total bile salt assay. All measurements are in µmol/l.  Three separate runs were initially 
performed and an average result determined. Positive readings were verified with a further set of readings. 
Zero values indicate readings lower than the limit of detection. 
  
Numb
er 
Run 1 Run 2 Run 3 Average S.D. Rerun 
1 
Rerun 
2 
Rerun 
3 
Average S.D. 
1 0 0 0 0 0      
2 3 27 5 12 11 2 2 12 6 5 
3 0 0 0 0 0      
4 1 2 1 1 0 1 6 4 4 2 
5 0 0 0 0 0      
6 1 0 0 0 0      
7 1 0 1 1 1 1 1 0 1 0 
8 0 1 0 0 0      
9 0 0 0 0 0      
10 0 0 0 0 0      
11 1 0 0 0 0      
12 0 0 1 0 1      
13 0 0 0 0 0      
14 0 0 0 0 0      
15 1 0 0 0 0      
16 0 xxx 0 0 0      
17 0 0 0 0 0      
18 0 xxx 0 0 0      
19 0 0 0 0 0      
20 0 0 0 0 0      
21 0 0 0 0 0      
22 0 xxx 0 0 0      
23 xxx xxx 0 0 0 2 2 0 1 1 
24 1 0 xxx 0 0      
25 0 0 0 0 0      
26 0 0 0 0 0      
27 0 0 0 0 0      
28 0 0 0 0 0      
29 0 0 0 0 0      
30 0 0 0 0 0      
31 0 0 0 0 0      
32 0 0 0 0 0      
33 0 0 0 0 0      
34 0 1 0 0 0      
35 0 0 0 0 0      
36 0 0 xxx 0 0      
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Cytology 
Bronchoalveolar lavage fluid was captured after the tip of the bronchoscope was wedged 
into a right middle lobe subsegmental bronchus. The median fluid volume retrieved was 
82.8ml. After 5ml of fluid was sent for microbiology, the remaining sample was transferred 
to university laboratories on ice for processing. Processing was undertaken within 1 hour of 
retrieval in all cases. 
The median total BAL cell count was  19.2 x 104 cells/ml. Summary figures for BAL cytology 
are detailed in Table 4-12 with reference to values recorded in a group of healthy controls 
(Zheng et al., 2000). The IPF study subjects had higher total cell counts and a higher 
proportion of neutrophils. There were lower proportions of lymphocytes and eosinophils in 
the study subjects. 
Table 4-12. Differential cell counts for bronchoalveolar lavage fluid retrieved from the 36 study participants. 
Values are expressed as mean (range). p-values refer to a one-sample T-test comparing the study data to the 
reference mean. 
 IPF study patients Normal values p-value 
Total BAL cell count (cellsx104/ml) 19.2 (1.8 -236.0) 14 (12-16) 0.006 
Macrophages (%) 87.9 (23.4-99.4) 73 (66-80) 0.376 
Neutrophils (%) 6.8 (0.2-93) 2.1 (1.6-2.6) 0.001 
Lymphocytes (%) 3.0 (0.4-58.0) 20 (14-26) <0.001 
Eosinophils (%) 0.7 (0-12.0) 1.1 (0-2.2) 0.044 
 
Lipid ingestion 
Cytospin slides from each subject were stained with Oil Red O for enumeration of a lipid-
laden macrophage index (LLMI). The cytoplasmic opacification of 300 macrophages was 
enumerated using a scale from 0-4. In order to improve the consistency of enumeration, a 
reference chart was produced using images from the current study subjects, Figure 4-13. 
LLMI scores are listed in Table 4-13. 
One in four samples were second read by an experienced biomedical scientist in the 
research laboratories at the Freeman Hospital (KJ).  The Pearson correlation coefficient for 
the paired readings was 0.913, conventionally regarded as a very strong positive 
relationship. 
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In addition, the Bland-Altman method for evaluating inter-rater agreement was used to 
assess the difference between the reported ORO scores, as described in section 3.1.13 
(Bland and Altman, 1986). The mean difference between the two readings was -1.5 and the 
standard deviation of the differences was 2.7. The limits of agreement were therefore -6.8 
to 3.9. 
Figure 4-13. Reference chart used to support LLMI grading 
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Oxidative stress 
A further 200 macrophages were counted on separate cytospin slides after staining with 
Perls Prussian Blue. Haemosiderin scores are listed in Table 4-13. Illustrative 
photomicrographs are shown in Figure 4-14 and Figure 4-15. 
Table 4-13. LLMI and haemosiderin scores enumerated from BAL cytospins 
Study number LLMI Haemosiderin score 
1 52 19.5 
 
 
2 23 236.5 
3 6 4.5 
4 8 19.5 
5 139 9.5 
6 0 8 
7 13 67 
8 57 115.5 
9 12 89 
10 34 11.5 
11 30 109.5 
12 0 9 
13 73 207.5 
14 0 6.5 
15 7 44 
16 18 3 
17 11 46.5 
18 5 71.5 
19 310 4.5 
20 24 74.5 
21 5 0 
22 3 417 
23 19 69 
24 0 12 
25 18 248 
26 73 10 
27 11 2 
28 10 344 
29 0 78 
30 0 60 
31 2 67 
32 5 7 
33 8 15 
34 0 79 
35 0 34 
36 5 2 
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Figure 4-14. Illustrative photomicrographs of cytospin cell staining with Giemsa, Perls Prussian Blue and Oil 
Red O stains. 
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Figure 4-15. Illustrative photomicrographs of cytospin cell staining with Giemsa, Perls Prussian Blue and Oil 
Red O stains.  
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Summary values for cell staining are illustrated in Table 4-14. Thirty-three of 36 subjects had 
haemosiderin scores in excess of the normal range for healthy control subjects (Reid et al., 
2001). With respect to Oil Red O staining, a marker of lipid-laden macrophages, only six of 
the study subjects had values in excess of the normal range. 
Table 4-14. Summary values for cell staining counts. Results are expressed as median (range). 
 Study patients 
Published healthy controls 
(Reid et al., 2001; Basset-Leobon et al., 2010) 
Haemosiderin score 39 (0-417) 0 (0-2) 
Lipid-laden macrophage index 9 (0-310) 5.47 (0-49) 
 
There was no good correlation between objective markers of reflux and the lipid-laden 
macrophage index. Figure 4-16 and  
Figure 4-17 illustrate the relationship between the DeMeester score and the LLMI, for which 
the Spearman Rho correlation coefficient was 0.056. The correlation coefficients relating to 
impedance monitoring parameters (total refluxes and proximal refluxes) were lower still. 
As a group, haemosiderin scores for the IPF subjects in the current study were significantly 
higher than those reported in healthy controls (Reid et al., 2001). Scores in excess of the 
normal range were calculated in 33 of the 36 study subjects.  
The relationship between disease severity and haemosiderin score was assessed by splitting 
the group into two with respect to the vital capacity. Subjects with percentage predicted 
vital capacity higher than the median value (77.6%) had lower haemosiderin scores (9.5 vs 
71.5, Kruskal-Wallis p=0.038, Figure 4-18). As with the LLMI, haemosiderin scores were not 
associated with reflux status (Figure 4-19). There was no association with smoking status, 
age or N-acetyl cysteine use or BALF neutrophilia. 
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Figure 4-16. The relationship between LLMI and DeMeester scores for the 36 study subjects 
 
 
Figure 4-17. LLMI calculated for study subjects grouped by DeMeester score; 14.7 is the upper limit of normal 
in healthy controls and values above this are consistent with a high level of gastro-oesophageal reflux 
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Figure 4-18. Haemosiderin scores for study subjects stratified by lung disease severity.  Subjects were 
dichotomised with respect to the median figure for % predicted vital capacity. 
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Figure 4-19. Haemosiderin score calculated for study subjects grouped by DeMeester score 
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4.6 Multidisciplinary review and subsequent management 
The participants in the current study volunteered to undergo invasive clinical testing. The 
oesophageal physiology data generated are equivalent to those which would guide the 
clinical management of patients in the upper gastrointestinal surgery clinic. The optimal 
management of gastro-oesophageal reflux in IPF remains unclear, so the appropriate 
response to these clinical data was not well defined. 
As a result, an aerodigestive multidisciplinary team was convened to discuss the results 
generated in the current study. The team meets monthly and the core membership 
comprises oesophago-gastric surgeons, respiratory physicians, anaesthetists and research 
scientists. To the present day, the MDT continues to run. The majority of the cases discussed 
relate to: 
- Reflux in IPF patients and lung transplant recipients 
- Smaller numbers of patients with cystic fibrosis, systemic sclerosis, bronchiectasis 
- Management of giant hiatal hernias with suspected pulmonary compromise 
- Investigation and management of adult trachea-oesophageal fistula 
The management of all 36 patients was formally discussed by the aerodigestive 
multidisciplinary team. Antireflux surgery was recommended for three patients; to date two 
have undergone surgery and the third declined surgery for the present time. Of the two that 
underwent fundoplication, one patient had received a lung transplant prior to 
fundoplication.
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4.7 Summary 
In the current study, 36 consecutive patients with a well-characterised diagnosis of IPF were 
recruited from the regional interstitial lung disease clinic at the Royal Victoria Infirmary in 
Newcastle upon Tyne. 
Of those who were booked into the study, two individuals died before they were due to 
participate and two more did not attend due to disease progression. All but one subject 
were able to tolerate both oesophageal physiology monitoring and bronchoalveolar lavage. 
From existing clinical assessments, 31% of subjects had prior evidence of GORD. Structured 
questionnaire (GerdQ) assessment suggested GORD in 29% of subjects off-PPI. In the small 
group of subjects who repeated structured assessments of respiratory HR-QOL 
questionnaires on-and off-PPI, significantly better scores were recorded after cessation of 
therapy. Extra-oesophageal reflux was evident from questionnaire assessment in 37% of 
subjects off-PPI. 
The results of oesophageal manometry were normal in 44% and abnormal in 56%. The 
majority of subjects with abnormal swallows had weak peristalsis. 
Ambulatory pH monitoring identified pathological levels of reflux in 56% of subjects and 
impedance monitoring demonstrated pathological reflux in 11%. In combination, pH-
impedance monitoring suggested objectively high levels of reflux in 61% of subjects. 
At bronchoalveolar lavage, bile acids were essentially undetectable. High levels of pepsin 
were detected in 44% of study subjects. The combination of pepsin quantification and 
oesophageal monitoring identified a subgroup with evidence of reflux and aspiration, but 
there was no correlation between levels of reflux and pepsin concentrations. 
Cytological staining of BAL fluid samples suggested high levels of oxidative stress in 92% of 
subjects. Abnormal macrophage lipid uptake was only seen in 17%, half of whom had 
physiological levels of reflux on ambulatory monitoring. 
After formal multidisciplinary review, two patients who participated in the current study 
have undergone fundoplication.
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Chapter 5. Results of Patient Attitudes Study 
5.1 Interview summary and stratification by disease severity 
Subjects with a secure diagnosis of idiopathic pulmonary fibrosis were identified from the 
regional interstitial lung disease clinic and invited to complete a scripted interview.  The 
interview comprised four stages: 
1. Demographic survey 
2. Respondents were asked to read six health states (Box 3. Health state descriptions 
used in the standard gamble. Outcome W: mild IPF. Outcome X: moderate IPF. 
Outcome Y: adverse outcome from antireflux surgery. Outcome Z: adverse outcome 
from medical antireflux therapy.) printed on cards and rank them. There were four 
descriptive health states in addition to the health states “Full health” and “Immediate 
death” 
3. Standard gamble utility analysis for the four descriptive health states, in addition to 
the health state “Own health” 
4. Euro-QOL 5D-3L 
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Box 3. Health state descriptions used in the standard gamble. Outcome W: mild IPF. Outcome X: moderate 
IPF. Outcome Y: adverse outcome from antireflux surgery. Outcome Z: adverse outcome from medical 
antireflux therapy. 
 
 
Pulmonary function tests are routinely recorded at every visit to the interstitial lung disease 
clinic. At the time of the study interview, the most recent vital capacity (measured and 
predicted) was recorded from clinic letters. The median interval between interview and 
pulmonary function testing was 54 days (0-242). The percentage predicted vital capacity 
ranged from 41.7 to 133.3%. The median percentage predicted vital capacity was 78% (IQR 
68.4-86.4). This midpoint was used to dichotomise the group into the “Top half” and 
“Bottom half”, with respect to objective pulmonary function. 
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5.2 Summary statistics 
A total of 59 subjects were interviewed. Fifty-eight patients were able to complete all parts 
of the interview. One patient did not complete the standard gamble. He was awaiting an 
outpatient review and explained that he was frustrated about the delay in being seen. 
The demographics of the respondents are summarised in Table 5-2. The mean age was 75.1 
years, with a range of 51-92 and a standard deviation of 8.5. 
The respondents were largely male, in a ratio of approximately 2:1. The overwhelming 
majority were retired. Half had no formal qualifications. All of the study subjects were White 
British. 
The respondents’ assessment of their own functional status was recorded using EQ5D-3L, 
summarised in Table 5-1. 
Table 5-1. Summary responses to the EQ5D-3L survey 
Domain Frequency of response 
Mobility No problems 12 Some problems 45 Confined to bed  1 
Self-Care No problems 45 Some problems 11 Unable to wash/dress 2 
Usual Activities No problems 17 Some problems 34 Unable 7 
Pain/Discomfort None 19 Moderate 32 Extreme 7 
Anxiety/Depression None 37 Moderate 21 Extremely 1 
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Table 5-2. Demographic summary statistics 
Demographic  n 
Male 38 
Female 21 
Marital status  
Married 40 
Single 3 
Divorced/separated 5 
Widowed 11 
Employment status  
Employed 4 
Retired 52 
At home/not looking for work 1 
Unable to work 2 
Qualifications  
None 28 
GCSE (1-4)  2 
GCSE (5+) 6 
A-level (2+) 2 
First Degree 6 
Higher degree 3 
NVQ level 3 1 
NVQ level 4-5 3 
Other 8 
Ethnicity  
White British 59 
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5.3 Validation statistics 
Of the 59 respondents, 50 returned health state utilities which differentiated between the 
respective health states. The remaining 9 recorded the same utility values across each of the 
health states. 
All respondents regarded Full health as preferable to all remaining scenarios in both the 
ranking exercise and the standard gamble utility measurement. 
With respect to the specific scenarios, only the mild and moderate IPF disease states had an 
inherently ordinal relationship. For 53 of 59 respondents, utility measurements indicated 
that the mild IPF disease state was perceived as preferable to the moderate IPF disease 
state. Using a restrictive test, 31 of 59 respondents returned higher utility values for the mild 
IPF disease state than for the moderate IPF disease state. For the group as a whole, the 
mean utility value for the mild IPF state was higher than that for the moderate IPF disease 
state. 
Test validity can also be assessed by comparing individual respondents’ rank preferences 
with the utility values they recorded through the standard gamble. Two formulae were used 
in Microsoft Excel: 
Permissive test: =IF((HS#1>=HS#2)AND(HS#2>=HS#3)AND(HS#3>=HS#4),"True","False") 
Restrictive test: 
=IF((HS#1>HS#2)AND(HS#2>HS#3)AND(HS#3>HS#4),"True","False") 
where HS#1…#4 represent the order of the health states as ranked by the individual 
respondent. 
The permissive test therefore accepts greater than/equal to relationships between health 
states ranked adjacent to each other. According to this test, health state rankings were 
concordant with health state utility valuations for 41 respondents and discordant for 18. 
According to the restrictive test, rankings and utility valuations were concordant for 2 of the 
59 respondents. 
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5.4 Health state ranking exercise 
Respondents were asked to put the four descriptive health states, in addition to the health 
states “Full health” and “Death”, into their personal order of preference. The majority of 
respondents (33 of 59) ranked the health states in the following order: 
1. Full health 
2. Mild IPF 
3. Moderate IPF 
4. Antireflux medication 
5. Antireflux surgery 
6. Death 
Full results of the ranking exercise are illustrated in Figure 5-1. 
Figure 5-1. The frequency with which respondents ranked the health states in a specified order. Figures in 
brackets indicate respondents who ranked death as preferable to one of the descriptive health states. 
 
 
All respondents ranked the Full health state as preferable to all the remaining health states. 
Two respondents valued death as preferable to one of the descriptive health states. The 
majority of respondents (38 of 59) regarded both the mild and moderate IPF disease states 
as preferable to either of the adverse outcomes from antireflux therapy. 
The vignette describing an adverse outcome from medical antireflux therapy was regarded 
as preferable to that for an adverse outcome from antireflux surgery by 51 of 59 
respondents. 
Of the descriptive scenarios, 46 respondents ranked antireflux surgery as the least 
preferable and eight ranked moderate IPF as the least preferable.  
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5.5 Health state utility analysis 
The health state valuations recorded in the current study are detailed in Table 5-3 and Figure 
5-2. 
Table 5-3. Health state valuations. SD = standard deviation. OSG = own health evaluation by standard 
gamble. OE = own health evaluation by EQ5D). The terms “Top half” and “Bottom half” refer to a subdivision 
with respect to objective pulmonary function (section 5.1). 
 Mean SD 
Full sample (n)   
Mild IPF (W) 0.862 0.108 
Moderate IPF (X) 0.760 0.198 
Antireflux surgery  (Y) 0.679 0.230 
Antireflux medication (Z) 0.759 0.204 
Own health (OSG) 0.798 0.188 
Own health (OE) 0.613 0.280 
Top half (n)   
Mild IPF (W) 0.860 0.108 
Moderate IPF (X) 0.752 0.201 
Antireflux surgery  (Y) 0.686 0.211 
Antireflux medication (Z) 0.767 0.202 
Own health (OSG) 0.821 0.174 
Own health (OE) 0.656 0.236 
Bottom half (n)   
Mild IPF (W) 0.864 0.111 
Moderate IPF (X) 0.769 0.201 
Antireflux surgery  (Y) 0.666 0.254 
Antireflux medication (Z) 0.752 0.214 
Own health (OSG) 0.788 0.196 
Own health (OE) 0.590 0.301 
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Figure 5-2. Mean health state evaluations recorded by standard gamble. P-values relate to 2-sample T-tests. 
Descriptive health states are as follows: W=mild IPF; X=moderate IPF; Y=surgical antireflux therapy; 
Z=medical antireflux therapy. Own health was also evaluated using the standard gamble. 
 
Consistent with the results of the ranking exercise, the mean health state utility recorded for 
mild IPF was significantly higher than that recorded for moderate IPF. The utility values for 
both of these states were significantly higher than those recorded for the adverse outcome 
from antireflux surgery. The scenario describing an adverse outcome from medical antireflux 
therapy was valued as similar to the moderate IPF health state but significantly worse than 
the mild IPF health state.  
On average, respondents’ own health was rated worse than the mild IPF health state 
(p=0.03). The difference between the utility values for respondents’ own health and the 
moderate IPF health state was not significantly different (p=0.28). 
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Figure 5-3. Mean health state evaluations recorded for respondent’s own current health. P-value refers to a 
2-sample T-test. 
 
Own health utility values measured by standard gamble were higher than those measured 
by EQ5D, the utilities for which are generated with reference to the results of time trade-off 
interviews. The utility values recorded with the visual analogue scale within EQ5D were not 
significantly different from the values by the tool as a whole. 
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Figure 5-4. Health state evaluations stratified by disease severity 
 
There were no statistically significant differences between the sub-groups of respondents 
after stratification by lung function but there were some trends: The mean utility values 
recorded for the IPF health states were slightly higher in those patients with worse 
pulmonary function, and the converse was true for the scenarios relating to antireflux 
therapy, Figure 5-4. The mean utility values that respondents recorded for their own health 
was slightly higher in those with better lung function. Again, this difference was not 
statistically significant (p=0.36 for EQ5D ratings).  
As with the unstratified analysis, the health state utilities recorded by standard gamble were 
significantly higher than those recorded by EQ5D. These differences were statistically 
significant for the Top half and for the Bottom half (p=0.004 and p=0.006, respectively). 
  
0
.8
6
0
0
.7
5
2
0
.6
8
6 0
.7
6
7
0
.8
2
1
0
.6
5
6
0
.8
6
4
0
.7
6
9
0
.6
6
6 0
.7
5
2
0
.7
8
8
0
.5
9
0
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
State W State X State Y State Z  Own health
(SG)
 Own health
(EQ5D)
Top half
Bottom half
134 
 
5.6 Correlation between lung function and own health utility values 
Finally, reported utilities were assessed against physiological disease severity.  
To begin, we compared the two subjective measures of own health. There was a weak 
correlation between the paired valuations for respondents’ own health, as measured by 
standard gamble and EQ5D (Figure 5-5); Pearson co-efficient of correlation 0.366, p=0.005. 
There were numerous examples of respondents who scored high scores with one 
assessment and low scores on the other assessment. 
Figure 5-5. Scatterplot comparing respondents' own health valuations as measured by standard gamble and 
EQ5D 
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Figure 5-6 and Figure 5-7 illustrate the correlation between respondents’ vital capacity and 
own-health valuations. The correlation between standard gamble-derived utilities and vital 
capacity was weak (Pearson correlation coefficient 0.129, p-value 0.342). 
The relationship was marginally closer when the EQ5D scores were analysed (Pearson 
correlation co-efficient 0.191, p-value 0.16 (Figure 5-7). 
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Figure 5-6. Scatterplot comparing the percentage predicted vital capacity with respondents' own health 
valuations as measured by standard gamble 
 
Figure 5-7. Scatterplot comparing the percentage predicted vital capacity with respondents' own health 
valuations as measured by EQ5D 
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5.7 Summary 
The overwhelming majority of study subjects were able to complete the entirety of the 
interview, including multiple iterations of the standard gamble exercise. 
The face validity of the defined health states was assessed with the use of logical checks. 
Similarly, the respondents’ own health states could be compared to their valuations of the 
defined IPF health states. On average, respondents’ own health was not significantly 
different to the health state defined as moderate IPF. 
The use of Full health and Death as anchor states was largely supported by the respondents’ 
valuations, although this pattern was not universally applicable. 
The majority of respondents regarded both IPF health states as preferable to either 
antireflux therapy outcome. An adverse outcome from antireflux surgery was generally 
perceived to be the worst of all the health states. 
In this study, own health was valued higher by the standard gamble than it was when 
assessed by EQ5D, or the visual analogue scale that forms part of the EQ5D tool. 
Health state valuations were not significantly different after stratification by physiological 
disease severity. 
Vital capacity was poorly correlated with valuations for Own health.
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Chapter 6. Discussion 
Idiopathic pulmonary fibrosis is a progressive and disabling lung disease associated with high 
rates of mortality and morbidity, for which there are very limited treatment options. 
Evidence from the epidemiological literature suggests it is increasingly common 
(Navaratnam et al., 2011). The last decade has seen a significant increase in research efforts. 
Whilst the disease process is now better characterised, understanding the aetiology and the 
development of effective therapies has been more difficult. 
IPF is largely a disease of the elderly. The association of significant morbidity is partly related 
to the advanced age of typical sufferers, but there is clear evidence of comorbidities 
occurring at higher levels than they do in age-matched controls. Coronary heart disease and 
diabetes are two well-documented examples (Raghu et al., 2015a). 
Gastro-oesophageal reflux is common in IPF patients and pulmonary fibrosis is also common 
in those with reflux disease (El-Serag and Sonnenberg, 1997; Savarino et al., 2013). Whilst 
reflux may simply represent a comorbidity in IPF, several strands of evidence suggest that 
reflux may contribute to the parenchymal changes seen in IPF lungs: 
 Bronchoalveolar lavage analysis suggests an association between microaspiration and 
high rates of acute exacerbations in IPF (Lee et al., 2012) 
 Retrospective studies have reported a benefit of antireflux therapy in patients with 
IPF (Lee et al., 2011) 
 Imaging studies also suggest a possible link between gastro-oesophageal reflux and 
disease severity, as evidenced by asymmetrical disease (Tcherakian et al., 2011) 
This area of research has proved challenging for a number of reasons. The identification of 
gastro-oesophageal reflux identifies a risk of microaspiration, but the difficulty of sampling 
the intrapulmonary environment makes microaspiration more difficult to demonstrate 
directly. The damaging effect of weakly acid reflux in the lung means that definitive 
antireflux control can only be achieved mechanically. Given the age and comorbidities of the 
IPF population, high quality trial data is limited. Low mortality animal models have been 
developed, but their applicability to IPF in humans has been debated (Brownlee et al., 2010). 
138 
To date, a causative role for reflux and microaspiration in IPF has never been convincingly 
demonstrated. 
Traditionally, respiratory and gastrointestinal clinicians work within distinct areas of clinical 
practice. Respective specialists train in distinct pathways and research efforts have been 
organised within distinct teams. Developing a better understanding of the interplay between 
gastro-oesophageal reflux, microaspiration and chronic lung disease demands a 
multimodality approach to both research and clinical practice. The traditional barriers 
between these different teams may provide another reason why progress in this area of 
practice has been modest. 
Despite the limitations of the current IPF literature, the possibility that antireflux therapy 
might stabilise disease progression has been enthusiastically explored. One investigator 
concludes, “we do know that stopping reflux in IPF patients by a fundoplication can halt the 
progression of the disease” (Allaix et al., 2014). Unless better evidence can be found to 
support an aetiological link between reflux and the progression of fibrosis in IPF, this stance 
will remain contentious. In general, the age and frailty of people with IPF make them poor 
candidates for major surgery. The links between general anaesthesia, surgery and acute 
exacerbations indicate that an aggressive, surgical approach can cause more harm than good 
(Luppi et al., 2015). 
In this early phase of research, the aim of the current study was to explore the feasibility of a 
systematic, multimodal assessment of reflux and aspiration in IPF. In the setting of a 
prospective research study, a consecutive series of patients with well-characterised IPF were 
invited to undergo a panel of investigations designed to analyse symptoms, oesophageal 
physiology and bronchoalveolar environment. 
6.1 Recruitment and feasibility 
In total, half of the 76 clinic attenders invited to participate in the study were recruited. 
During recruitment we explained to all patients that this was a research study, with invasive 
tests associated with a risk of morbidity and mortality. Whilst all participants had their 
investigations discussed by a dedicated MDT, it was made clear to all that in some cases, no 
change to clinical management would be made. Given the nature of the study, the 50% 
accrual rate attests to the enthusiasm that this group of patients have for research 
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participation, which in turn relates to the paucity of effective treatment options that are 
currently available. 
Of the 44 patients who indicated their preliminary agreement to take part in the study, 36 
completed the study protocol. Four patients died from their disease before they were able 
to participate in the protocol, a figure which demonstrates the unpredictable and potentially 
rapid decline which may be seen. Clinical trials involving patients with IPF should be 
designed to reflect this finding; recruitment of these patients will generally be associated 
with an attrition rate, and the recruitment process must be sensitive to the fact that clinical 
deterioration can happen quickly. 
Of those patients that commenced the study protocol, all but one were able to tolerate both 
the oesophageal physiology and the bronchoalveolar lavage. The protocol completion rate 
was 97%, which would be acceptable to any clinical bronchoscopy or oesophageal 
physiology lab. There were no complications associated with either oesophageal physiology 
or ambulatory oesophageal monitoring. Bronchoalveolar lavage resulted in one minor 
nosebleed and one subsequent hospital admission with symptoms of malaise and lethargy.  
There were a number of logistical issues related to the study protocol in this group of 
patients, in whom the median age was 72.5 years and the oldest study participant was 85 
years. Many were reliant on friends or family for transport to and from the hospital. One in 
ten patients remained as in-patients for the night in between the insertion of the 
oesophageal probe and the bronchoscopy. Those who stayed overnight all lived at least 20 
miles from the hospital. Many patients were taking multiple medications at the time of their 
participation in the study. Cessation of proton pump inhibitors, H2-receptor blockers and 
over-the-counter antacids were all stipulated by the study protocol. Aside from these drugs, 
the only group of medications that required any specific consideration were anticoagulants. 
One patient (IPF22) was taking the antiplatelet agent clopidogrel as secondary prevention 
following a previous cerebrovascular accident. He suffered a nosebleed at the time of his 
bronchoalveolar lavage, which was abandoned. After consultation with his own stroke 
physician, it was deemed safe to discontinue the clopidogrel temporarily and the lavage was 
repeated without complication. 
Overall, therefore, this IPF study population were able to tolerate the invasive protocol. The 
protocol could be employed amongst the wider IPF population in a larger study. 
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Subjective and objective assessments suggest that a broad spectrum of individuals 
participated in the study. Use of long-term oxygen therapy was listed within the study 
exclusion criteria. It is likely that clinicians involved in recruitment would also have passed 
over the frailest of individuals, given the invasive nature of the study protocol. Despite this, 
nearly half of individuals recruited had been classified as grade 3 or 4 on the MRC 
breathlessness scale (Fletcher et al., 1959). 
Off-PPI, the mean score recorded for the St George’s Respiratory Questionnaire was 45. In a 
review study which considered the psychometric properties of SGRQ in IPF, the mean 
baseline score aggregated from the individual studies was also 45 (Swigris et al., 2014). The 
respiratory symptomatology of the current study population therefore appears comparable 
with the broader IPF population. 
6.2 Subjective assessment of reflux and aspiration 
In patients with IPF in whom gastro-oesophageal reflux can be identified, the typical reflux 
symptoms (heartburn and reflux) are known to be less common (Tobin et al., 1998). This 
group of patients will generally see a respiratory physician more commonly than a 
gastroenterologist or gastro-intestinal surgeon. As a result, the initial identification of gastro-
oesophageal reflux can be challenging. 
Amongst the 36 patients included in the current study, 11 had pre-existing evidence of 
GORD based on clinical correspondence or endoscopy findings. In the latter group of 
patients who completed the structured GerdQ questionnaire, only 4 of 17 patients (24%) 
returned scores consistent with a diagnosis of GORD disease. With respect to symptoms of 
extra-oesophageal reflux, 16 of 36 participants (44%) returned scores consistent with 
pathological laryngo-pharyngeal reflux. When compared with the 60% of participants 
identified to have pathological levels of reflux on objective testing, these proportions are all 
very low. If structured symptom questionnaires make any contribution to the diagnosis of 
gastro-oesophageal reflux disease, there remains a significant proportion of patients in 
whom high levels of reflux are clinically silent.  
This is a significant finding: in an individual with high levels of reflux, microaspiration could 
still proceed in the absence of symptoms. In this patient population, it seems that objective 
oesophageal physiology testing should be used liberally, especially if there is any question 
that an individual might be a candidate for antireflux surgery. 
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Interestingly, the two-week cessation of proton-pump inhibitors had no consistent impact 
on reflux symptoms in the current study. The same was true for both gastro-oesophageal 
and extra-oesophageal symptoms. There are several possible explanations for this: 
One possibility is that respondents were unable to accurately recall their symptoms over the 
preceding period and may simply have considered their normal pattern of symptoms. The 
RSI tool has not been widely validated for a two week recall period. It seems likely, however 
that respondents would have been mindful of the fact that they discontinued their PPI 
medication two weeks previously and that this would provide an aide memoire in terms of 
their symptom chronology. 
Another possibility is that a significant proportion of participants continued taking their PPI. 
This also seems unlikely as our study attrition rate, for an invasive protocol, suggests a 
motivated group of participants. In addition, the pH traces obtained at ambulatory 
monitoring suggest that the patients had indeed discontinued PPI therapy: the median reflux 
index indicates that, on average, oesophageal pH was acidic for over 6% of the monitoring 
period. 
In reality, structured symptom assessment did not identify a high level of symptoms in this 
patient group, irrespective of PPI status. As a result, cessation of PPI would not be expected 
to have a big impact on symptoms. 
Within the latter cohort of participants, respiratory health-related quality of life was 
assessed using St George’s Respiratory Questionnaire. Individual scores indicated an 
improvement in quality of life after PPI medication had been discontinued. This is contrary to 
the pattern of change that would be expected were acid reflux and aspiration contributing to 
respiratory symptoms. 
In a study that made use of contrast-enhanced MRI, PPI use was shown to reduce the 
volume of gastric contents in the postprandial period (Babaei et al., 2009). It is possible that 
PPI use may be associated with a refluxate that has a lower volume but also a higher 
concentration of non-acid elements.  
If non-acid elements, such as bile, were a more potent stimulus for respiratory symptoms 
than acid refluxate, PPI cessation could result in an improvement in symptoms. The 
association between non-acid reflux and respiratory symptoms has been demonstrated in a 
pH/impedance study in children with chronic respiratory disease (Rosen and Nurko, 2004). 
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In the current study, the number of respondents on which these observations are based is 
small, but further study into the association between PPI therapy and respiratory symptoms 
is warranted. 
6.3 Oesophageal physiology monitoring 
All study participants completed ambulatory oesophageal monitoring with a multichannel 
intraluminal impedance pH catheter, which was sited after formal manometric localisation 
of the lower oesophageal sphincter. At the time of study design, this technique was the 
“state of the art” for quantification of gastro-oesophageal reflux. To date, only three 
published studies have combined pH and impedance techniques to assess gastro-
oesophageal reflux disease (Savarino et al., 2013; Kilduff et al., 2014; Gavini et al., 2015). 
Prior to ambulatory monitoring, all patients underwent oesophageal physiology analysis. In 
the first 11 patients, this was achieved through conventional 8-channel manometry. In the 
latter 25, high-resolution manometry was used. 
The key difference between these technologies is the number of manometers that are 
mounted within the catheter. As a result, HRM has a higher sensitivity for subtle dysmotility. 
The publication of normal ranges for the key study parameters means that subjects may still 
be dichotomised into normal and abnormal groups, with respect to the upper limits of the 
95% confidence interval for respective control populations. To an extent, the manometry 
results from 8-channel and HRM may therefore be compared. 
In those who were assessed using 8-channel manometry the combination of partial or 
complete LOS relaxation with swallowing and normal peristalsis was seen in 6 of 11 subjects 
(55%). In those assessed with HRM, ten of 25 subjects were defined as having a normal 
swallow by Chicago criteria (40%). Irrespective of which technique was used, a high 
proportion of subjects were demonstrated to have a degree of dysmotility. 
Published reference ranges do not provide the ideal data to use for comparison. In the case 
of manometry, the main concern is that the reference data were measured in a younger 
group than that recruited to the current study (Zerbib et al., 2005). In routine clinical 
practice however, it is these generic reference ranges that are used to assess a patient’s 
suitability for antireflux surgery. 
When individuals have oesophageal dysmotility, or failure of relaxation of the lower 
oesophageal sphincter with swallowing, there is a higher risk of complications following 
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antireflux surgery. Dysphagia and gas bloat are the major problems that result from an 
excessively tight LOS but malnutrition may also result. Dysmotility is therefore a relative 
contraindication to surgery. At worst, revisional surgery may be required and the likelihood 
of a good outcome is reduced with successive operations. In the frail IPF group, reoperation 
would be associated with significant risk of morbidity, and potentially, mortality. 
Many surgeons would now offer a tailored fundoplication in this situation. There is an 
argument that a 180o or 270o fundoplication causes less of the symptoms that can result 
from a tight lower sphincter. To date, there is no good evidence that this practice actually 
results in better outcomes. 
In previous IPF studies, the oesophageal manomety has been undertaken with conventional 
(5-9 channel) catheters and the results are mixed.    Raghu reported the “majority” of 
subjects to be normal, whilst Kilduff reported only 17% to have ineffective oesophageal 
dysmotility (Raghu et al., 2006a; Kilduff et al., 2014). In contrast, Soares and Patti reported 
abnormal manometry in 64% and 75%, respectively (Patti et al., 2005; Soares et al., 2011). In 
a recent study of subjects with IPF, Savarino noted comparable patterns of dysmotility when 
compared with a group of healthy volunteers, who were only slightly younger (Savarino et 
al., 2013). 
In summary, it seems likely that IPF patients have higher levels of oesophageal dysmotility. It 
is unclear whether this relates to age, comorbidities or the disease itself. In those considered 
for antireflux surgery, it would seem appropriate that modern manometry techniques are 
used and that the results are carefully considered. 
All study subjects were asked to discontinue PPI medication prior to the study protocol. All 
but one complied with this request. In this isolated case (IPF21), the subject reported that he 
had continued to take his medication because he forgot to stop it, rather than because he 
was fearful of symptom recurrence. The pH trace from his ambulatory study confirmed an 
elevated baseline pH, which confirms that he had continued to take his medication. 
Interestingly, both the pH and impedance readings demonstrate high levels of gastro-
oesophageal reflux. This case represents an example of GORD refractory to PPI therapy. In 
the IPF population, many of whom have asymptomatic GORD, it cannot be assumed that life-
long PPI therapy will control reflux effectively. 
Ambulatory monitoring was well-tolerated, as evidenced by the duration of monitoring that 
the study subjects managed. The shortest period captured was 16 hours, which is 
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conventionally regarded as the minimum required for representative results. The median 
monitoring period was 23 hours. 
Taken in isolation, the pH results identified supranormal levels of gastro-oesophageal reflux 
in 20 of 36 study subjects (56%). This figure relates purely to acid reflux detected at the 
distal oesophagus. The single most important reading used to assess the degree of gastro-
oesophageal reflux is the proportion of time for which the pH at this distal probe was lower 
than 4, sometimes referred to as the reflux index. In surgical practice this figure is often 
combined with the total number of refluxes, the number of long refluxes and the length of 
the longest reflux, to provide a composite marker of disease severity, the DeMeester score. 
In our study subjects, the reflux index and the DeMeester score identified the same 20 
individuals as having high levels of pathological reflux. This finding adds weight to our 
definition of normal and abnormal results. 
When the results of impedance monitoring were considered in addition, two further 
subjects were found to have objectively high levels of reflux. Both had high levels of weakly 
acid reflux. In total therefore, 22 of 36 subjects (61%) in the current study had objectively 
high levels of reflux after combined pH-impedance monitoring. 
Overall, impedance monitoring only identified a pathological level of reflux in a small 
proportion of subjects, despite the high proportion for whom a high pH index was recorded. 
This relates, in part, to the way we have defined normality with respect to impedance 
analysis. Until recently, most reports of oesophageal impedance analysis have quoted the 
75th centile from a healthy control population as the upper limit of normal. With respect to 
the broader biomedical literature, this is unconventional. Ordinarily the upper limit of 
normal for a test result is taken to be 2 standard deviations above the mean, approximating 
to the upper limit of the 95th centile. Recent publications, in addition to national association 
guidelines, support the use of the 95th centile as the upper limit of normal (Association of 
Gastrointestinal Physiologists, 2015). This is the standard used in the current analysis. 
With respect to the issue of oesophageal motility, impedance monitoring can be used to 
assess the efficiency with which the oesophagus clears a bolus of material. In the current 
study, mean bolus clearance time was prolonged in 11 of the 36 subjects.  Eight of these 
individuals (73%) also had evidence of dysmotility at manometry, which provides some 
corroborative evidence that dysmotility is a significant issue amongst this patient population. 
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Proximal reflux was not commonly detected amongst the subjects in the current study. Only 
seven individuals had a high number of reflux events detected at the proximal channel on 
impedance. All but one had high levels of reflux overall, as assessed by the combination of 
pH and impedance. 
In the current literature, there is no consensus as to how normality should be defined when 
pH-impedance data are analysed. Were parameters such as proximal reflux to be included 
within the definition of abnormality, the proportion of subjects with high levels of reflux 
would increase. As with many physiological tests, oesophageal monitoring can provide a vast 
array of data. Oesophageal volume exposure could be taken into account, as could sub-
analyses based on supine/upright posture. 
On balance it seems reasonable to combine the reflux index, from the pH trace, with the 
number of reflux events, from impedance monitoring, to provide an objective definition of 
pathological gastro-oesophageal reflux in the IPF population. Additional parameters may 
provide further information, without defining a disease state. Few of the papers in the IPF 
literature specify how pathological levels of reflux were defined at ambulatory monitoring. 
Table 6-1 illustrates the prevalence of pathological reflux amongst IPF patients, as 
represented in the current literature. Whilst the higher prevalence figures are often quoted 
(Tobin et al., 1998; Raghu et al., 2006a), the figure of 61% in the current study is comparable 
to most published estimates.  
There are other factors that may have influenced the prevalence estimate from this 
prospective study. The clinic patients who were approached were aware that the protocol 
involved a series of invasive tests, the results of which would be considered by a 
multidisciplinary team. The potential for additional therapy may have enticed those with 
more severe reflux symptoms to participate. This issue is inherent to many prospective 
clinical studies. 
Albeit in a relatively small sample, the unselected, prospective nature of the current study 
adds validity to our prevalence estimate. 
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Table 6-1. Reported prevalence of pathological gastro-oesophageal reflux detected by ambulatory 
monitoring. N/S=not specified 
Reference n Recruitment source Technique 
Prevalence of 
pathological GOR (%) 
(Tobin et al., 
1998) 
17 ILD clinic pH 94 
(Raghu et al., 
2006a) 
65 ILD clinic pH 87 
(Salvioli et al., 
2006) 
18 N/S pH 67 
(Sweet et al., 
2007) 
30 
Pre-transplant swallow 
assessment 
pH 67 
(Bandeira et al., 
2009) 
28 ILD clinic pH 36 
(Soares et al., 
2011) 
16 Routine swallow assessment pH 56 
(Savarino et al., 
2013) 
40 N/S pH-impedance 83 
(Kilduff et al., 
2014) 
18 
Patients recruited for a study 
of PPI and cough 
pH impedance 44 
(Gavini et al., 
2015) 
54 
Pre-transplant swallow 
assessment 
pH-impedance 39 
 
6.4 Bronchoalveolar lavage 
In this study ambulatory oesophageal monitoring was combined with a standardised 
bronchoscopy and bronchoalveolar lavage (BAL) in all subjects. To date, this is the first 
report in which these techniques have been combined. 
BAL was performed in accordance with a protocol that is now well established within our 
research group (Stovold et al., 2007). A volume of 180ml was used consistently. All studies 
were performed by the same respiratory physician, who has extensive experience in 
bronchoscopy and BAL (IAF). 
For each subject, between 5 and 10ml was sent from the bronchoalveolar lavage fluid (BALF) 
and transported to the microbiology lab for processing. Subsequently, the median volume 
available for analysis was 78ml (range 35-113; IQR 64-87). Our median yield of 43% 
compares favourably with the recommended minimum yield of 30%, quoted in the American 
Thoracic Society’s guidelines (Meyer et al., 2012). 
The control group for bronchoalveolar lavage is one of the key limitations of this study. The 
controls in the current study were healthy volunteers and younger than the study subjects. It 
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would have been more informative to compare the markers of aspiration from the study 
group with a control group of similar size and comparable age range. Ideally, the control 
group would have been selected from a population with a similar restrictive pattern of lung 
disease. At this early phase of research, it was difficult to justify a high volume BAL in such a 
group. 
6.4.1 Pepsin 
Clinically, the concentration of solutes in BAL fluid is most commonly measured after lung 
transplantation. The association of pathological reflux and accelerated onset of bronchiolitis 
obliterans syndrome (BOS) has been investigated using these solutes as a biomarker for 
microaspiration (Robertson et al., 2012). High levels of pepsin and bile salts have been 
correlated with adverse outcomes (Stovold et al., 2007). The proposed links between reflux, 
aspiration and the pathogenesis of IPF has prompted their use in interstitial lung disease, but 
this literature is less well established. 
In the present study, pepsin concentrations were measured using a validated in-house assay 
with a limit of detection of 3ng/ml. In our small control group, the range of pepsin 
concentrations reported using the same assay was 0-2.3ng/ml, with a median of 1.1ng/ml. 
With reference to this upper figure, 17 subjects in the current study had high levels of pepsin 
measured in BALF. Once the group was dichotomised by reflux status, there was no 
difference in the proportion of subjects with high levels of reflux: 7 of 14 in the GOR- group 
vs 11 of 22 in the GOR positive group.  
Two previous studies have investigated BALF pepsin concentrations in IPF. Lee et al reported 
median concentrations of 35ng/ml in 24 cases where BAL was performed around the time of 
an acute exacerbation and 47ng/ml in 30 “stable” patients (Lee et al., 2012). The authors 
conclude that aspiration may play a role in some cases of acute exacerbation. The design of 
this study is initially appealing, but there are some methodological issues. First, there is no 
objective assessment of gastro-oesophageal reflux. Second, the BAL was performed with “at 
least 100ml sterile saline” instilled. This variation makes the pepsin concentrations difficult 
to interpret. Third, there were seven subjects in which BAL was repeated, such that patients 
featured in both the “stable” and “acute exacerbation” groups. This duplication raises 
questions about comparisons between two groups. Six of the seven patients had similarly 
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low BAL pepsin levels at the two time-points, which challenges the validity of the authors 
conclusions.  
Savarino et al used the Peptest lateral flow device to assess the presence or absence of 
pepsin in saliva/sputum and BAL samples captured from 21 IPF patients (Savarino et al., 
2013). Pepsin was detected in BALF in 67% of cases and in saliva/sputum in 61%. Bile acids 
were also measured. The authors report that all IPF patients with bile acids or pepsin 
detectable in BALF had abnormal impedance-pH test results. The detail of this statement is 
unclear from the manuscript, as the proportion of subjects with abnormal bile salts and 
pepsin within this group is not given.  
In the current study the association between high pepsin levels and pathological GOR is less 
clear. The correlation between these data was low. There were individuals who had 
detectable pepsin but no pathological reflux, and vice versa. That said, 31% of subjects had 
pathological reflux and high levels of pepsin. It is possible that this microaspiration might 
contribute to lung disease in this subgroup. Using pepsin as a marker of aspiration remains 
attractive therefore, but a number of methodological barriers remain. 
The sensitivity of pepsin as a marker of aspiration may be diminished as a result of the 
dilution inherent to BAL. In addition, a conventional BAL will only sample one subsegmental 
bronchus and the small airways with which it communicates. HRCT-guided lavage may 
improve sensitivity, but there is no good evidence base to support this modification. 
The significance of ectopic pepsin production has yet to be fully resolved. Pepsin A is known 
to be specific to the stomach, but type II alveolar epithelial cells have been shown to 
produce pepsin C (Gerson et al., 2008; Elabiad and Zhang, 2011). These proteins are distinct 
gene products (Taggart et al., 1985; Hayano et al., 1988).  The assay used in the current 
study is specific for type A pepsin so detectable BALF pepsin levels should accurately reflect 
gastro-oesophageal reflux and subsequent aspiration. 
Once in the lung, the speed of pepsin clearance after an aspiration event is unknown. 
Internalisation of pepsin within hypopharyngeal epithelial cells has been demonstrated, but 
internalisation within the pulmonary epithelium has yet to be evaluated (Johnston et al., 
2010). In the IPF lung, it is possible that fibrotic changes would influence epithelial 
permeability. Pepsin remains a promising biomarker for reflux and aspiration, but its 
behaviour with the lung must be clarified if its detection is to inform clinical practice. 
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The current data suggest that it is possible to combine oesophageal physiology monitoring 
and bronchoalveolar lavage analysis to identify a proportion of IPF patients with evidence of 
aspiration. With further validation of pepsin as a biomarker of aspiration, this combination 
of tests may provide a clinical insight into the IPF patients for whom aspiration is most 
significant. 
6.4.2 Bile salts 
In this study we used a commercially available spectrophotometric assay to quantify the 
concentration of bile salts in bronchoalveolar lavage fluid. This is the methodology that has 
been used most often in the studies that have established bile salts as a marker of 
aspiration, largely in the field of lung transplantation (D'Ovidio et al., 2005; Blondeau et al., 
2008). Samples were run in duplicate to generate each measurement. This process was 
performed three times for each study subject. Three subjects were found to have detectable 
levels of bile salts. In each case, three further runs were performed so as to improve the 
reliability of the result. For one additional subject, only one of the readings from the first 
three runs was valid. Three further runs were performed in this case also. In total, four 
subjects had positive bile salt readings, of 0.7, 1, 2.3 and 8.5µmol/l. The highest of these 
readings came from the one BALF sample that was turbid on visual inspection. The accuracy 
of the assay may be lower in these circumstances. 
 The results of a previous validation study indicate a lower limit of detection of 5µmol/l for 
this specific assay. In this context, the current data suggest bile salts were not detectable in 
the BAL fluid. 
The study by Savarino et al. is the first to evaluate BAL and saliva/sputum samples from IPF 
patients for total bile acids (2013). In keeping with previous attempts to evaluate bile acids 
as a marker of aspiration, a commercial assay (Bioquant, San Diego, USA) was used (D'Ovidio 
et al., 2005). Savarino et al. concluded that patients with IPF had more bile acids in BAL and 
saliva than non-IPF patients and controls. This assumes an accurate detection of levels below 
1umol/L, which were not reproduced in the validation study (Parikh et al., 2013).  
In a head-to-head comparison, Parikh et al reported a superior sensitivity for the TBA assay 
used in the current study, in comparison with the Bioquant assay used by Savarino et al 
(Parikh et al., 2013). This is due to the reversible nature of the reaction in the TBA method, 
which permits enzymatic recycling. 
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In general, spectrophotometric assays do not appear sensitive enough to detect bile salts in 
BAL fluid. This is unsurprising given that they were designed to detect far higher levels of bile 
salts in the serum of patients with liver disease. Lower concentrations of bile salts may be 
detectable using analytical chemistry techniques such as tandem mass spectrometry, but the 
physiological relevance of these lower concentrations requires clarification. In contrast to 
pepsin, aspiration of bile salts would also require duodenogastric reflux. 
6.5 Bronchoalveolar cytology 
6.5.1 Differential cell counts 
In the current study total BAL cell counts were calculated with a haemocytometer. After 
standardised preparation of cytospins, differential cell counts were estimated by counting 
500 cells and recording the number of neutrophils, lymphocytes, macrophages, eosinophils 
and basophils. 
With reference to the values reported for healthy controls, the IPF subjects in this study had 
elevated levels of macrophages, and markedly elevated levels of neutrophils. These findings 
are consistent with the reported characterisation of IPF patients using BALF (Meyer et al., 
2012). 
6.5.2 Cell staining 
In previous reports, pulmonary aspiration of gastric contents has been evaluated 
cytologically through selective staining of bronchoalveolar lavage fluid. Using an oil red stain, 
lipid uptake into macrophages can reportedly be measured (Colombo and Hallberg, 1987). 
The lipid-laden macrophage index (LLMI) gives a measure of the density of lipid uptake. 
In the current study, only a minority of subjects had cytospins which demonstrated 
significant lipid uptake within pulmonary macrophages. The limits of agreement for the LLMI 
figures were -6.9 to +3.8. This inter-rater reliability suggests that the measurement error for 
the larger, positive LLMI values was acceptable. LLMI values less than 10 were less accurate. 
With reference to the lipid-laden macrophage index (LLMI) for healthy controls, only six 
subjects had evidence of significant lipid uptake. The relationship between reflux and LLMI 
was assessed through correlation and by GOR status (normals vs refluxers). Neither analysis 
revealed any evidence of association. 
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Oil red staining has been used effectively within our research group in the past. I adjusted 
the standard operating protocol by using Cilestin Blue as a counterstain, in place of Harris 
Haematoxylin. This provided a more vivid result and enumeration of the requisite 300 
macrophages was possible in all cases. To counter enumeration bias, a proportion of the 
slides were second read by an observer blinded to the physiology and pepsin results. 
Correlation analysis suggested a high level of inter-observer agreement. 
Several authors have also reported negative results. Limited specificity of the test may be 
explained by the finding of lipid uptake into alveolar macrophages in non-aspiration lung 
disease, such as pneumonia (Kitz et al., 2012). Theoretically any process which leads to 
increased lysis of intrapulmonary cell walls, with subsequent release of lipids, could result in 
an increased LLMI. Conversely, the sensitivity of the LLMI for detection of aspiration relies on 
thorough sampling of the intrapulmonary environment, which is rarely possible with BAL. 
The half-life of alveolar macrophages is another area that is poorly understood, with data 
currently available only in animal models (Colombo et al., 1992).  In the paediatric 
population, LLMI may have a role in identifying reflux and pulmonary aspiration, but the 
technique appears less useful in adults. 
In addition, we assessed haemosiderin uptake in macrophages using a Perls Prussian Blue 
stain. Macrophage haemosiderin uptake has been used to explore oxidative stress in lung 
transplant recipients. Reid et al suggested that under inflammatory conditions, activated 
neutrophils release harmful free iron from ferritin (Reid et al., 2001). Alveolar macrophages 
sequester free iron as haemosiderin in order to prevent the generation of free radicals and 
reactive oxygen species. 
In contrast to the results of LLMI evaluation, macrophage haemosiderin uptake was visible in 
the majority of the study subjects. With reference to haemosiderin scores reported for 
healthy controls, 33 of 36 subjects in the current study had high results (Reid et al., 2001). 
Haemosiderin scores were not associated with reflux status, but were found to be higher in 
subjects with more severe lung disease, as assessed by vital capacity. 
The significance of iron deposition has been studied in IPF, in relation to putative 
associations with occult alveolar haemorrhage, angiogenesis and pulmonary hypertension 
(Kim et al., 2010; Puxeddu et al., 2014). 
These issues seem increasingly pertinent in light of positive findings from recent clinical 
trials. Nintadenib, a tyrosine kinase receptor inhibitor, has potent angiostatic activity in both 
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in vitro and ex vivo studies (Hilberg et al., 2008). Pirfenidone has been shown to have 
antioxidant properties (Salazar-Montes et al., 2008). Techniques that characterise oxidative 
stress may be useful to personalise therapy in the future. 
6.6 Multidisciplinary review 
This research study was possible due to an ongoing collaboration between respiratory 
physicians, general surgeons and translational scientists with an interest in reflux and 
chronic lung disease. Whilst the design was largely observational, it was clear that the data 
generated could have implications for clinical management. Optimal management has yet to 
be defined in this area of practice, so we set up a multidisciplinary team to consider the 
study results and plan future management accordingly. In addition to surgical and 
respiratory input, the core clinical membership includes anaesthetic support. Only three 
patients from the current cohort were recommended for antireflux surgery; two have 
undergone fundoplication to date. One of these two patients was initially being considered 
for antireflux surgery but underwent urgent lung transplantation first, in light of declining 
pulmonary function. 
In the context of the current literature, this approach to antireflux surgery may be regarded 
as overly conservative. However, the same MDT has demonstrated a positive approach to 
the management of reflux and aspiration in chronic lung disease, particularly in the setting 
of lung transplantation (Griffin et al., 2013; Jones et al., 2013). 
Some of the barriers to antireflux surgery have included the risks of anaesthesia and major 
surgery in a frail elderly population, in addition to concerns about oesophageal dysmotility in 
many of the study subjects. These issues have been easier to confront in a multidisciplinary 
setting, where there is a growing awareness of the nuances of the IPF population. The 
proposed links between anaesthesia, surgery and acute exacerbation is one such example. 
Individual clinicians also find it easier to counsel patients on conservative therapy when this 
has been the joint perspective within the MDT. 
For some patients, it was clear that the subclinical nature of their reflux meant that patients 
were reluctant to undergo treatment. Despite acknowledging the potential risks of 
persistent reflux and aspiration, many subjects were reluctant to consider treatment, 
medical or surgical, for something that was imperceptible to them. 
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When this range of attitudes came to light, the decision was taken to investigate this issue 
more closely. The data from the current study highlight the challenges of characterising 
reflux and aspiration in IPF. It will take time to clarify the possible role of aspiration in IPF. It 
is crucially important that we consider patients’ views as we continue to research this area 
and to better define the group of patients that might benefit from antireflux therapy.  
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6.7 Evaluating patient attitudes: measuring the perceived burden of IPF and 
antireflux therapy 
In the work designed to characterise reflux and aspiration in IPF, around 50% of patients 
approached were willing to participate in a study which involved two different invasive tests. 
For an observational study, this represents an impressive proportion. Compliance with the 
study protocol was also high. 
Conversely, around 50% of patients did not wish to take part. This might be consistent with a 
proportion of patients who were more conservative and risk averse. Such a dichotomy might 
also be expected for attitudes to treatments with a degrees of risk. 
Exploring the patient perspective in IPF involved a very different approach than the work to 
characterise reflux and aspiration. Evaluating attitudes towards health is a complex area but 
the theoretical and practical basis is increasingly well established within the health 
economics literature. 
6.7.1 Study design 
For the current study, the standard gamble was identified as the most appropriate tool to 
use. The impact of reflux on lung disease and the outcomes from antireflux therapy will 
always be associated with a degree of uncertainty. It was felt that the standard gamble was 
the best technique with which to frame that uncertainty. 
Health state utility analysis has not been undertaken in idiopathic pulmonary fibrosis or any 
other interstitial lung disease previously. The unprecedented nature of this work made for 
some specific challenges. Whilst health state vignettes are available for many other chronic 
lung diseases, this is not the case in IPF. Therefore, the first step was to construct 
appropriate health states. These vignettes needed to be easily understood, provide a valid 
reflection of the disease and be concise enough to be incorporated into a standard gamble 
interview. Using longer vignettes may have provided a richer and more realistic account of 
living with the disease, but the concise nature of our health state cards made them 
accessible to the interview participants. 
The most difficult aspect of designing the study came in integrating the diverse 
considerations of lung disease and antireflux therapy. The use of utilities made this 
comparison possible, but the standard techniques will only generate a utility for one health 
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state at a time. Colleagues from our own unit have described a chained standard gamble 
technique, in which health state vignettes are successively used within the gamble 
(McNamee et al., 2004). This technique is feasible because the utility recorded for each 
health state can be used to provide the anchor for the next standard gamble. In the current 
study, it was felt that a chained standard gamble would have introduced another, 
unwelcome layer of complexity and added burden for participants. Instead, four health 
states were measured consecutively using separate, conventional standard gambles. 
Ideally, this study would have been designed to compare the burden of IPF with the range of 
possible outcomes associated with antireflux therapy. In time, this may provide an insight 
into patient perceptions of the risks and benefits of treating reflux in IPF. At present, the 
data on the pulmonary benefit of antireflux therapy in patients with IPF are essentially 
anecdotal. In the absence of high-quality study data with which to quantify potential benefit, 
the focus of the analysis shifted. The four rounds of the standard gamble were designed to 
compare the burden of disease in IPF with the potential burden of antireflux therapy. This 
latter concept can be readily derived from the experience of clinicians and patients in the 
upper GI surgery clinic. These groups informed the design and revision of the health state 
vignettes that were eventually used. 
There is no accepted process for the design of health state vignettes in utility analysis. Some 
studies simply use the name of the condition or treatment outcome to characterise the 
scenario in question (Laccourreye et al., 2012). It is increasingly accepted that this is not the 
most robust technique as the details of the health state are left entirely to the imagination 
of the respondent, introducing a high degree of subjectivity. Alternatively it has been shown 
that study methodology becomes more reproducible if “word pictures” can be used 
(Hamilton et al., 2014). 
This approach was utilised in the current study. Where possible, validated descriptors of 
disability were used. Qualitative study data were also incorporated where possible. Most 
importantly, the process was iterative, with successive rounds of input from patients and 
clinicians, until the vignettes became stable and acceptable. 
The accuracy with which vignettes reflect a health state is difficult to prove but their validity 
is enhanced by the inclusion of explicit detail. As with more traditional biomedical studies, 
there are a number of techniques that can be used to assess validity, both of the vignette 
and the standard gamble process. In the current study, two key validation steps were the 
156 
inclusion of the ranking exercise and the comparison with EQ5D, which provides an indirect 
comparison with health state utilities derived from time trade-off. 
6.7.2 Study subjects 
The selection of interview respondents was another important decision in the design of the 
current study. At this early stage of research, the aim of this work was to capture the patient 
perspective, so IPF patients were chosen as the target audience. Almost all subjects 
preferred to participate in their interviews through home visits. Given the relative rarity of 
the disease, completing the interviews involved travelling across a large geographical area, 
including Greater Newcastle, North and South Tyneside, Northumberland and Gateshead. 
There are therefore resource implications for future studies of this type. 
The study subjects appear to be representative of the broader IPF population in the North 
East of England. Median percentage predicted vital capacity was equivalent to that in the 
characterisation study population (78% in both studies). They were largely elderly, male, 
retired and with a relatively low level of formal qualifications; 11 of 59 participants had 
completed either A-levels or degrees and a further three had NVQ level 4-5. They were 
universally White British by ethnicity. Given the age and level of formal qualification within 
the group, the ease with which the interview could be completed would seem to be an 
important consideration. 
In a previous postal study of diabetic subjects a standard gamble was administered both at 
interview and by post (Hammerschmidt et al., 2004). While the results showed good 
consistency, only about two-thirds of the completed postal forms were usable. The results of 
the current study demonstrate that a standard gamble is feasible in the IPF population. 
Telephone interviews or postal formats would have been more challenging as additional 
explanation was required at times. 
6.7.3 Key findings 
The majority of respondents rated both of the IPF health states as preferable to either of the 
antireflux therapy outcomes. A significant minority, however, regarded either one of the 
antireflux therapy outcomes as preferable (36% of respondents). This split indicates a 
genuine division of opinion across the group as a whole. 
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Almost all respondents (54 of 59) regarded either an adverse outcome from antireflux 
therapy or the moderate IPF health state as the least preferable health state. 
Interestingly, five people in the study regarded the antireflux medication scenario as worse 
than moderately severe IPF and an adverse outcome from antireflux surgery. In the absence 
of any qualitative analysis, it is unclear from the present data whether respondents were 
more concerned about the prospect of having to take supplementary medication or about 
the risk of side effects. 
The average utilities for the health states suggest that respondents rated mild IPF as the 
most preferable health state and an adverse outcome from antireflux surgery as the least 
preferable. The utilities recorded for the mild IPF state and for medical antireflux therapy 
were equivalent. 
By the end of the interview, each respondent had evaluated his or her own health using 
three different techniques: standard gamble, EQ5D and the visual analogue scale, which is 
included within EQ5D. The mean utilities recorded by these latter techniques were 
equivalent (0.613 vs 0.611) but the utility recorded by the standard gamble was significantly 
higher (0.798). 
The precise reason for these differences cannot be established from these data, but the 
subject of bias has been extensively discussed within the healthcare measurement literature. 
Bias occurs when responses result in a systematic departure from true values under 
consideration. When subjects are questioned about health, factors related to one’s own 
circumstances often have an influence. From my own observations, interview respondents 
would sometimes try to understand the vignettes by thinking about which elements they 
could relate to, or which were consistent with their own current health. 
Bias can occur due to personality traits, attitudes, behaviours or might be more associated 
with the use of a specific measurement tool (McDowell, 2011). One respondent might 
exaggerate disability in an bid to delay their return to work, whilst another might play down 
their problems in a bid to return more quickly. 
 In the current study, there are several factors that could account for the observed pattern of 
results. 
Stoicism is a personality trait that would be expected to inflate utility scores which were 
recorded for an individual’s own health. Defensiveness may have the same effect. 
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Hypochondriasm or a tendency towards attention-seeking behaviour would have the 
opposite effect. 
Response shift is a phenomenon that has been described in individuals with chronic, 
progressive disease. Individuals have been shown to reframe their perceptions of disease 
severity as it progresses (Sprangers and Schwartz, 1999). Similarly, it has been shown that 
individuals living with a significant disability tend to report higher utilities for their situation 
than respondents considering the same health state objectively (Albrecht and Devlieger, 
1999). This would explain the trend towards higher utilities recorded by the respondents 
with worse pulmonary function for the IPF health states. 
Bias has also been reported for the use of devices where the middle section and end points 
are clearly visible, such as a visual analogue scale. End-scale aversion describes how some 
individuals will preferentially record responses at the extremes of the scale, whilst more 
conservative individuals will be drawn to respond in the mid-section of the scale (Parkin and 
Devlin, 2006). 
Another explanation relates more specifically to the methodology of the standard gamble. 
At each stage, the respondent is asked to choose between the certainty of a defined health 
state, and the uncertainty of a gamble. Risk-averse individuals will be less happy to gamble, 
which has been shown to result in higher utility scores. The converse would apply to risk-
takers. It is tempting to conclude that the issue of risk aversion might explain why the 
utilities from the standard gambler were higher. With respect to the figures generated by 
the visual analogue scale, this may be true. 
The same argument is less applicable when the results of the standard gamble and EQ5D are 
compared. As discussed in section 3.2.9, EQ5D works by mapping a multi-dimensional 
assessment of health to a set of pre-calculated utility scores. The utility scores that have 
been calculated for the various permutations of EQ5D were derived from a time-trade off 
study. As discussed previously, the time trade-off can be thought of as simplified version of a 
standard gamble rather than a distinct technique. In the time-trade off, there is a group of 
people who are reluctant to trade, in a way that is analogous to the risk averse respondents 
in a standard gamble (Hamilton et al., 2014). 
It seems more likely therefore, that the respondents in the current study displayed other 
behaviours which would give rise to inflated utilities for their own health state. Based on my 
experience of conducting the interviews, I was struck by the stoical nature of the group.  
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Various attempts have been made to measure and correct for bias in utility assessments, but 
no single approach has gained widespread support (McDowell, 2011). There is a counter-
argument that the combined effects of different biases form an integral part of the health 
beliefs that are being studied. 
Either way, utilities derived from a standard gamble have generally been shown to be higher 
than equivalent utilities derived from a time trade-off or visual analogue scale (Torrance, 
1986). Conversion factors can be used to correct between the different tools. 
6.7.4 Validity, strengths and limitations  
In conventional biomedical research, the quality of data can often be assessed through 
direct comparison with pre-existing reference points. Physical data points might be 
compared to normal ranges, or assessed statistically to assess validity, reliability or 
responsiveness. 
In health economics, many concepts are abstract so “true” values are never revealed. Scaling 
procedures and validated tools can provide more meaningful results, but the extent to which 
a measurement reflects the concept it is designed to reflect to will generally remain elusive. 
In the absence of any previous utility analysis in interstitial lung disease, a number of 
internal checks were incorporated into the study design.  These provide some logical 
reference points against which the validity of the data can be appraised. 
With respect to the standard gamble, the anchor points “Full Health” and “Immediate 
Death” were defined as the extremes health states. The most important of these was Full 
Health, as this was set up as a “perfect” state. All 59 of the respondents ranked Full Health as 
the most preferable of all the states.  
Interestingly, two of the respondents classed one of the descriptive health states as worse 
than Immediate Death. The concept of a state worse than death appears repeatedly in the 
literature and does not inherently challenge the fitness of the individual in question to 
complete the interview. In the current study, however, the standard gamble was predicated 
on extreme health states as the anchor points in the gamble. For this reason, the standard 
gamble-derived utilities for these two individuals were excluded from the analysis.  
In the overwhelming majority of respondents, the utilities generated by the standard gamble 
differentiated between the respective health states. This demonstrates two points: Firstly, 
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the technique appears sufficiently sensitive to distinguish between the perceived quality of 
life associated with the different states. Secondly, it suggests that the respondents were able 
to express opinions as to their preferences between the different states.  
This pattern is not universally reported in the literature. In a study of rhinoconjunctivitis, 
patients faced the choice of remaining in their current state for ten years or a gamble, where 
the possible outcomes were symptom relief and death. The utility values did not correlate 
well with other quality of life indices, as patients were unwilling to accept anything other 
than a minimal risk of death (Juniper et al., 2002). 
There was also a reasonable degree of consistency between the opinions expressed in the 
ranking exercise and in the standard gamble. In 41 respondents (70%), health state rankings 
were concordant with utility estimates. 
There were two further logical checks, both of which were satisfied. Firstly, the results of the 
ranking exercise and the standard gamble both indicated the mild IPF health state to be 
preferable to the moderate IPF health state. Secondly, the mean utility recorded for 
respondents’ own health was comparable to that for moderate IPF and worse than the mild 
IPF. This result is consistent with the inclusive nature of the study recruitment criteria. 
Health state utilities are now available for an increasing number of diseases. The main use 
for these data is in health economics strategy, but they are increasingly used to provide an 
insight into individual patient preferences. The largest repository is the Cost-Effectiveness 
Analysis Registry, based at Tufts University in Massachusetts. With reference to this 
database, it appears that the current study reports IPF utility estimates for the first time. The 
disease burden associated with this condition can now be compared with that for some of 
the commoner pulmonary diseases, which will provide an opportunity to raise the profile of 
the condition. 
In lung cancer, for example, health state utilities have been extensively reported, Table 6-2. 
Chouaid et al reports on EQ5D interviews with 263 patients with advanced non-small cell 
lung cancer (Chouaid et al., 2013). The study by Sturza et al is a meta-analysis of 23 original 
reports with varied measurement techniques and varied respondent groups. By comparison, 
the mean EQ5D utility of 0.613 in the current study demonstrates the significant burden of 
IPF disease. 
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Table 6-2. Published health state utilities for lung cancer. 
Author Condition Tool Severity grading  Mean utility 
(Chouaid et al., 
2013) 
NSCLC EQ5D Line of 
treatment 
First 
Second 
Third/Fourth 
0.71 
0.74 
0.62 
(Sturza, 2010) Lung cancer Mixed Stage Metastatic 
Mixed 
Non-metastatic 
0.57 
0.77 
0.87 
 
Given utility estimates and prevalence data, pharmaceutical companies can start to calculate 
the cost per QALY and the potential returns which research and development can be 
weighed against in IPF. 
There are significant limitations in the current study. Firstly, there was no clear reference 
point with which to say how bad the outcomes of the antireflux therapy should be. Patients 
who have an adverse outcome from a given treatment represent a broad spectrum. With 
respect to the medical vignette, it was possible to incorporate the conventional definitions 
of “rare” and “common” with reference to omeprazole’s product characteristics. Both 
clinicians and patients felt that the vignettes used gave a convincing account of a bad 
outcome, but this was not possible to quantify in any meaningful way. 
Secondly, we made no assessment of reproducibility in the current study. This would seem 
particularly relevant to the standard gamble, with its relatively complex methodology. As 
discussed in section 1.5.4, several previous reports have included high levels of 
reproducibility for the standard gamble. This would seem to be an important area for future 
health state utility research in the IPF population. 
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Chapter 7. Summary and Recommendations for Future Research 
In this study, I have completed a panel of assessments in order to characterise the nature of 
gastro-oesophageal reflux and pulmonary aspiration in 36 individuals with IPF. The findings 
suggest that a significant proportion of patients experience pathological levels of reflux, 
although reflux may not be as universal as previously reported in this group. In the majority, 
pathological levels of gastro-oesophageal reflux were clinically silent. 
In addition to gastro-oesophageal reflux, there were high levels of oesophageal dysmotility. 
This finding is relevant because weak peristalsis is a risk factor for bloating, dysphagia and 
malnutrition after fundoplication. Dysmotility is regarded as a relative contraindication to 
antireflux surgery. Individuals with IPF must therefore undergo careful manometric 
assessment if they are to be considered for antireflux surgery. 
In our study population, we used biochemical and cytological methods to look for direct 
evidence of aspiration in fluid retrieved at bronchoalveolar lavage. Of the techniques under 
review, pepsin provided the best evidence of aspiration in the study population, with high 
levels detected in the BAL fluid of 47% of subjects. There was no convincing correlation 
between markers of gastro-oesophageal reflux and any marker of aspiration. Whilst there 
was a reflux-positive, pepsin-positive subgroup, there were also groups who were reflux-
positive, pepsin-negative and vice versa. 
In a series of interviews with another 59 IPF patients, a standard gamble was used to 
generate health state utilities relating to IPF and to the treatment of gastro-oesophageal 
reflux disease. Data analysis indicated that respondents were comfortable with the 
methodology, engaged in the process and able to express clear opinions in the answers they 
gave. The own-health valuations confirmed, for the first time, the relative burden of disease 
that is associated with IPF. Comparable utility scores were also recorded for the descriptive 
IPF health states, indicating the validity of these vignettes. 
Respondents were also asked to evaluate health states constructed to represent the adverse 
outcomes of antireflux surgery. The use of utility scores as a marker of preference enabled a 
direct comparison between the health states related to the burden of disease in IPF and to 
the outcomes of antireflux therapy. The majority of respondents regarded both the mild and 
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moderate IPF disease states as preferable to either of the antireflux therapy outcomes, 
whilst a significant minority (21 of 59 respondents) did not.  
These findings do not allow for conclusions as to the level of risk and benefit that patients 
with IPF would accept before going ahead with antireflux surgery. There is a clear 
suggestion, however, that different individuals within a group have very different ideas on 
the subject. This finding is especially important in an area of medical practice where the 
balance of risk and benefit has yet to be defined. 
At present, the literature on reflux and aspiration in IPF is difficult to interpret. 
Microaspiration may contribute to the aetiology of IPF but this remains unproven. With 
respect to clinical practice, some commentators assert that reflux is almost universal in IPF 
and antireflux surgery could help to stabilise lung disease. 
The current findings do not support that statement: significant reflux and aspiration was 
only evident in the minority of patients, the group that would benefit from antireflux surgery 
are difficult to identify and a proportion of patients regard the potential burden of surgical 
complications as worse than that of living with IPF. 
The aggregated results of this study demonstrate the importance of multidisciplinary team 
working and shared decision-making. In time we will develop a better understanding of the 
risks and benefits of treatment options in reflux and IPF. As clinicians we must communicate 
this information clearly to patients and listen carefully as they share their values and 
preferences. 
From a research perspective further efforts must be made to identify the group of patients 
in whom reflux and aspiration may be contributing to the trajectory of lung disease. pH-
impedance monitoring is now well established in clinical practice, but far less is known about 
the markers of aspiration that can be detected in bronchoalveolar lavage fluid. 
In the absence of major developments with alternative biomarkers, the results of this study 
suggest that pepsin may be the most promising option available. An improved 
understanding of pepsin in the lungs would help to clarify discordant results from a given 
patient’s reflux and aspiration tests.  
One approach to this would be to assess the pepsin subtypes found in gastric juice and BAL 
fluid. High-pressure liquid chromatography could be used to quantify the relative proportion 
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of pepsin subtypes in these two compartments. The same technique could be used to 
confirm the extent of cross-reactivity of pepsin subtypes when measured at BAL. 
Secondly, it would be helpful to clarify the rate at which pepsin is cleared from the lungs. At 
present the relationships between pepsin, chronic micro-aspiration and acute exacerbations 
of IPF are poorly understood. Serial measurements in a low-mortality animal model would 
help to clarify the significance of detectable pepsin in BAL. This would be a more difficult 
study, but the current data suggest that oesophageal physiology alone is unlikely to identify 
those with IPF for whom aggressive antireflux therapy will be of most use. 
Lastly, the results of BAL cytology suggested a negative correlation between objective lung 
function and oxidative stress: individuals with lower percentage-predicted vital capacity had 
higher levels of oxidative stress. Perls staining, as a simple marker of oxidative stress, could 
be used to inform studies of IPF pathophysiology and pharmacological therapy in the future. 
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